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Obesity increases the risk of tumourigenesis, but paradoxically may predict better prognosis after 
cancer has been diagnosed. There is a general lack of understanding of interactions between cancer 
cells and adipose tissue. Obesity is characterised by activated endoplasmic reticulum (ER) stress and 
increased infiltration of macrophages in the adipose tissue. Little is known about the connection 
between the ER stress and infiltration of macrophages in the adipose tissue. Additionally, the impact 
of each characteristic on the biology of cancer cells is unclear. This PhD project attempted to define 
the adipose tissue microenvironment in the setting of cancer, in particular, kidney cancer. The thesis 
adds knowledge that helps to define the heterogeneous adipose tissue microenvironment and its 
functions in cancer development. 
The thesis is presented as a literature review (Chapter 1) followed by four original research sections 
(Chapters 2-5) that have, in some cases, been published (Chapter 2) or submitted (Chapters 3 and 
4).  
The literature review (Chapter 1) will initially introduce the epidemiology, pathophysiology and 
prognostic factors for kidney cancer, followed by a summary of the advances in biomarker discovery 
in renal cell carcinoma (RCC). The literature review then introduces the structure, function and 
signaling pathways of the ER, followed by a discussion of the involvement of ER stress in cancer. 
The crosstalk between obesity, cancer and ER stress is also discussed. Finally, the role of 
macrophages in the tumour microenvironment is summarised.  
Chapter 2 is an immunohistochemistry-based retrospective cross-sectional study. Software-assisted 
quantification of staining intensity and proportion of positive pixels was applied to measure 
expression of glucose-regulated-protein-78/GRP78 (an ER stress marker) in archived specimens of 
renal tumour tissues (n=114), adjacent non-neoplastic renal tissues (n=68), and perinephric adipose 
tissues (n=60) in participants diagnosed with clear cell RCC (ccRCC), the commonest subtype of the 
RCC. Results demonstrated that GRP78 was not an optimal risk stratification marker for ccRCC. 
However, upregulated GRP78 in perinephric adipose tissue may be linked with a lower chance of 
metastasis. 
Chapter 3 introduces a liquid-overlay based method to generate reproducible and functional mature 
adipocyte spheroids using human perinephric adipose tissue-derived mesenchymal stem cells and the 
murine 3T3-L1 cell line. The established adipocyte spheroids were responsive to the ER stress 
activator, tunicamycin. and could secrete adiponectin, monocyte chemoattractant protein-1 (MCP-1) 
and interleukin/IL-8. Hence, the three-dimensional culture platform was able to serve as an adipose 
tissue microenvironment that could be applied in in vitro experiments.  
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In Chapter 4, macrophage behaviour in the adipose tissue microenvironment was investigated using 
the 3D culture platform introduced in Chapter 3. Co-culture experiments were performed to measure 
the polarisation, migration and invasion of murine and human macrophages. Results demonstrated 
that mature adipocyte spheroids caused an MCP-1 independent recruitment of Raw 264.7 cells 
(murine macrophage cell line), which was abolished by tunicamycin treatment. The normal adipose 
tissue microenvironment induced the unpolarised macrophages to shift into an M2 macrophage 
phenotype. M1 and M2 macrophages exhibited distinct invasion capacity towards adipocyte 
spheroids. The presence of M1 macrophages inhibited the invasion of Kirsten mouse sarcoma virus-
transformed non-producer human osteosarcoma (KHOS) cell line and 786-0 cancer cells (human 
kidney cancer cell line).  
In Chapter 5, the association of macrophage immunophenotyping of perinephric adipose tissue with 
aggressiveness of ccRCC was investigated, particularly with regard to distant metastasis. Multiplex 
immunofluorescence was applied to stain CD68, CD163 and CD206 in the perinephric adipose tissue. 
Three pixel-based algorithms, based on either individually optimised thresholding or consistent 
maximal and minimal thresholding, were applied to quantify the positivity of the cluster of 
differentiation (CD) markers across the whole image and in the segmented cytoplasm compartment. 
Results demonstrated that the most aggressiveness subtype, ccRCC with distant metastasis, exhibited 
higher expression of CD206 and CD163 compared to the non-metastatic ccRCC and oncocytoma. 
Finally, a general discussion of the results and an outlook of future directions are presented in 
Chapter 6.  
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 General introduction 
There is increasing interest in understanding the interaction of tumour cells with the surrounding 
stromal structure, including adipose tissue, with a long-term aim to target the tumour 
microenvironment to inhibit the proliferation and metastasis of tumour cells [1]. Renal cell carcinoma 
(RCC) is among the five cancer types that have achieved the most attention regarding the association 
between obesity and the increased incidence of cancer, other types being colon, oesophagus, breast 
and corpus uteri cancers [2]. However, recent findings suggest that, at the time of RCC diagnosis, 
being overweight might be associated with a better prognosis [3, 4]. The obesity paradox in RCC 
highlights the importance of crosstalk between adipose tissue and carcinomas in the progression of 
kidney cancer. 
An association between increased body mass index (BMI) and increased ER stress levels in adipose 
tissue has also been reported in healthy populations [5]. Obesity-induced ER stress is responsible for 
the pro-inflammatory microenvironment in adipose tissue [6]. It is classically accepted that cancer is 
a chronic inflammatory and metabolic disease, and obesity-associated adipose tissue inflammation 
and oxidative stress are pathogenetic for cancer [1]. However, little is known about obesity-associated 
ER stress levels in perinephric adipose tissue and its influence on RCC progression. Understanding 
the effects of obesity-associated ER stress on cancer development may deepen our understanding of 
the heterogeneous tumour microenvironment. 
We have recently found through immunohistochemistry (IHC) that the perinephric adipose tissue 
from patients diagnosed with renal tumours who had higher BMI had more chances to express higher 
level of an ER stress marker (as demonstrated by lower average gray value), glucose-regulated-
protein-78 (GRP78) (Spearman correlation coefficient=-0.23, p=0.04). Simultaneously, a trend that 
the downregulated expression of GRP78 in perinephric adipose tissue might be associated with a poor 
prognosis of kidney cancer was found, with the downregulation of GRP78 correlating with increased 
probability of metastasis (95 % confidence interval [CI] of OR: 0.99 to 1.38, p=0.07). The results 
suggested that the activated ER stress under an obese microenvironment may exert a protective role 
for patients diagnosed with kidney cancer. Coincidently, this result was consistent with the obesity 
paradox in RCC [3, 4].  
The focus of interaction between obesity and cancer has long been the tumour-promoting role of 
obesity-associated chronic inflammation. What has been largely ignored is that the inflammatory 
reaction also functions as a crucial tumour-eliminating mechanism in immune-surveillance [7]. 
However, evidence from our one-point IHC study is insufficient to deduce that activated ER stress in 
the obese perinephric microenvironment impedes RCC progression. Hence, research was undertaken 
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based on cell culture to mimic the ER stress-activated obese microenvironment of adipose tissue and 
reflect the in vivo interaction among carcinomas, adipose tissue and surrounding immune cells. 
The literature review will initially introduce the epidemiology, pathophysiology and prognostic 
factors for kidney cancer, followed by a summary of the advances in biomarker discovery in RCC. 
The commonest form of RCC is clear cell RCC (ccRCC) and this subtype became the focus of the 
thesis. The literature review introduces the structure, function and signaling pathways of the ER, 
followed by a discussion of the involvement of ER stress in cancer. The crosstalk between obesity 




 Literature review 
1.3.1 Epidemiology, pathophysiology and prognostic factors of kidney cancer 
1.3.1.1 Epidemiology of kidney cancer 
Kidney cancer is a silent killer disease which develops without specific symptoms in its early stages 
and is often found incidentally in imaging screening for other indications [8]. The median age at 
diagnosis is around 64 years of age [9]. As per a recent report from the World Cancer Research Fund 
International [10], kidney cancer is the 14th most common cancer in the world, with 403,262 of new 
cases and 175,098 of deaths in 2018. It is estimated that there will be 184,416 deaths in 2020 and the 
number will reach 310,968 in 2040. A gender disparity in the incidence for kidney cancer is distinct, 
with men being nearly twice as likely as women to develop kidney cancer (age standardised incidence 
rates per 100,000: 6.0 versus 3.1, respectively). The distribution of kidney cancer incidence varies by 
geographic area, with the highest age standardised incidence rates found in North American and 
Europe, and the lowest incidence in Africa (Fig 1.1) [10]. 
1.3.1.2 Histopathological classification of kidney cancer  
The most common kidney cancer, at around 90 %, is RCC. RCC are classified as ccRCC (75-85 %), 
papillary RCC (type 1 and type 2) (10-15 %), chromophobe RCC (5-10 %), collecting duct RCC 
which is very rare, and unclassified RCC at less than 5 %. Some of the renal neoplasms are benign, 
with very low or no malignant potential, such as papillary renal adenoma, oncocytoma (3-7 % of 
kidney neoplasms), and angiomyolipoma [11]. In histological appearance, the most common subtype 
ccRCC is characterised by compact alveolar or acinar-like nests interspersed with arborizing 
vasculature. The malignant epithelial cells clustered in the nests have transparent cytoplasm [12]. 
This is due to the dissolving of the lipid and glycogen-rich cytoplasmic deposits during histological 
processing [13].  
1.3.1.3 Pathogenesis of RCC 
Genomic analysis has found 16 significantly mutated genes across ccRCC, papillary RCC and 
chromophobe RCC and the mutation feature in each subtype is distinct [14]. As per the report from a 
group of Chinese scientists who applied rigorous bioinformatics analysis, 50 % of the 98 Chinese 
ccRCC patients carried altered gene expression (including but not limited to mutations in the Von 
Hippel Lindau gene/VHL) that are involved in the ubiquitin-mediated proteolysis pathways which 




Fig 1.1 Estimated age-standardised incidence rates in 2018 for kidney cancer 
The heatmap demonstrates the heterogeneous geographic distribution of kidney cancer incidence (age standardised risk/ASR per 100,000 people). The 10 top-ranking 
countries are Belarus, Latvia, Lithuania, Czech Republic, Estonia, Slovakia, France, Hungary, Iceland and Croatia. In 2018, Australia ranked 19th with ASR being 
9.8. The figure was created using the online data visualisation tool provided by International Agency for Research on Cancer, World Health Organization 
(http://gco.iarc.fr).  
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 the protein of VHL (pVHL), which binds to elongin B, elongin C or cellulin 2 to form complexes 
that are essential for the degradation of intracellular proteins, such as hypoxia-inducible factor (HIF) 
1α and 2α. Accumulated HIF1α and HIF2α bind to HIFβ and the complex transports into the nucleus, 
acting as a transcription factor. Alterations in VHL result in the upregulation of mRNA that codes for 
proteins which contribute to tumour development, including vascular endothelial growth factor 
(VEGF), transforming growth factor α (TGF α), platelet-derived growth factor-β (PDGF-β) and 
matrix metalloproteinase protein (MMP) [16]. The VHL mutation is also responsible for the altered 
lipid metabolism in ccRCC. It was reported recently that the mitochondrial fatty acid transporter 
carnitine palmitoyltransferase 1A (CPT1A) is suppressed by HIF1 and HIF2, thus forcing the 
accumulation of lipid droplets in the cytoplasm of ccRCC [17]. 
1.3.1.4 Prognostic factors for RCC 
To date, various prognostic factors have been identified for RCC, including clinical and biomedical 
features, histological subtypes and pathological diagnosis [18]. For example, severe anaemia and 
upregulated lactate dehydrogenase (LDH) after RCC diagnosis indicate short overall survival (OS) 
[19, 20]. By histological subtype, the OS of metastatic non-ccRCC patients (12.8 months) was 
significantly poorer than that of ccRCC patients (22.3 months) when treated with targeted therapies 
(hazards ratio/HR for death = 1.41, P<0.0001) [21]. The OS (5 to 12 months) and treatment response 
for RCC with sarcomatoid differentiation is the poorest [22]. Overexpression of the prevalent 
programmed cell death ligand-1 (PD-LI) and active epithelial-mesenchymal transition (EMT) 
contribute to the escape of antitumour immunity and metastasis for sarcomatoid RCC [23]. 
Tumour-node-metastasis (TNM) staging is the most widely applied risk stratification system for 
predicting RCC prognosis: T indicates tumour size and whether it has grown into a nearby area; N 
describes the presence of regional lymph nodes invasion; and M indicates whether the cancer has 
metastasised [24]. The numbers 0 through 4 appearing after T, N and M, and the letter “a” or “b” after 
the numbers, indicate increasing severity. Once the categories have been assigned, patients will be 
classified into an overall stage of I, II, III, or IV [25]. According to data reported by the American 
Cancer Society, approximately 65 % of the patients have tumours confined to the kidney at diagnosis. 
For this group, the 5-year survival rate is 93 % (stage I, II). If kidney cancer has spread to surrounding 
tissues or the regional lymph nodes (stage III), the 5-year survival rate is 69 %. If the cancer has 
distant metastasis (stage IV), the 5-year survival rate is 12 % [26]. 
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1.3.1.5 Obesity is an uncertain predictive factor for RCC 
Although being overweight is an established risk factor for developing kidney cancer [2, 27], renal 
tumours growing in an obese microenvironment may exhibit less aggressiveness. A meta-analysis 
involving retrospective data from 20 cohort studies reported an improved recurrence-free survival in 
RCC patients with BMI ≥25 kg/m2 prior to nephrectomy compared with those with BMI <23 kg/m2 
(HR = 0.49, p = 0.14) [3]. Consistently, a prospective multi-centre randomised controlled trial 
reported that there was an insignificant prolongation of the disease-free survival, and a decrease of 
lymphatic spread with increasing BMI, for patients who were diagnosed with high risk ccRCC [28]. 
However, there are discrepancies regarding the prognostic influence of being overweight on specific 
histological subtypes of non-metastatic RCC. For example, as was shown by a large cohort study 
using multivariate analyses, increased BMI was significantly associated with higher recurrence-free 
survival and cancer-specific survival rates in patients diagnosed with ccRCC (HR = 0.94 and 0.875, 
respectively). In contrast, in patients with chromophobe RCC, increased BMI was associated with 
poor prognosis, whereas no significant correlation was found between the prognosis of papillary RCC 
and BMI [29].  
The promising prognostic role of obesity was reconfirmed when visceral fat instead of BMI was 
measured to reflect the degree of obesity. For example, retrospective data from 2187 patients 
diagnosed with RCC between 1994 and 2012 in Korea demonstrated that a larger visceral fat area 
was predictive of better prognosis, as the median cancer-specific survival length for patients with 
visceral obesity was 26.1 months longer than those with smaller visceral fat area (p=0.006) [30]. The 
promising predictive role of preoperative visceral obesity was consistent with results from two studies 
in Japan with smaller sample size. In the earlier retrospective study, the RCC five-year recurrence-
free survival was higher in patients with larger visceral fat area compared those with smaller area 
(HR = 1.974, p = 0.042) [31]. In the other study, a large visceral fat area (≥100 cm2) demonstrated a 
significant correlation with the better prognosis of metastatic RCC (HR = 0.625, p = 0.029) [32]. 
However, data from another retrospective study in Korea including 706 RCC patients who underwent 
nephrectomy showed that both the highest and the lowest visceral adipose/total adipose ratios were 
correlated with a high chance of recurrence, with significant HR values being 4.760 and 3.198, 
respectively. Additionally, a high visceral adipose/total adipose ratio was associated with high grade 
of tumours at diagnosis (HR = 1.023, p = 0.037), further challenging the promising prognostic role 
of visceral obesity [33].  
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1.3.1.6 Advances in biomarker discovery in RCC 
The first-line therapies for advanced ccRCC target the VHL-HIF-VEGF signaling pathway [34]. 
However, responses to the targeted agents vary between individuals. Understanding the association 
of altered gene/protein expression with aggressiveness of cancer and treatment responses advances 
targeted therapy. For example, Choueiri et al. found that outcomes of metastatic ccRCC patients 
treated with targeted tyrosine kinase inhibitors sunitinib and pazopanib worsened with increased PD-
L1 expression in tumour tissues [35]. The finding boosted a series of clinical trials to further evaluate 
the effects of systematic treatment for ccRCC by including PD-L1 inhibitors [36].  
Research into other histological biomarkers is also underway to further improve the accuracy of 
diagnosis and treatment responses. For example, results from IHC indicate that GRP78, an ER stress 
resident protein, is a promising prognostic marker for ccRCC. Fu and colleagues tested GRP78 
expression in renal tumour tissues and adjacent non-tumourous renal tissues from 42 Chinese ccRCC 
patients and found GRP78 expression was significantly higher in renal tumour tissues than in the 
adjacent non-tumourous renal tissues. Moreover, they found the level of GRP78 expression was 
positively correlated with later TNM stages and larger tumour sizes [37]. Targeting ER stress by 
turning on its pro-apoptotic signaling may compromise the failed anti-tumour effect of other 
treatments. For example, mutation of p53 (the tumour guardian gene) is a shared feature for ccRCC, 
papillary RCC and chromophobe RCC [14]. Research by Schwarzenberg et al. identified that the 
proteasome inhibitor bortezomib could overcome the resistance of RCC against troglitazone, which 
targets apoptosis mediated by the peroxisome proliferator-activated receptor γ (PPARγ)-p53 
signaling pathway [38]. 
1.3.2  ER stress and cancer 
1.3.2.1 A brief introduction to the structure and function of the ER 
The ER network is a continuous lipid double-layered system comprising a nuclear envelope, 
peripheral ER and cortical ER. The peripheral ER comprises two sub-domains which are functionally 
and morphologically different: peripheral ER sheets and peripheral ER tubules. The primary 
difference in structure is that ER sheets are flat and studded with ribosomes while ER tubules are 
highly curved and largely lack ribosomes. Hence, ER sheets and ER tubules are often termed rough 
ER and smooth ER, respectively. Having partly flat and rough, or partly high curved and smooth 
surfaces, the cortical ER is tethered to the plasma membrane and works as a mediator of Ca2+ 
concentration between the ER lumen and the extracellular environment, which regulates muscle 
contraction [39]. This elaborate internal membrane system has a series of specialized functions: (1) 
secretory protein synthesis, modification, quality control and transportation; (2) lipid synthesis and 
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distribution; (3) sterol synthesis; (4) Ca2+ storage and regulation; and (5) interior 
compartmentalisation and interconnection within cells [40]. The variation of the abundance of the ER 
is likely related to the heterogeneity in functions of different cells. For example, the ER structure is 
rare in cells of the thin limb of Henle’s loop in the kidney, which plays a non-significant role in 
electrolyte transport [41]. However, in podocytes in Bowman’s capsule of the glomeruli, where there 
is active Ca2+ flow, the ER is abundant [42]. 
1.3.2.2 ER quality control mechanism 
The protein folding process is inherently error-prone [43]. Environmental stress such as ultraviolet 
light exposure, depletion of Ca2+, osmotic stress, oxidative stress, and deprivation of nutrients in 
pathological conditions such as malignancy, increase the accumulation of improperly folded 
polypeptides [44]. If they are not removed from the ER via a process known as ER-associated 
degradation (ERAD), the partially folded or misfolded polypeptides are susceptible to aggregation in 
disordered structures, which are toxic to the cell [45]. Providentially, the ER has an orchestrated 
quality-control system to facilitate the processes of protein folding and misfolded protein degradation, 
in which adenosine triphosphate (ATP)-dependent chaperones, also known as heat shock proteins 
(Hsps), play a crucial role [46, 47]. For example, GRP78, a 70 kDa protein which binds to the 
hydrophobic surface of the non-native proteins and cooperates with Hsp110, is capable of interfering 
with protein aggregation [48], assisting the unfolding and refolding of misfolded protein [49, 50]. 
GRP78 also keeps the stability of unfolded proteins until they are competent for the correct folding 
process under normal conditions [51]. Despite the support offered for primary quality control by all 
of the above factors, many newly synthesized proteins end up misfolded. The unwanted misfolded 
proteins are recognised and then retro-translocated to the cytosol for ultimate degradation by the 
ubiquitin-proteasome pathway, as a secondary quality control [52]. Misfolded proteins are flagged by 
glycosylation with a specific oligosaccharide structure (Man7GlcNAc2 with α 1, 6-linked mannosyl 
residual) [53]. The mannose-6-phosphate receptor homology domain of osteosarcoma amplified 9 
(OS-9), an ER-resident lectin, recognises α 1, 6-linked terminal mannose [54, 55]. OS-9 interacts 
with the 3-hydroxyl-3-methylglutaryl-coenzymeA reductase degradation ligase for ubiquitination 
[56]. Finally, ubiquitinated proteins are recognised and degraded by the 26S proteasome [57].  
If the ERAD is insufficient, the ER will be congested with immature proteins in a process known as 
ER stress, initiating a complicated and dynamic signaling network which enhances the resistance of 
cells to ER stress and is collectively known as the unfolded protein response (UPR) [58] (Fig 1.2).  
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1.3.2.3 Signaling cascades elicited by UPR 
There are three ER stress proximal transducers: activating transcription factor-6 (ATF6), double-
stranded RNA-activated protein kinase/PKR-like ER kinase (PERK), and inositol-requiring enzyme 
1 (IRE-1), which all have binding sites for GRP78. In unstressed cells, the stress transducers are 
maintained in an inactivated state by GRP78 so as to block their activity. Under ER stress, GRP78 
dissociates from these ER-residential proteins to initiate downstream cascades [59] (Fig 1.2). ATF6 
is the only transducer that departs the ER via translocation in the membrane of the Golgi [60]. ATF6 
signaling functions to enhance protein folding and degradation capacity. Upon translocation from the 
ER to the Golgi apparatus, ATF6 undergoes structural modifications which release a cytosolic 
fragment, pATF6 (N) [61]. PATF6(N) then moves into the nucleus to activate the transcription of 
genes encoding most ER chaperones and some ERAD components [62].  
PERK signaling decides the cell fate after exposure to ER stress. Upon ER stress, PERK 
phosphorylates eIF2α (eukaryotic translation initiation factor 2α) and consequently deactivates 
eIF2B. This results in blocking guanosine triphosphate (GTP)-dependent transportation of the 
initiator Met-tRNAi
Met to the rough ER, which consequently downregulates global translation. 
Activated eIF2 also inhibits the influx of nascent polypeptides into the ER [63]. The immediate result 
of this translation inhibition is a reduction in the rates of global protein synthesis, which saves energy 
consumption when oxygen and ATP levels are low. Although PERK signaling reduces the synthesis 
of most proteins, it preferentially increases the biosynthesis of some proteins that can help cells 
survive in stressed conditions, for example, inhibitor of Bruton’s tyrosine kinase α (IBTKα), growth 
arrest and DNA-damage-inducible protein (GADD34) and Gcn4p. Alternatively, PERK signaling 
may increase the biosynthesis of some proteins that induce cell death (e.g. ATF4) if the stress is 
irreversible. IBTKα can protect cells from caspase3/7-dependent cell death [64]. Activated ATF4 
induces the expression of C/EBP homologous protein (CHOP), also known as growth arrest and 
DNA-damage-inducible protein 153 (GADD 153), which can induce the apoptotic pathway [65]. In 
contrast, activated ATF4 and CHOP also conjointly target genes, such as GADD 34, that relieve 
translation attenuation for recovering cells from stress [66]. Similarly, Gcn4p enhances biosynthesis 
of amino acids, which helps cells withstand starvation [67]. In addition, PERK inhibits the synthesis 
of cell cycle regulators, such as cyclin D1, resulting in cell cycle arrest in the G1 phase [68]. 
Consequently, if the UPR is transient, these adaptive responses promote cell survival. However, if 
the UPR is prolonged, overconsumption of nutrients and energy during protein synthesis causes 
oxidative stress which can further enhance protein misfolding by interfering with disulphide bond 
formation during protein folding [68]. This effect is enhanced by the pro-apoptotic influence of CHOP 
that, together with a prolonged UPR, pass the molecular thresholds for induction of apoptosis. 
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 In the case of inositol-regulating enzyme 1 (IRE1), dissociation from GRP78 initiates the 
phosphorylation and dimerization of IRE1. This in turn results in removal of a 26 nucleotide intron 
from X-box binding protein 1 (XBP1) mRNA, leading to the synthesis of the isoform XBP1(S), which 
translocates into the nucleus to induce the upregulation of its target genes. The protein products of 
these genes facilitate every aspect of the secretory pathway ranging from protein folding and entry of 
 
Fig 1.2 ER stress and UPR 
When newly synthesized proteins translocate into the ER lumen, they rapidly associate with chaperone proteins 
that facilitate protein folding. Upon adopting the native state, proteins are released from the ER to pass down 
the secretory pathway via the Golgi. Proteins that fail to adopt their native conformation are eventually 
degraded by the proteasome. This process is called ERAD. The protein folding process is error prone. 
Approximately 70 % of the nascent polypeptides end up misfolded even with the assistance of ER chaperones. 
If the loading of the misfolded proteins exceeds the capacity of ERAD, the ER lumen will be crowded with 
misfolded proteins, and this situation is called ER stress. Under ER stress, three signaling molecules IRE1, 
ATF6 and PERK are released from the core ER stress protein GRP78, thereby initiating the UPR, which 
inhibits translation, blocks the entrance of nascence polypeptides, helps the processes of protein folding and 
ERAD, and ultimately relieves ER stress and maintains cell survival. However, if the ER stress is irreversible 
and becomes chronic, UPR can trigger signaling pathways that induce cell death.  
Abbreviations: ATF, activating transcription factor; ER, endoplasmic reticulum; ERAD, ER-associated 
degradation; GRP, glucose-regulated protein; IRE, inositol-regulating enzyme; PERK, double-stranded RNA-
activated protein kinase/PKR-like ER kinase, UPR, unfolded protein response 
  
13 
proteins into the ER to ERAD [44, 69]. IER1α is another branch of the UPR that can convert pro-
survival ER stress to pro-apoptotic ER stress, depending on the activation of c-Jun amino-terminal 
kinase (JNK) [70]. The prolonged activation of JNK is known to induce tissue and stimulus-specific 
apoptosis through mitochondrial-dependent caspase activation [71]. Unlike the broad expression of 
IRE1α, IRE1β is exclusively expressed in intestinal and bronchial epithelial cells [71]. In contrast 
with the high cleavage activity of IRE1α against XBP1 mRNA, the RNase domain of IRE1β has 
higher cleavage potential against 28S ribosome RNA, which may cause apoptosis [72]. Regarding 
the cell protective role, IRE1β is required for the production of mucins (Muc5b and Muc5ac) in the 
respiratory tract [73] and Muc2 in the goblet cells in the colon [74]. Consistent with the dual functions 
of the PERK branch of the UPR, the existence of IRE1 signaling further indicates that the UPR, which 
had been thought to be pro-survival under ER stress, could also induce cell death when ER stress is 
persistent and harmful. Hence, targeting apoptotic ER-stress induced pathways might be effective in 
eliminating unwanted cells, such as tumour cells. 
1.3.2.4 Activation of ER stress as an adaptive behaviour of cancer cells  
Due to uncontrolled proliferation, cancer cells often live in a condition with insufficient oxygen and 
nutrition accompanied by an upregulation of HIF-1. As discussed previously, HIF-1 promotes 
tumourigenesis. Additionally, HIF-1 decreases ATP consumption during glycolysis via stimulating 
the gene expression of pyruvate dehydrogenase kinase, which inhibits pyruvate dehydrogenase [75]. 
Hence, cancer is known to inherently maintain a highly efficient proliferation rate when confronting 
hypoxia [76]. Apart from assisting the pro-survival signaling in tumourigenesis, the hypoxic stress 
also activates the IRE1 and PERK arms of the UPR, which launches downstream cascades to increase 
insensitivity of tumour cells towards pro-apoptotic signaling [77] (Fig 1.3). The activation of ER 
stress in response to oxygen-glucose deprivation has been reported in previous studies. For example, 
in primary cultures of mixed rat brain cortical cells which were deprived of oxygen and glucose, the 
PERK-eIF2α and IRE1-XBP1 branches of the UPR were stimulated [78]. In the context of tumours, 
the upregulation of GRP78 was also related to glucose depletion [79].  
1.3.2.5 ER stress levels in cancers  
It has now become clear that the activation of ER stress is a common phenomenon in tumourigenesis 
[80-82]. The altered expression of ER stress proteins has been observed in various cancer types, 
including lung [83], breast [84], colon [85], gastric [86], pancreatic [87], liver [88, 89], prostate [90, 
91], kidney [37], skin [92], uterine [93], and ovarian cancers [94], leukaemia [95], myeloma [96] and 
glioblastoma [97]. 
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GRP78 is the common UPR component that has upregulated expression in most of the tumour tissues 
as mentioned previously. The activation of GRP78 correlates with the severity and prognosis of 
cancer. For example, the activation of a rarely known splicing variant of GRP78, GRP78va, as a result 
of unleashing PERK signaling, is associated with enhanced viability of leukaemic cells [98]. The 
cancer supporting role of PERK signaling has been revalidated in other research. Meixia et al. found 
that xenograft tumours grown from Ki-RasV12 and Ha-RasV12-transformed mouse fibroblasts with 
wild-type PERK-eIF2α-ATF4 were 6 times larger than tumours with a compromised PERK-eIF2α-
ATF4 pathway, suggesting that inhibiting PERK-eIF2α-ATF4 activity inhibits the growth of tumours 
[82]. The silencing of IRE1β, however, may contribute to the carcinogenesis of colorectal cancer, 
which is characterised by a dysregulated expression of mucins [99], because the integrity of IRE1β 
is crucial for the normal characterisation of Muc2 in the colon [74]. Consistently, it has been found 
that there was a downregulated IRE1β expression in colorectal adenocarcinomas compared with 
normal colon [100]. Clinical studies based on archived tumour tissues demonstrate that the expression 
levels of specific ER stress markers can work as predictors of cancer (summarised in Table 1.1). 
1.3.2.6 The immune-surveillance sabotage mediated by hyperactive XBP1 signaling  
Blunted anti-cancer immunity is an underlying process of cancer development. By means of utilizing 
ER stress, tumours may successfully suppress or evade immune scavenging [76]. In physiological 
conditions, tumour-irrelevant CD8+ dendritic cells constitutively activate the IRE1-α/XBP1 axis 
without triggering the UPR cascades, and so regulate the gene expression that maintains ER 
homeostasis and the phenotype of dendritic cells. Furthermore, intact IRE1-α/XBP1 signaling plays 
a significant role in the cross-presentation by CD8+ dendritic cells [101]. Overexpression of XBP1 
has been discovered in tumour-associated dendritic cells in aggressive cancers. This overexpression 
has negative effects on the function of dendritic cells in the tumour microenvironment [102]. For 
example, Cubillos-Ruiz et al. [94] found that the expression of the spliced XBP1 was positively 
correlated with the volume and weight of ovarian tumours in murine models. They further found the 
lipid peroxidation product 4-hydroxy-trans-2-nonenal in ovarian cancer-associated dendritic cells 
stimulated the production of XBP1. The dendritic cells which were devoid of XBP1 demonstrated 
significant suppression of genes, such as Agpat6, Fasn, Scd2, and Lpar1, which are involved in lipid 
metabolism pathways, and genes such as ATF6, Sec61α1, Pdia4, Sec24, which are involved in the 
ER stress response. Large intracellular lipid bodies were only found in the XBP1-sufficient dendritic 
cells but not in the XBP1-deficient cells. The accumulation of triglyceride in bone-marrow derived 
dendritic cells decreased the surface expression of the major histocompatibility complex-1 (MHC-1) 
which was loaded with ovalbumin-derived peptide epitope, thus hindering the activation of CD8+ T 
cells. The immune sabotage of XBP1 is revalidated in XBP1 deficient mice where the T cells 
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exhibited enhanced capacity to hamper tumour growth. Moreover, silencing IRE1α/XBP1 signaling 
prolonged survival of mice bearing aggressive orthotopic ovarian tumours. These results collectively 
indicate that the XBP1-dependent turbulence of lipid metabolism contributes to the dysfunction of 
dendritic cells, which weakens the T-cell mediated anti-tumour responses (Fig 1.3).  
1.3.2.7 Cancer killing potential of the UPR by interfering with the cell cycle  
The presence of cell cycle-mediated cancer resistance is a great challenge for antitumour therapies 
[103]. The UPR facilitates the tumouricidal treatment by blocking cell cycling of cancer cells. 
Upregulation of the G1/S phase regulator, cyclin D1, in G1 phase is found in various malignant 
neoplasms [104-109]. As is shown by Brewer et al., PERK-eIF2-ATF4 signaling activated by 
tunicamycin (an ER stress inducer) inhibits the translation of cyclin D1, thereby inhibiting cyclin D1 
forming a complex with cyclin dependent kinase (CDK). Thus, the retinoblastoma protein is not able 
to be phosphorylated, which results in cell-cycle arrest in G1 phase [68]. It is worth noting that the 
G1 phase arrest mediated by the UPR may lead to resistance to agents that target the succeeding 
phases of cell cycle, indicating the importance of selecting the appropriate therapy when the intact 




Fig 1.3 Dual roles of UPR in cancer 
Cancer cells often live under hypoxic conditions which activate the IRE1 and PERK branches of the UPR to 
support cancer growth. On the one hand, cancer cells exploit the prosurvival UPR signaling to conquer the 
lethal effect of treatments. On the other hand, upregulated XBP1 induces the accumulation of TG in dendritic 
cells, which decreases the expression of the MHC1, thereby hindering the activation of CD8+ T cells. The 
immune sabotage of XBP1 contributes to a blunted immune elimination of cancer cells. In contrast, the G1 
phase arrest of cancer cells is also related to the activation of the PERK branch of the UPR, suggesting that 
UPR has dual roles in determining the fate of cancer cells. 
Abbreviations: ATF, activating transcription factor; CDK, cyclin dependent kinase; CTL, cytotoxic T 
lymphocyte; eIF2α, eukaryotic translation initiation factor 2α; IRE, inositol-regulating enzyme; MCH1, major 
histocompatibility complex1; PERK, double-stranded RNA-activated protein kinase/PKR-like ER kinase; TG, 
triglyceride; XBP1: X-box binding protein 1
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Table 1.1 Summary of the upregulation of ER stress markers in different human tumour 
types and the association with aggressiveness and prognosis of cancer 
















IHC  246 1. CHOP expression paralleled the 
GRP78 expression in adipocytes and in the 
tumour. 
2. High visceral adipocyte GRP78 
expression positively correlated with 
advanced-stage disease and deep 
myometrial invasion. 
3. High visceral adipocyte GRP78 
expression was significantly associated with 





42 1. GRP78 expression was 
significantly higher in RCC tissues 
compared with nontumourous renal tissues. 
2. The high levels of GRP78 mRNA 
expression and protein expression were 




GRP78 IHC  46 1. Patients with OSCC exhibited an 
upregulation of the expression of GRP78 
than the health control. 
2. GRP78 expression was positively 
correlated with tumour size, stage, grade, 
lymphatic invasion and distant metastasis. 
3. Positive GRP78 expression was 




GRP78 IHC  153 1. The intensity of the GRP78 
expression was markedly higher in the 
primary tumour compared with areas of 
benign epithelium. 
2. Patients with strong GRP78 
expression had higher risk of death and 


















52 1. Expression of HSP27, HSP70, 
HSP90, GRP78, and GRP94 increased along 
with the stepwise progression of 
hepatocarcinogenesis. 
2. There was a positive correlation 
between the expression of GRP78, GRP94, 
HSP90, and HSP70 and prognostic factors 
of hepatocellular. 









54 1. There was a significant 
overexpression of GRP94 and GRP78 in 
cancer tissues as compared to normal 
tissues. 
2. The overexpression of GRP94 and 
GRP78 was correlated with poor 
differentiation and late stage. 
Melanoma 
[115] 
GRP78 IHC 171 1. The IRS of GRP78 increased with 
the progression of melanoma. 
2. The IRS of GRP78 increased with 
increasing tumour thickness and with 
increasing dermal tumour mitotic index. 
3. Compared with patients whose 
IRS<25, patients with IRS≥25 had shorter 
disease-free survival and OS. 
4. The overexpression of GRP78 was 
not an independent predictor of disease-free 
survival or OS. 
Promising 
prognostic 














137 1. Significant higher mRNA levels of 
GRP78 were found in the well differentiated 
tumours as compared to moderately and 
poorly differentiated tumours. 
2. A strong GRP78 IHC staining was 
correlated with early tumour stage. 
3. A weak GRP94 IHC staining was 
correlated with early tumour stage and less 
lymph node involvement. 
4. A trend towards better prognosis 
was found in patients with high GRP78 and 




urinary tract  
[117] 
GRP78 IHC  126 1. There was a significantly higher 
incidence of GRP78 expression in low-grade 
invasive tumours than in high-grade invasive 
tumours. 
2. The overexpression of GRP78 was 









42 1. IRE1β expression was significantly 
lower in cancer tissues compared with 
nontumourous colorectal tissues. 
2. The low levels of IRE1β 
expression, RNA and protein expression 
were related to the presence of lymph node 
metastasis and high clinical stage. 
Abbreviations: ER, endoplasmic reticulum; GRP, glucose regulated protein; HSP, heat shock protein; CHOP, 
C/EBP homologous protein; IHC, immunohistochemical; FFPE, formalin-fixed, paraffin-embedded; RCC, 
renal cell carcinoma; RT-PCR, reverse transcription polymerase chain reaction; IRS: immunoreactivity score; 
OSCC, oral squamous cell carcinoma; OS, overall survival 
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1.3.3 Crosstalk between adipose tissue and cancer 
1.3.3.1 Characteristics of general and kidney tissue-specific adipose tissue 
Distributed throughout the body, adipose tissue is mainly stored subcutaneously and around large 
organs, such as the lungs, kidneys, heart, liver, stomach and intestines. It is also found in the bone 
marrow and surrounding the vascular adventitia [118]. Adipose tissue is composed mostly of 
adipocytes and includes stromal vascular fraction (SVF). The SVF constitutes pre-adipocytes, 
fibroblasts, immune cells, endothelial cells and vascular smooth muscle cells [119]. Factors secreted 
by these cellular components (known as adipokines) are crucial for adipose tissue to exert its functions 
as an endocrine organ. The cellular origin and functions of adipokines have been extensively reviewed 
previously [119]. The counterbalance between the anti-inflammatory and pro-inflammatory 
adipokines is crucial for maintaining the metabolic homeostasis. The changed secretory profile of 
adipose tissue under obesity can cause systemic metabolic disorder. For example, the secretion of the 
anti-inflammatory adipokine, adiponectin, is suppressed under obesity, which decreases insulin 
sensitivity and is correlated with greater risk of ischemic heart disease [120]. Insulin resistance is also 
observed when the secretion of another anti-inflammatory protein, secreted frizzled-related protein 5 
(SFRP5), is decreased in the obese adipose tissue [121].  
Except for sharing the above common features of white adipose tissue (WAT), brown adipose tissue 
(BAT) has a special morphological phenotype and subcellular microstructure. These characteristics 
of BAT correspond to their functional state. Early research in mammals discovered that there was a 
type of the brown-coloured adipose tissue existing for the lifetime of rodents and hibernating animals, 
which was catabolically active during exposure to the conditions of alarm or stress [122]. Aherne and 
Hull reported the distribution and morphology of BAT in human infants: occurring around the 
adrenals, kidneys, thyroid, thymus and oesophagus, BAT had rich capillaries and showed various 
amount of lipid locules in the cytoplasm of adipocytes. Moreover, they discovered that there were 
abundant mitochondria in cytoplasm where the lipid was depleted [123]. A later retrospective study 
based in Japan using samples from human perinephric adipose tissue demonstrated that brown 
adipocytes are located centrally in the fat lobules, surrounded by a layer of unilocular white 
adipocytes. Moreover, the content of BAT decreased with aging, as characterised by the multilocular 
brown adipocytes gradually being replaced by the unilocular white adipocytes [124, 125].  
The adipokine secretory profile of BAT is distinct from that of WAT. Although there has not been a 
confirmed factor that is exclusively produced by BAT, the brown fat adipokines are crucial for BAT 
to exert its metabolic functions [126]. For example, BAT is known to produce the active thyroid 
hormone, triiodothyronine, which contributes to the thermogenesis of brown adipocytes after 
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exposure to noradrenaline and cold [127]. Fibroblast growth factor 21 (FGF-21) is another 
upregulated brown fat adipokine during exposure to cold, which is responsible for promoting glucose 
oxidation and improving dyslipidaemia [128]. The thermogenic activation in BAT also favours an 
anti-inflammatory phenotype shift of the adipose tissue macrophages via an IL-4 dependent manner 
[129]. This change will potentially influence the immunomodulation of adipose tissue. Although the 
secretory pattern of brown perinephric adipocytes is unknown, data indicate that the specificities of 
the kidney-specific adipose tissue may affect the progression and prognosis of kidney-related diseases. 
For example, it was recently found that the secretion of neuregulin 4, a healthy metabolic modulator, 
was decreased in BAT under chronic kidney disease [130, 131]. The secretory profile of BAT remains 
elusive in cases of kidney cancer, however data is available that the content of peri-adrenal BAT was 
positively correlated with high incidence of cancer-induced cachexia [132]. Future research is 
warranted to detect the possible relationship between the secretory pattern within the kidney tissue-
specific adipose tissue and progression of the kidney cancer.  
1.3.3.2 Nutritional status and survival of cancer 
Due to the growing awareness of the metabolic functional change after weight gain and weight loss, 
there is an increasing interest in studying the interplay between tumour-associated adipose tissue and 
tumour progression. In the real-world setting, the “obesity paradox” is not limited to kidney cancer. 
Growing evidence suggests that malnutrition can increase risk of cancer-associated mortality [133, 
134]. For example, results from a retrospective study including 1,762 participants diagnosed with 
various types of cancer (including colon/rectal, respiratory, pancreatic, oesophageal, stomach and 
kidney cancer) demonstrated that low total adipose tissue index was an independent mortality risk 
factor (adjusted HR=1.26, p<0.001) [135]. To date, most research has focused on the catabolic effect 
(e.g. lipolysis) of cancer-associated cachexia on adipose tissue and on the contributory roles of 
adipose tissue in tumour development [136]. However, there appears to be an antagonistic feedback 
from adipose tissue to cancer cells under an obese microenvironment, which remains elusive. 
1.3.3.3 Link between obesity and cancer 
There is strong evidence supporting cancer as an obesity-associated complication [137]. Multiple 
mechanisms (for example, inflammation, lipid metabolism and macrophage biology) bridge obesity 
and cancer. Firstly, chronic low-grade systemic inflammation is probably the most well-known player 
linking obesity and cancer. The secretion of pro-inflammatory adipokines, such as C-reactive protein, 
IL-6, tumour necrosis factor/TNF and IL-17 are increased under obese conditions [119, 138]. Results 
of a recent meta-analysis demonstrate that the circulatory upregulation of IL-6, TNF α and leptin is 
positively associated with aggressiveness of various types of cancer, including breast, endometrial, 
ovarian, kidney and colorectal cancer and multiple myeloma [139]. The pro-proliferative effect of 
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inflammation facilitates cancer development via promotion of angiogenesis and survival of cancer 
cells. The mechanism is related to the activation of signaling pathways that can support cell 
proliferation and angiogenesis or inhibit apoptosis. Such pathways include the IL-6/signal transducer 
and activator of transcription 3 (STAT3) and TNF α/nuclear factor κB (NFκB) signaling pathways 
[140]. Moreover, obesity-associated inflammation can induce genomic instability and interfere with 
DNA repair, therefore favouring tumourigenesis [141]. Secondly, obesity-associated inflammation 
provides connections between energy metabolism and cancer development. For example, the 
proinflammatory cytokine, IL-17A favours the uptake of palmitic acid by ovarian cancer cells, 
therefore promoting their proliferation [142]. Finally, obesity and cancer are also linked through the 
immune mechanism. For example, obesity reconstitutes the mammary adipose tissue, characterised 
by an increased density of myofibroblasts (labelled by α–smooth muscle actin/α-SMA) [143]. In vivo 
immune phenotype detection uncovered that the obesity-mediated ECM remodelling was causally 
associated with an increased infiltration of M2 macrophages which demonstrated an upregulated 
expression of angiogenic genes [144]. 
1.3.3.4 Characteristics of tumour-associated adipose tissue 
Adipose tissue has high plasticity in response to different pathophysiological conditions, including 
cancer [118]. As an important component of the tumour stroma, adipose tissue grown in proximity to 
cancer cells undergoes dramatic changes in morphology, lipid metabolism and secretory profile [145]. 
Such alterations shape the tumour-modified adipocytes into a specific phenotype, which is named as 
cancer-associated adipocytes [146]. The close coordination between adipocytes and cancer cells is 
crucial for mediating the progression of cancer, resulting in significant adipose tissue remodelling in 
cancer-associated cachexia (Fig 1.4). 
The tumour microenvironment could induce the dedifferentiation of adipocytes. In the invasive edge 
of breast cancer, the size and lipid content of adipocytes were less than which was seen distant from 
the tumour [147]. Using an in vitro model, the process of delipidation was reconfirmed when the 
expression of adipocyte markers (for example, FABP4 and adiponectin) was decreased in adipocytes 
co-cultured with breast cancer cells [148]. The liberated lipids can fuel the growth of cancer cells. 
The free fatty acids released by adipocytes can be translocated into nearby cancer cells where the 
gene expression involved in lipogenesis is upregulated [149]. Huang and colleagues have found a 
mechanism that may explain the reverse lipid metabolism in cancer cells and adipocytes [150]. Huang 
et al. found adipogenesis and lipid metabolism related genes, for example, genes coding for 
mammalian target of rapamycin receptor complex 1 (mTORC1) and peroxisome proliferator-
activated receptor α (PPARα), were suppressed in adipocytes but upregulated in cancer cells. This 
change, favoured energy utilisation of cancer cells while saving energy consumption in the adipose 
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tissue. They further found the lipid metabolic remodelling aggravated the invasive capacity of 
prostate cancer cells in a mouse model, which was dependent on the activation of the CPT1A (a 
PPARα target gene)-osteopontin/Spp1 signaling pathway when the upstream gene P62 was silent. 
Moreover, the macrophages infiltrated in P62 ablated adipose tissue were reprogrammed from M1 to 
M2, which may synergise the metastasis of tumour cells [151]. 
Cancer-associated adipocytes exhibit a fibroblast-like phenotype, promoting invasiveness of cancer 
through regulating the secretion of both soluble factors and extra-cellular matrix (ECM) molecules. 
Muller and her team found both the gene and protein expression of IL-6 and matrix 
metalloproteinases-11 (MMP-11) was significantly higher in the breast cancer-associated adipose 
tissue compared with those from healthy donors [148]. In their research, the adipose stroma-derived 
IL-6 exerted a pro-invasive effect on cancer cells. The ECM protease MMP may synergise the pro-
invasive effect of IL-6 by facilitating cancer cells to overcome the ECM barrier [152, 153].  
Loss of WAT during cachexia is a common comorbidity in late stage of malignant cancer [154]. 
Treatment with IL-6 receptor antibody rescued the atrophy of adipocytes, decreased the serum free 
fatty acid levels and downregulated the expression of uncoupling protein-1 (UCP-1) in the WAT of 
the colon cancer cachexia mice model, indicating the lipolysis and browning of adipose tissue in late 
stage of cachexia might be IL-6 signaling pathway dependent [155]. Cancer cachexia also activates 
the fibrotic remodelling of adipose tissue. For example, Alves and colleagues found using IHC that 
the ECM proteins, for example, collagen, fibronectin and elastin, were upregulated in the 
subcutaneous adipose tissue from cachectic patients with gastrointestinal cancer compared with 
weight-stable controls. αSMA staining and fibroblast-specific protein 1 (FSP1) expression showed in 
cachectic patients that there were more myofibroblasts around the adipocytes, which contributed to 
the activation of the TGF β signaling pathway [156]. The increased ECM promotes the M2 




Fig 1.4 Characteristics of tumour associated adipose tissue in cancer cachexia 
In the adipose tissue at late stage of cachexia, adipocytes with atrophic morphology have an active browning 
process, as demonstrated by an upregulated UCP-1. Tumour associated adipose tissue and the tumour exhibit 
opposite profiles of lipid metabolism: the adipogenesis and lipogenesis is suppressed in the adipose tissue 
whereas the catabolic process is activated in cancer cells. This change is dependent on downregulation of an 
autophagy adaptor P62 in the adipose tissue and related to a reverse modulation of mTROC1 and PPAR α: 
downregulation in adipocytes and upregulation in cancer cells. The downstream cascades of PPAR α promote 
cancer metastasis through a PPAR α-CPT1A signaling pathway, which increases synthesis of OPN. Tumour-
associated adipose tissue accumulates increased ECM components as a result of an activated TGF β-smad 
signaling pathway. The remodelling of tumour associated adipose tissue is also characterised by an increased 
infiltration of M2 macrophages, which may facilitate invasion of the tumour through activating EMT. The 
proinflammatory adipokines (e.g IL-6 and TNF α) activate IL-6-JAK-STAT3 and TNF α-NFκB signaling 
pathways, and collectively exert pro-tumourigenic and anti-apoptotic effects. 
Abbreviations: ECM, extra cellular matrix; EMT, epithelial mesenchymal transition; JAK, Janus Kinase; 
mTORC, mammalian target of rapamycin receptor complex; NFκB, nuclear factor κB; OPN, osteopontin; 
PPAR, peroxisome proliferator-activated receptor; STAT, signal transducer and activator of transcription; 
TGF, transforming growth factor; TNF, tumour necrosis factor; UCP, uncoupling protein; VEGF, vascular 
endothelial growth factor 
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1.3.3.5 Adipose derived stem cells promote cancer metastasis 
Mesenchymal stem cells (MSC) are known to support the migration of endothelial cells in vitro via a 
paracrine manner [158]. The increased migration capacity of endothelial cells in tumour stroma is a 
proangiogenic feature, which facilitates intravasation [159]. Hence, there is an increasing interest in 
investigating the role of adipose tissue derived mesenchymal stem cells (ASC) in promoting the 
invasion of cancer cells [160]. For example, a group of Chinese scientists recently reported that 
conditioned medium from murine ASC promoted the invasiveness of breast cancer cell lines, 
accompanied by the upregulation of VEGF. Moreover, they found the stem cell factor (SCF) secreted 
by ASC caused the downregulation of microRNA 20b (miR 20b), known to display tumour 
suppressor gene characteristics. Chromatin immunoprecipitation (Chip) assay showed that the 
promoter region of miR 20b had a binding site to E2F transcription factor 1 (E2F1) which was 
exported from the nucleus after activation of the SCF-mitogen activated protein kinase (MAPK)-P38 
signaling pathway. Silencing of P38 or upregulating miR 20b blocked the SCF-induced invasion of 
cancer cells [161].  
1.3.3.6 Adipocytes impede the metabolism of chemotherapeutic agents 
Recently, there has been recognition that adipose tissue is involved in drug catabolism [162]. For 
example, a promising anti-cardiovascular disease agent, anacetrapib, was retained in the adipose 
tissue, inducing a prolonged and unwanted half-life. The drug was, therefore, banned from entering 
the market [163]. In the case of cancer chemotherapy, adipocytes were able to quickly absorb and 
catabolise daunorubicin into daunorubicinol which had less cytotoxicity [164]. The researchers 
demonstrated the abundant expression of daunorubicin-metabolising enzymes (e.g. aldo-keto 
reductases and carbonyl reductases) in adipocytes compared with other cell types, however they did 
not compare these enzymes in adipocytes derived from obese and lean donors. Hence, deductions 
could not be made regarding whether the distinct anti-cancer drug responses between the obese and 
lean individuals were directly related to the different distribution of drug metabolising enzymes in 
adipocytes [165]. Future research is warranted to investigate the crosstalk between adipose tissue and 
cancer prognosis from the angle of drug metabolism. 
1.3.4 The role of macrophages in the tumour microenvironment 
1.3.4.1 Tumour-associated macrophages - the allies of tumour cells 
Macrophages can constitute up to 50 % of the solid tumour mass [166]. Most evidence suggests that 
the number of macrophages in tumour tissue is associated with poor cancer prognosis [167]. 
Typically, however, macrophages are responsible for cell killing [168]. As efficient phagocytic 
leukocytes in the innate immune response, monocytes migrate across vascular walls, then activate to 
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macrophages to engulf invading pathogens in infected tissue mediated by a system of receptors on 
macrophages [169]. Upon binding to the helper T lymphocytes (Th1, CD4+), the interferon-gamma 
(IFN-γ) receptors on macrophages are activated, which enables the macrophages to release lysosomal 
enzymes and nitric oxide to destroy microorganisms within the phagolysosome [170]. However, in 
the case of cancer, tumour-associated macrophages (TAM) do not phagocytose cancer cells. Instead, 
they are disguised as allies of tumour cells, hampering the anti-tumour effects of CD8+ cytotoxic T 
lymphocytes [171] and promoting angiogenesis both in the primary site of tumour and in the pre-
metastatic niches (PMN) [172].   
1.3.4.2 The subtypes and origin of macrophages 
The application of flow cytometry and fate-mapping techniques enables us to better distinguish the 
individual components of the macrophage system. In a broad sense, macrophages compromise two 
subsets: infiltrating macrophages; and tissue-resident macrophages. Macrophage infiltration only 
happens at the site of pathologies, such as plaques in atherosclerosis [173] and adipose tissue in 
obesity [174]. Those infiltrating macrophages originate from circulating monocytes [168]. Tissue-
resident macrophages are located throughout all tissues and they are often named specifically based 
on their location (e.g. mesangial cells in the glomeruli of kidneys, osteoclasts in bone, Kupffer cells 
in liver) [175]. The tissue-resident macrophages are crucial for the organogenesis and homeostasis of 
different organs [176, 177]. 
There has long been a dogma that all macrophages are derived from monocytes and originate from 
adult heamatopoietic stem cells (HSC) [178]. In fact, only the circulating monocytes originated 
entirely from HSC; most tissue resident macrophages originate from yolk sac-derived erythro-
myeloid progenitors. They are minimally replaced by HSC-derived cells at different stages after birth 
in mice [179]. The maturation of fetal macrophages does not require the transcription factor, Myb, 
which regulates the proliferation of HSC [180]. Tissue-resident macrophages have life-long in situ 
self-renewing capacity, which is CSF dependent but IL-4 independent [168]. Hence, tissue-resident 
macrophages and infiltrating macrophages have distinct lineages. Studies exploring the origin of 
human TAM are limited. Using immunofluorescent staining for three cases of invasive secondary 
tumours (including breast, liver and oral mucosal cancer) after sex-mismatched bone marrow 
transplantation, Kurashige et al. found CD163+ TAM are originated from bone marrow (mainly 
contributed by the donor) [181]. Additionally, they found the macrophages in non-tumour tissue are 
completely replaced by bone marrow-derived cells, which is different from the findings in mice [179]. 
The discrepancy may be due to the longer life span of humans and a disruption of homeostasis by 
radiation therapy in their experiments. 
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1.3.4.3 Macrophage reprogramming in the tumour microenvironment 
Macrophages have strong plasticity in response to different tumour microenvironment as 
demonstrated by a reprogramming of their immune phenotype (M1 or known as classically-activated 
macrophages and M2 or known as alternatively-activated macrophages) [182]. Although being 
criticised for its oversimplification, educating macrophages with specific chemokines (e.g. INFγ and 
lipopolysaccharide, LPS for M1; IL-4 and IL-13 for M2) is still widely applied and accepted to 
generate polarised macrophages in vitro to mimic the in vivo macrophage reprogramming [183]. The 
immune phenotype of macrophages in the tumour microenvironment is orchestrated by complicated 
signaling pathways and interaction with stromal cells.  
As a downstream product of many cancer gene mutants (e.g. p53), the level of IL-6 is often high in 
the tumour microenvironment [184]. IL-6 exerts tumourigenic effects mainly through the IL-6-STAT 
signaling pathways [185] Additionally, IL-6 induces macrophage differentiation from monocytes and 
is also a product of differentiated macrophages [186]. IL-6 is also an important mediator of 
macrophage polarisation. For example, IL-6 activates the alternative macrophage polarisation 
through upregulating IL-4 receptors in mice and sensitising the IL-4-pSTAT6 effects on 
macrophages, causing an upregulation of genes associated with M2 macrophages, including Mrc1, 
Arg 1, IL-10 and Retnla [187]. The upregulation of these M2 macrophage-associated genes was also 
observed in the murine macrophages bearing JNK1 and JNK2 mutations. The M1 macrophage-
associated genes, including cd11c, IL-1β, Il6, Nos2 and TNF α, were downregulated in this situation, 
indicating the JNK signaling pathway is crucial for M1 macrophage polarisation [188]. However, the 
mTOR signal may be indispensable for M2 macrophage polarisation, as demonstrated by a more 
significant M1-like shift for both immune phenotype and cytokine secretory profile in LPS-stimulated 
human peripheral blood mononuclear cells (PBMC) after rapamycin (an mTOR inhibitor) treatment 
[189]. 
Tumour stromal cells accelerate recruitment of macrophages in tumour tissues and modify the 
configuration of macrophages in the tumour microenvironment [190]. It was reported that co-culture 
of follicular lymphoma-associated MSC with CSF 1-activated monocytes for 7 days upregulated 
mRNA expression of IL-10, VEGF and IL-6 in macrophages, which facilitated angiogenesis. 
However, it blunted the sensitivity of macrophages following exposure to LPS, as demonstrated by a 
mild upregulation of TNF α, IL-10 and IL-12 compared with the culture without MSC [191]. 
Mutations of genes associated with lipid (e.g. SQSTM1) and glucose (e.g. Sirtuin 6) metabolism are 
frequent in many cancers [192]. As was discussed in a previous section, macrophages were driven 
into a M2 phenotype in P62 (coded by SQSTM1)-ablated adipose tissue [151]. Similarly, the M2 
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configuration of macrophages was present in Sirtuin 6 ablated adipose tissue of mice in an IL-4-
dependent manner [193]. 
1.3.4.4 Prognostic value of infiltrating M2 macrophages in tumour 
Increased infiltration of M2 macrophages in tumour tissue has significant prognostic value for poor 
cancer outcome. Results from a transcriptomic analysis investigating immune cell profiles from 
21,000 breast cancer samples demonstrated distinct prognostic potency for M1 and M2 macrophages, 
with upregulation of M2 but downregulation of M1 macrophages predicting poor cancer outcomes in 
most cases [194]. Additionally, high expression of M2 macrophage-associated genes was 
significantly associated with low response for chemotherapy (odds ratio [OR] = 0.78, p = 0.003) for 
both oestrogen receptor positive and negative breast cancer in that study. The last decade has seen an 
emerging interest in investigating the prognostic value of macrophage infiltration in tumour tissue, 
especially in the field of breast cancer (Table 1.2). Most evidence supports the lethal effect of high 
infiltration of M2 macrophages (CD163+, specifically). However, the prognostic implications were 
often different according to the cancer subtypes, the aggressiveness of the cancer, cancer therapy, the 
markers being detected and whether univariant or a multivariant statistics were applied.  
Targeting of tumour-infiltrating M2 macrophages is promising in cancer therapy. For example, 
blocking the chemokine C-C motif ligand 2 (CCL2)/ C-C chemokine receptor 2 (CCR2) signals 
decreased the number of tumour infiltrating macrophages and suppressed the polarisation of 
macrophages to a M2 phenotype in a mouse hepatocellular carcinoma model. The mRNA expression 
of M2 macrophages and cytokines secreted by M2 macrophages were downregulated after CCR2 
knockdown or blockade. The postsurgical recurrence of tumours was decreased in a CD8+ T cell-
dependent manner, indicating blocking the CCL2/CCR2 signals can release the M2 macrophage-
mediated immune-suppression in the tumour microenvironment [195]. 
1.3.4.5 The protumoural role of TAM 
The popular gene profile to distinguish M1 and M2 macrophages is a result of an in vitro experiment 
using specific cytokine stimulation on monocytes [196]. TAM in the real tumour microenvironment 
often have a more complicated profile of gene expression and cytokine secretion [197]. The high 
expression of M2 macrophage markers (e.g. CD163) can independently predict poor cancer 
prognosis, though it is now more acceptable to refer to them as TAM from a functional point of view. 
The protumoural role of TAM will be discussed in this section in three aspects: immunosuppression, 
angiogenesis and metastasis (Fig 1.5).  
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Transcriptomic analysis has demonstrated that numbers of tumour-infiltrated macrophages and 
regulatory T (Treg) cells increase while CD8+ T cells and Th cells decrease with aging, in cancers 
which have an aging-associated poor prognosis. These data indicate that macrophage infiltration in 
tumour tissue may favour an immune-suppressive tumour microenvironment [198]. The upregulation 
of IL-4 receptor α (IL-4Rα) is seen in M2-polarised macrophages and in CD14+ PBMC isolated from 
cancer patients [199]. IL-4Rα expressed on macrophages is important for maintaining the T-cell 
immune suppression in tumour microenvironment, because knock-out of the gene coding IL-4Rα in 
macrophages completely rescued the inhibited anti-tumour immunity after CD8+ T cell 
supplementation in mice. Although the CD11b+ myeloid cells had a M2-like gene expression profile 
(e.g. Arg, mrc1, IL-10, TGF-β), the high expression of IL-4Rα was collectively induced by IL-13 and 
TNF-α rather than by IL-13 alone [200]. Granulocyte-macrophage colony stimulating factor (GM-
CSF) overexpression in the setting of cancer is responsible for the recruitment of myeloid-suppressor 
cells [201]. It was recently reported that GM-CSF supported the secretion of IL-8 by macrophages, 
which is necessary for the upregulation of PD-L1 on macrophages. This autonomous PD-L1 
expression suppressed the anti-tumour immunity of CD8+ T cells [202]. 
Altered macrophage metabolism favours the formation of abnormal vasculature in the tumour 
microenvironment [203]. The infiltration of CD163+ cells is correlated with the density of vasculature 
in the tumour stroma, indicating macrophages may promote cancer progression through supporting 
angiogenesis [204]. Upregulation of the development and DNA damage response 1 (REDD1), a 
suppressor for mTORC1, in hypoxic TAM inhibited glucose uptake and glycolysis in TAM, 
supporting the usage of glucose in surrounding endothelial cells. Knockdown of REDD1 in hypoxic 
TAM recovered the pericyte coverage and cadherin junctions between endothelial cells in the highly 
permeabilised vasculature, therefore preventing metastasis [205].  
TAM support metastasis of tumours [206]. MMP is a family of enzymes that can degrade components 
constituting ECM and is important in tumour invasion [207]. In an estrogen receptor negative breast 
cancer cohort (n = 89), the high expression of MMP-9 in CD163 and CD68 double positive cells was 
associated with a worse OS (p<0.001), indicating TAM may support tumour metastasis through 
secreting MMP-9 [208]. Hiratsuka et al. found that cancer cell lines injected through the tail vein of 
mice were preferably metastasised to lung in a VEGF receptor 1 (VEGFR 1)-dependent manner. 
Moreover, MMP-9 expression was higher in lung than other organs which did not show metastasis. 
They further proved that the interaction between endothelial cells and TAM is necessary for MMP-9 
expression in both endothelial cells and macrophages. These results suggest that TAM are important 




Table 1.2 Prognostic value of macrophage infiltration in tumour tissue 
Macrophage (mc) markers/ 
statistics/annotation (if any) 
Prognostic significance Sample 
size 
Type of cancer Year Country Ref 
CD68, CD163, CD11c/ 
Multivariant Cox regression 
analysis 
 
1. Infiltration of higher number of CD163+mc in 
TN was correlated with shorter DFS. 
(HR=1.86*). 
2. Infiltration of higher number of CD11c+ mc in 
TS was correlated with longer DFS. 
(HR=0.32**). 




Cox proportional hazards 
model/ 
No adjustment for covariant 
1. Infiltration of higher number of CD163+mc 
in adipose stroma was associated with shorter 
DFS in node-negative breast cancer (n=42*). 
2. High presence of CD68+ CLS was associated 
with shorter DSF in node-positive breast cancer 
(n=56*). 
140 Breast cancer tissue 
harbouring>50 % of 





Spearman correlation and 
simple linear regression 
analysis/ 
No adjustment for covariant 
1. High CD163 expression in ER negative and 
triple negative cohorts was associated with 
longer OS*. 
2. High CD68 expression in ER negative cohort 
was associated with shorter OS*. 




Multivariant Cox regression 
model 
Infiltration of higher number of CD163+ mc in 
TS was associated with short OS (HR=2.9**). 




Multivariant cox regression 
analysis 
High density of CD68+ CLS (>5 per tissue) was 
associated with high chance to develop 
malignant cancer (HR=6.8*). 
172 Adipose stroma of 




CD68/ Multivariant cox 
regression analysis 
High infiltration of CD68+ mc was significantly 
associated with shorter OS. 





Cox regression analysis/ 
No adjustment for covariant 
1. Overall, high CD163 positive did not show 
prognostic significance for DFS. 
2. Only in the cohort accepting radiation therapy 
(n=40), high CD163 positivity was correlated 
with short DFS*. 
83 Breast cancer treated 
by conserving surgery 
showing no evidence 
of metastasis 
2018 Sweden [214] 
CD163/ 
Multivariant Cox regression 
analysis 
Infiltration of higher number of CD163+ mc was 
associated with shorter recurrence free survival 
(HR=2.2*) and increased lymph node metastasis 
(HR=4.4***). 
282 Invasive breast cancer 2017 Norway [215] 
CD163/ 
Multivariant Cox regression 
analysis 
1. Infiltration of higher number of CD163+ mc 
was associated with shorter OS (HR=4.15***). 
2. Infiltration of higher number of CD163+ mc 
was associated with shorter DFS (HR=3.83***). 
278 Triple negative breast 
cancer 
2018 China [216] 
CD68, CD163, CD204/ 
Multivariant Cox regression 
analysis  
1. Infiltration of higher number of CD204+ cells 
was associated with shorter recurrence free 
survival (HR=4.61**), distant recurrence free 
survival (HR=8.57**) and breast cancer specific 
survival (HR=15.87***).  
2. No significant prognostic value was found for 
CD68 and CD163. 
149 Breast cancer 
including luminal-
like, Her2 positive and 
triple negative 
subtypes 
2017 Japan [215] 
CD68, CD206 and CD11c/ 
Multivariant Cox regression 
analysis 
1. Combined CD206/CD11c signature (CD206 
low and CD11c high) was an independent 
prognostic variable for longer DFS (HR=0.65*). 
2. No significant prognostic value was found 
when CD68, CD206 or CD11c was evaluated 
singly as an independent variable. 
185 ccRCC 2014 China [217] 
CD163/ Multivariant Cox 
regression analysis 
Infiltration of higher number of CD163+ cells 
was associated with shorter DFS. (HR=2.5*). 
75 Colorectal cancer 2014 Sweden [193] 
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CD163/ 
Multivariant Cox regression 
analysis 
1. Infiltration of higher number of CD163+ cells 
was associated with shorter progression free 
survival (HR=2.68**) and OS (HR=2.30**).  
2. No significant prognostic value was found for 
CD68. 
110 Stage 3 and 4 
epithelial ovarian 
cancer 
2013 China [218] 
CD163/ 
Multivariant Cox regression 
analysis 
1. The number of CD163+ cells are more in 
pancreatic undifferentiated carcinoma with 
osteoclast-like giant cells than in anaplastic 
carcinomas of pancreas, without osteoclast-like 
giant cells. 
2. CD163 expression did not show prognostic 











Student t test/ 
Direct prognostic value is 
unavailable. 
CD163 positivity was higher in the high atypical 
score group than in the low atypical score 
group**. 
50 Meningioma 2013 Japan [193] 
Abbreviations: ccRCC, clear cell renal cell carcinoma; CLS, crown-like structure; DFS, disease free survival; ER, estrogen receptor; HR, hazard ratio; 
mc, macrophages; OS, overall survival; TN, tumour nest; TS, tumour stroma; *p<0.05, **p<0.01, *** p<0.001 
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pathway [220]. The activated downstream phosphoinositide 3-kinase (PI3K)-AKT signaling may 
favour the tumour progression both in the primary and metastatic sites [221]. 
 
Fig 1.5 The protumoural role of TAM 
In the tumour microenvironment, GM-CSF activates TAM to secrete IL-8, which upregulates the expression 
of PD-L1 on TAM; TNF-α and IL-3 activate TAM in cooperation, which upregulates the expression of IL-4R 
on TAM. These changes collectively impede the CD8+ T cell mediated anti-tumour immunity. The hypoxic 
microenvironment upregulated REDD1 on TAM, which is an inhibitor of mTORC1. Consequently, the uptake 
of glucose and glycolysis was suppressed in TAM. The saved O2 and glucose were exploited by neighbouring 
endothelial cells, therefore favouring the formation of the abnormal vasculature which is leaky. MMP-9, the 
protease for degrading ECM, is upregulated on TAM, which facilitates the tumour invasion at primary site and 
translocation of TAM at pre-metastatic niches. The interaction between TAM and endothelial cells at pre-
metastatic niches further upregulates the MMP-9 expression on both TAM and endothelial cells in an auto-
stimulatory manner. The normal ECM was disrupted. Cooperating with the activated PIK3-AKT signaling 
pathway, this change prepares the pre-metastatic niche for tumour seeding and progression.  
Abbreviation: ECM, extra cellular matrix; Glu, glucose; GM-CSF, granulocyte-macrophage colony 
stimulating factor; IL-4R, IL-4 receptor; MMP-9, matrix metalloproteinases 9; mTORC1, mammalian target 
of rapamycin complex 1; PD-L1, Programmed cell death ligand 1; PI3K, phosphoinositide 3-kinase; O2, 
oxygen; REDD1, regulated in development and DNA damage response 1; TAM, tumour-associated 
macrophages; TNF, tumour necrosis factor 
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1.3.4.6 Macrophages – a link between adipose tissue and cancer 
The importance of macrophages that reside in adipose tissue in driving cancer progression has been 
highlighted, but the molecular mechanisms underlying their regulation of the crosstalk between 
adipocytes and cancer cells have not been well established. 
There is a reverse regulation of energy metabolism between cancer cells and the proximal adipose 
tissue [150]. Additionally, adipose tissue resident macrophages are important in maintaining the 
metabolic homeostasis of adipose tissue, highlighting the pivotal role that macrophages play in 
connecting adipocyte and cancer cell metabolism [222]. M2 macrophages, the predominant cancer-
associated macrophages, have a distinct metabolic profile, as characterised by a high level of fatty 
acid oxidation as a response of the IL-4/PPAR-ɤ-coactivator-1β/STAT6 signal activation [223]. It 
was reported in Nature that the activation of M2 macrophages was indispensable in the process of 
WAT browning in exposure to cold [129]. The lipid metabolic profile in this process resembles that 
in cancer-associated cachexia where WAT lipolysis is increased, indicating M2 macrophages may 
fuel cancer cells through facilitating the lipolysis of cancer associated adipose tissue [136]. M2 
macrophage derived exosomal apoprotein E is known to contribute to the invasion of gastric cancer 
cells through the PI3-AKT signaling pathway [224]. The lipid transport protein, apoprotein E, is 
crucial for maintaining the homeostasis of lipid metabolism in adipose tissue [225]. Hence, apoprotein 
E may be an important molecular regulator in the orchestration of adipose tissue remodelling in the 
context of cancer progression through both non-lipid and lipid functions. 
Obesity-associated macrophages also increases stemness of cancer cells. Single-cell technologies 
have shown that tumour tissue compromises non-malignant stromal compartments (for example, 
fibroblasts, endothelial cells and immune cells), stem cell-like populations and differentiated cancer 
cells [226]. Aggressive cancer cells often exhibit profiles shared by stem cells, such as stem-like 
transcriptional features and uncontrolled proliferative ability [227, 228]. It was recently reported that 
infiltrating macrophages from obesity-associated mammary fat promote the stem-like properties of 
breast cancer cell lines [229]. Payal et al. found a predominant phenotype of macrophages in 
mammary fat tissue under a pre-existing obese microenvironment, which expressed CD36 and Plin2 
in mice, and ABCA1 and CD36 in humans. These proinflammatory and metabolically activated 
macrophages, or their conditioned medium, facilitated the formation of tumour spheroids, 
accompanied by an upregulated stem-like mRNA expression in cancer cells. The mechanism was 
dependent on the activation of the IL-6-glycoprotein 130-phosphorylated STAT 3 (IL-6-GP130-
pSTAT3) signaling pathway.  
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 Knowledge gaps 
Based on the literature review and the research interest, the following knowledge gaps have been 
recognised: 
1. The ER stress expression level in the perinephric adipose tissue and relevant association with the 
prognosis of kidney cancer have not been studied. 
2. The precise mechanism which can explain “obesity paradox” in kidney cancer is largely 
unknown. 
3. There has not been a cost-effective in vitro model to mimic the functional perinephric adipose 
tissue microenvironment. 
4. Whether an ER stress-activated adipose tissue microenvironment will impact the macrophage 
behaviour and whether the “obesity paradox” in kidney cancer can be partially explained through 
related mechanisms are unclear. 
5. The macrophage phenotype in kidney cancer-associated adipose tissue has not been mapped in 
human samples. 
6. The invasive capacity of kidney cancer cells towards adipocytes in the presence of different 
macrophages has not been compared in vitro. 
 Aims 
The hypothesis of this thesis was that the heterogeneous adipose tissue microenvironment had a role 
in cancer development, especially for kidney cancer.  
The primary aims of this thesis were to:  
i Evaluate the risk stratification potential of an ER stress marker GRP78 in the perinephric adipose 
tissue of ccRCC (Chapter 2);  
ii Establish a three-dimensional (3D) in vitro culture platform to mimic the functional adipose tissue 
microenvironment (Chapter 3);  
iii Investigate macrophage behaviour in the adipose tissue microenvironment (Chapter 4), in 
particular to:  
a. Evaluate polarisation of macrophages;  
b. Evaluate the migration and invasion of macrophages;  
c. Evaluate the different invasion capacity of cancer cells in the presence of different 
macrophage phenotypes;  
iv Evaluate the association of immunophenotyping of adipose tissue with aggressiveness of ccRCC, 
with particular regard to distant metastasis (Chapter 5). 
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Chapter 2  
GRP78 expression in tumour 
and perinephric adipose tissue is 
not an optimal risk stratification 
marker for ccRCC 
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stratification marker for clear cell renal cell carcinoma. PLOS ONE 14(1): e0210246. 
https://doi.org/10.1371/journal.pone.0210246 
The candidate was the lead author of this original research article. She contributed significantly to the 
conception and design of this study (80 %) and analysis and interpretation of the literature (70 %), 
and drafted the majority of the manuscript (90 %). © Copyright 2019 Shen et al. Reproduced in 




Objective: ccRCC is the most common subtype of kidney cancer, which is difficult to treat and lacks 
a reliable prognostic marker. A previous study showed that the ER stress marker, GRP78, is a 
potential prognostic marker for ccRCC. The present study aimed to: (1) examine whether GRP78 was 
upregulated in ccRCC compared with matched non-neoplastic renal tissue; and (2) investigate 
whether GRP78 expression in ccRCC tissue or perinephric adipose tissue has any association with 
ccRCC aggressiveness. 
Methods: A retrospective cross-sectional study of 267 patients who underwent nephrectomy for renal 
tumours between June 2013 and October 2017 was conducted at Princess Alexandra Hospital, 
Brisbane, Australia. Software-assisted quantification of average grey value of staining (staining 
intensity method) and proportion of positive pixels (positive pixel method) was applied to measure 
expression of GRP78 in archived specimens of renal tumour tissues (n = 114), adjacent non-neoplastic 
renal tissues (n = 68), and perinephric adipose tissues (n = 60) in participants diagnosed with ccRCC. 
Results: GRP78 was not upregulated in renal tumour tissue compared with paired normal renal tissue. 
In tumour tissue, GRP78 expression did not show any association with ccRCC aggressiveness using 
either quantification method. In adipose tissue, downregulation of GRP78 demonstrated poor 
correlation with increased probability of metastasis, with one unit increase in average grey value of 
GRP78 staining weakly correlating with a 17 % increase in the OR of metastasis (95 % CI: 0.99 to 
1.38, p = 0.07). 






The kidney is the 14th most common site for primary malignancy worldwide [8]. Approximately 
90 % of kidney cancers are RCC, of which ccRCC is the most common variety, constituting 
approximately 75 % of all RCC diagnoses [230]. The next most common RCC variants are papillary 
and chromophobe RCCs, which have a lower rate of metastasis compared with ccRCC. Common 
benign renal tumours include papillary adenoma, renal oncocytoma, and angiomyolipoma [231]. 
Although imaging modalities, such as computerised tomography, are able to differentiate between 
malignant and benign renal tumours, this process is not completely reliable, and approximately 5-8 % 
of lesions remain indeterminate [232]. Identification of molecular markers which are better able to 
identify tumours expected to have worse patient outcomes would therefore be of great value to 
patients and clinicians.  
ER stress markers show promising risk stratification potential for ccRCC [37]. The ER is responsible 
for the quality control of protein folding. Accumulation of misfolded proteins causes ER stress, which 
is correlated with tumourigenesis [233]. GRP78 is a chaperone of the heat shock protein 70 family 
and is one of the best-recognised ER stress markers [96]. Fu and colleagues first reported the 
upregulation of GRP78 in the renal tumour tissue from 42 Chinese ccRCC patients, where they 
showed association between GRP78 expression with clinicopathological features [37]. There was a 
significantly higher expression of GRP78 in renal tumours compared to the adjacent non-neoplastic 
kidney, and the level of GRP78 expression was positively correlated with advanced TNM stages and 
larger tumour size. However, the conclusions that could be drawn from this study were limited by 
lack of adjustment for confounders (e.g. BMI, diagnosis of hypertension and smoking history), 
possible observer bias due to the subjective nature of semi-quantitative measurement, small sample 
size and limited generalisability with respect to race. Moreover, the clinical translation of the finding 
was restricted due to its dependence on renal biopsy, which is not consistently performed in the 
diagnosis of kidney cancer considering the low diagnostic accuracy and various complications [234].  
The biopsy of perinephric adipose tissue poses less risk for patients than renal biopsy if we could find 
a marker which can predict aggressiveness of ccRCC. Expression of ER stress markers in adipose 
tissue has been shown to be a potent prognostic marker for endometrial cancer. In a retrospective 
study (n = 179), Koji et al. [110] investigated the correlation between clinical outcomes of 
endometrial cancer and expression of ER stress markers in visceral adipose tissue. They found that 
the proportion of positive staining for GRP78 and CHOP was positively correlated with higher 
tumour stage (p = 0.005) and negatively associated with disease-free survival (HR = 2.88, p = 0.005). 
Similar to the contributing role of obesity for endometrial cancer, being overweight (BMI ≥ 25kg/m2) 
is an established risk factor for developing ccRCC, with the observed relative risk being 1.5 times 
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higher than that of patients with a normal BMI [235]. Paradoxically, overweight patients appear to 
have a lower risk of dying from kidney cancer (HR = 0.49) [3]. Little is known about the expression 
of GRP78 in perinephric adipose tissue and its potential prognostic role for ccRCC. 
To further elucidate the relationship between ER stress, obesity and kidney cancer, we applied IHC 
staining to investigate GRP78 expression in renal tumour, non-neoplastic renal tissue and perinephric 
adipose tissue. The study hypotheses included that, 1) GRP78 expression is upregulated in tumour 
tissue compared with matched normal renal tissue; and 2) the expression levels of GRP78 in both 
tumour tissue and perinephric adipose tissue are positively associated with ccRCC aggressiveness. 
Understanding the expression patterns of the ER stress marker GRP78 in renal samples and 
perinephric adipose tissue may prove to be translationally meaningful, by allowing risk stratification 
of ccRCC patients and development of effective therapies which modulate ER stress levels. 
Moreover, exploring the prognostic role of GRP78 expression in perinephric adipose tissue would 




2.4.1 Sample and data collection 
This study received ethics approval from the Metro South Human Research Ethics Committee 
(HREC/05/QPAH/95; HREC/16/QPAH/353) and utilised archived formalin-fixed, paraffin-
embedded (FFPE) specimens from consenting patients who underwent nephrectomy for renal 
tumours at the Princess Alexandra Hospital, Brisbane, Australia between June 2013 and September 
2017 [236]. Inclusion criteria include that, 1) aged over 18 years old; 2) did not accept treatment for 
kidney cancer before surgery and 3) diagnosis of ccRCC. Following nephrectomy, samples of tumour 
tissue, distal non-neoplastic cortical tissue, and tumour-adjacent perinephric adipose tissue were 
excised, fixed in 4 % formaldehyde for 24 hours, and stored at 4°C prior to being blocked in paraffin. 
Clinical data were recorded in a database. Demographic data, medical and smoking history were 
collected from structured interviews and corroborated through chart review. Pathological diagnosis 
was recorded from the pathology report. Tumours were staged according to the 7th TNM 
Classification of Malignant Tumours [237] and graded according to the International Society for 
Urological Pathology (ISUP) grading system for RCC by two pathologists [238]. Work flow of study 
participation is summarised in Fig 2.1. 
2.4.2 IHC staining 
Sections of 4 μm thickness were cut onto Superfrost Plus slides. Paraffin was removed by xylene and 
the tissue was rehydrated through graded washes of ethanol in water, ending in a final rinse in water. 
Endogenous peroxidase activity was quenched by incubation in 3 % hydrogen peroxide/H2O2 (H-
1009, Sigma) for 10 min. A microwave (Whirlpool, 850W) was used for antigen retrieval. Slides 
were put into a lidded glass container which was filled with 250 mL of Tris-EDTA solution 
(10mM Tris Base, 1mM EDTA solution, 0.05 % Tween 20, pH=9). Two cycles of antigen retrieval 
(first cycle: power of 10 for 2 min and 20s; second cycle: power of 2 for 15 min) were applied. Non-
specific binding was blocked by Background Sniper (BS966, Biocare Medical) for 15 min, followed 
by an incubation with the primary antibody (GRP78, 1:50, SANTSC-376768, Santa Cruz 
Biotechnology) at room temperature for one hour. MACH 1 Universal HRP-Polymer detection kit 
(901-M1U539-082914, Biocare Medical) containing anti-mouse secondary antibody (incubated for 
15 min), signal amplification reagent (incubated for 30 min) and diaminobenzidine hydrochloride 
chromogen (DAB) (incubated for 5 min), was used per manufacturer’s instructions followed by 
counterstaining with haematoxylin (AHH-1L ProSciTech). A section of liver tissue (gifted by Clay 
Winterford, Berghofer Medical Research Institute, Brisbane) known to express GRP78, as indicated 
by the primary antibody datasheet, was used as the positive control. The negative control was done 
by eliminating the primary antibody prior to adding the secondary antibody. The specificity of the 
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GRP78 antibody was tested by mixing the primary antibody with a blocking peptide (GL 
Biochem/Shanghai-687830, amino acid sequence: ee edkkedvgtv vgidlgttys cvgvfkngrv) at a 
concentration ten times of the primary antibody. The mixture was left at room temperature for one 
hour before being added to the slides (Fig 2.2). Staining of slides was carried out blinded to the 
medical records. 
 
Fig 2.1 Flow chart of participation in the study 
267 participants recorded in the database were assessed for eligibility. 90 participants who did not meet the 
inclusion criteria were excluded. Included 177 participants were further assessed for tissue availability for 
immunohistochemistry staining. Finally, 68 participants with both tumour and non-neoplastic renal tissue 
available were included in the paired-t test. Participants with the tumour tissue available (n = 114) or with the 
perinephric adipose tissue available (n = 60) were included in the binary logistic regression analysis. 
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Fig 2.2 Staining patterns of GRP78 in different tissues 
Images were captured at x40 using Nikon Brightfield microscopy. (A) Non-neoplastic renal tissue; (B) 
Negative control of non-neoplastic renal tissue (blocking peptide mixed with primary antibody); (C) Negative 
control of non-neoplastic renal tissue (eliminating primary antibody); (D) Clear cell renal cell carcinoma; (E) 
Negative control of clear cell renal cell carcinoma (blocking peptide mixed with primary antibody); (F) 
Negative control of clear cell renal cell carcinoma (eliminating primary antibody); (G) Perinephric adipose 
tissue; (H) Negative control of perinephric adipose tissue (blocking peptide mixed with primary antibody); (I) 
Negative control of perinephric adipose tissue (eliminating primary antibody). 
2.4.3 Image capture and analysis 
The stained slides were scanned with Olympus Slide Scanner VS120 (rm4026,) using the x20 
objective. The scanned images were viewed using the OlyVia image reading software. Three to five 
snapshots were captured randomly at 50 % view size from each original image. The cropped images 
were saved in TIFF format and exported into the software Fiji for analysis [239]. Firstly, a statistical 
model was built using IHC toolbox to detect the DAB-stained colour in renal tissues and adipose 
tissues [240]. Secondly, images were manually edited by deleting glomeruli, large blank areas, vessels 
and fibrosis. Macro language was written for processing series of commands. Colour threshold was 
set to “0-254” prior to measuring average grey value and proportion of positive pixels. Methods used 
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for measuring the proportion of positive pixels were based on previous studies [241]. Average grey 
value was used to measure staining intensity of DAB. The more chromogen presented in stained 
areas, the darker the brown colour appeared macroscopically. However, as measured by the standard 
intensity function of Fiji, standard red-green-blue (RGB) colour images acquired from bright field 
microscopy had the lowest average grey value of 0 for a black, dark-stained area and the highest 
average grey value of 250 for a white, unstained area [242]. This resulted in an inverse correlation 
between average grey value and staining intensity. 
2.4.4 Statistical analysis 
Categorical data were reported as count (percentage). Continuous data were reported as mean (95 % 
CI or standard deviation) or median (interquartile range [IQR]), depending on whether or not the data 
were normally distributed. Outcome variables regarding ccRCC aggressiveness were dichotomised 
as follows: tumour grade: low [1-2] and high [3-4]; tumour stage: low [1-2] and high [3-4]; tumour 
size: [≤70mm] and [>70mm]; metastases: [presence] and [absence]. A paired-t test was used to 
compare GRP78 expression (measured by both average grey value of staining intensity and 
proportion of positively stained pixels) between renal tumour tissue and adjacent non-neoplastic renal 
tissue. Binary logistic regression was applied to model ccRCC aggressiveness based on the expression 
value of GRP78, adjusting for potential covariates, including BMI, history of smoking and diagnosis 
of hypertension. To evaluate the predictive ability of the logistic models, receiver operating 
characteristic (ROC) curves were fitted to the logistic models and the area under the ROC curve 
(AUC) reported. Differences in GRP78 expression between benign tumour and ccRCC, and 
distribution of GRP78 between different outcome variables were displayed descriptively. P-
values<0.05 were considered statistically significant. Statistical analysis was performed using 




2.5.1 Patient characteristics 
267 participants recorded in the database were assessed for eligibility. After excluding 90 participants 
who did not meet the inclusion criteria (missing data about kidney cancer diagnosis n = 5, diagnosis 
other than ccRCC n = 85), 177 participants were further assessed for tissue availability when included 
in specific statistical analysis. 68 participants with both tumour and non-neoplastic renal tissue 
available for IHC were included in the paired-t test when comparing the GRP78 expression between 
the tumour tissue and the matched non-neoplastic renal tissue. Participants with the tumour tissue 
available (n = 114) or with the perinephric adipose tissue available (n = 60) for IHC were included in 
the binary logistic regression analysis when predicting ccRCC aggressiveness based on the expression 
value of GRP78 in either tissue type (Fig 2.1). Demographic and clinicopathological characteristics 
of 68 participants for whom both tumour tissue and normal renal tissue were available for IHC 
analysis are displayed in Table 2.1.  
2.5.2 Staining patterns of GRP78 in tumour tissue and non-neoplastic renal tissue 
In ccRCC tissue, the expression of GRP78 was mainly observed in areas close to the cell membrane. 
The cytoplasm of some ccRCC cells was unstained due to the lipid-rich cytoplasmic deposits being 
washed away during tissue processing (Fig 2.3A). In non-neoplastic renal tissue, GRP78 is positive 
in all tubules with no distinctive difference of staining intensity between proximal renal tubule and 
distal renal tubule epithelial cells. However, in the capillary bundles of glomeruli, the GRP78 
expression is much lower (Fig 2.3B).  
 
Fig 2.3 Staining patterns of GRP78 in ccRCC tumour tissue and non-neoplastic renal tissue 
 (A) Image was captured at x40 under 100 % view for clear cell renal cell carcinoma tumour tissue. Scale 
bars=20 µm. Arrow: staining on the cytoplasm; arrow heads: staining close to the cell membrane; (B) Image 
was captured at x10 under 25 % view for non-neoplastic renal tissue 
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Table 2.1 Characteristics of the study population with both renal tumour and non-neoplastic 
renal tissue available for IHC 
Variables Study cohort(n=68) 
Age (years), mean (sd) 61 (11) 
Age <60 years 32 (47 %) 
Female 27 (40 %) 
White racea 65 (98 %) 
Diabetesa 13 (19 %) 
Hypertensiona 43 (65 %) 
Smoking historya 
  Former and current 
   Never 
 
37 (57 %) 
28 (43 %) 
BMI (kg/m2)a, mean (sd) 30 (7) 
BMI categorya  
   Underweight (<18.5 kg/m2) 
   Normal weight (18.5-24.9 kg/m2) 
   Overweight (25-29.9 kg/m2) 
   Obese (≥30 kg/m2)  
 
2 (3 %) 
11 (17 %) 
27 (42 %) 
25 (38 %) 
eGFR (ml/min/1.72m2), mean (sd) 77 (18) 
CKD stage 
   1 (eGFR >90 mL/min/1.73 m2) 
   2 (eGFR 60-90 mL/min/1.73 m2) 
   3 (eGFR 30-59.9 mL/min/1.73 m2) 
   4 or 5 (eGFR <30 mL/min/1.73 m2) 
 
14 (21 %) 
43 (63 %) 
11 (16 %) 
0 
Tumour size (mm), median [IQR] 50 [36, 74] 
Tumour size >70 mm 18 (26 %) 
Tumour stagea 
   1 
   2 
   3 
   4 
 
32 (48 %) 
4 (6 %) 
29 (43 %) 
2 (3 %) 
Tumour grade 
   1 
   2 
   3 
   4 
 
3 (4 %) 
24 (35 %) 
29 (43 %) 
12 (18 %) 
Presence of metastasisa 9 (13 %) 
Proportion of positive pixels in tumour tissues, 
mean (sd) 
0.47 (0.12) 
Proportion of positive pixels in normal tubules, 
mean (sd) 
0.44 (0.10) 
Staining intensity in tumour tissues, mean (sd) 202.0 (3.6) 
Staining intensity in normal tubules, mean (sd) 202.8 (4.0) 
aMissing data ≤4 %  
Abbreviations: BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration 
rate; sd, standard deviation 
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2.5.3 Difference of GRP78 expression in tumour tissue and non-neoplastic renal tissue 
Under both quantification methods, the difference in GRP78 expression between tumour and paired 
non-neoplastic renal tissue was modest (staining intensity method: mean difference = - 0.74, 
95 % CI:-1.67 to 0.19, p = 0.12; positive pixel method: mean difference = 0.03, 95 % CI: - 0.003 to 
0.06, p = 0.07; Table 2.2). 
Table 2.2 Difference of GRP78 expression between tumour tissues and adjacent non-
neoplastic renal tissues. (n=68) 





95 % CI for mean 
difference 
p-value 
 mean (sd)  mean (sd)   
Average grey value 202.04 (3.64)  202.78 (3.85) -1.67 to 0.19 0.12 
Proportion of 
positive pixels 
0.47  0.44 -0.003 to 0.06 0.07 
There was a statistically insignificant smaller average grey value (interpreted as stronger staining intensity) 
(mean difference = -0.74) in renal tumour tissues when it was compared with a paired non-neoplastic renal 
tissues (p = 0.12). There was a higher proportion (mean difference = 0.03) of positive pixels in renal tumour 
tissues when it was compared with a paired non-neoplastic renal tissues, which did not reach statistical 
significance (p = 0.07). 
2.5.4 Association of GRP78 expression in tumour tissue with ccRCC aggressiveness 
Distribution of GRP78 expression in tumour tissue among different categories of the outcome 
variables is summarised in Table 2.3. When adjusting for BMI, hypertension and history of smoking, 
we did not find any tumour grading categorising potential for either staining intensity measurement 
(adjusted odds ratio [aOR] = 0.99, 95 % CI: 0.88 to 1.12, AUC = 0.55, Fig 2.4A) or proportion of 
positive pixel measurement (aOR = 0.56, 95 % CI: 0.02 to 17, AUC = 0.50, Fig 2.4B). Since high 
tumour stage was largely ascribed by large tumour size (aOR = 16.6, 95 % CI: 5.3 to 52.0) and 
presence of metastasis (aOR = 2.5, 95 % CI: 0.36 to 17.5), tumour size and metastasis were set as 
two separate outcome variables to describe ccRCC aggressiveness. Neither staining intensity 
(aOR=0.98, 95 % CI: 0.84 to 1.14) nor proportion of positive pixels (aOR = 3.8, 95 % CI: 0.07 to 
217.9) was found to have any predictive potential for tumour size with ROC curves showing poor 
discrimination ability (AUC < 0.54, Figs 2.4C and 2.4D). Similar results were observed for metastasis 
for both staining intensity (aOR = 1.12, 95 % CI: 0.88 to 1.41, Fig 2.4E) and proportion of positive 
pixels (aOR = 1.39, 95 % CI: 0.00 to 814.4, Fig 2.4F).  
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Table 2.3 Distribution of GRP78 expression in tumour tissue (N=114) among different 





95 % CI Proportion of 
positive pixels 
95 % CI 
Tumour grade      
Grade1  13 202.6 [201.2, 204.0] 0.49 [0.42, 0.56] 
Grade2 43 202.5 [201.6, 203.3] 0.47 [0.44, 0.51] 
Grade3 42 201.8 [200.7, 202.9] 0.49 [0.45, 0.53] 
Grade4 16 202.9 [200.7, 205.0] 0.45 [0.39, 0.51] 
Tumour stagea      
Stage 1 64 202.4 [201.7, 203.1] 0.47 [0.44, 0.50] 
Stage 2 7 201.8 [199.7, 203.9] 0.47 [0.40, 0.53] 
Stage 3 39 202.6 [201.5, 203.8] 0.48 [0.44, 0.52] 
Stage 4 3 196.3 [183.7, 208.8] 0.53 [0.26, 0.84] 
Tumour size      
≤70mm 86 202.3 [201.7, 203.0] 0.47 [0.45, 0.50] 
>70mm 28 202.2 [200.8, 203.5] 0.49 [0.45, 0.54] 
Metastasisa     
No metastasis 104 202.22 [201.7, 202.8] 0.48 [0.45, 0.50] 
Presence of metastasis 9 203.1 [198.3, 207.8] 0.49 [0.38, 0.59] 




Fig 2.4 ROC curves with GRP78 expression in ccRCC tumour tissue 
GRP78 expression in ccRCC tumour tissue was applied to predict ccRCC aggressiveness, using receiver 
operating characteristic (ROC) curves. (A) ROC curve when staining intensity in tumour tissue was applied to 
predict tumour grade (OR = 0.96, AUC = 0.55); (B) ROC curve when proportion of positive GRP78 staining 
in tumour tissue was applied to predict tumour grade (OR = 0.95, AUC = 0.50); (C) ROC curve when staining 
intensity in tumour tissue was applied to predict tumour size (OR = 0.99, AUC = 0.52); (D) ROC curve when 
proportion of positive GRP78 staining in tumour tissue was applied to predict tumour size (OR = 4.26, AUC 
= 0.53); (E) ROC curve when staining intensity in tumour tissue was applied to predict whether there is a 
presence of metastasis (OR = 1.08, AUC = 0.50); (F) ROC curve when proportion of positive GRP78 staining 
in tumour tissue was applied to predict whether there is a presence of metastasis (OR = 1.93, AUC = 0.54). 
Abbreviations: AUC, area under the curve; ccRCC, clear cell renal cell carcinoma; OR, odds ratio; ROC, 
receiver operating characteristics. 
2.5.5 Association of GRP78 expression in adipose tissue with ccRCC aggressiveness 
Distribution of GRP78 expression in perinephric adipose tissue among different categories of the 
outcome variables is summarised in Table 2.4. Similar to the results in the tumour tissue, neither 
staining intensity measurement (aOR = 1.00, 95 % CI: 0.91 to 1.11, AUC = 0.57, Fig 2.5A) nor 
proportion of positive pixel measurement (aOR = 0.95, 95 % CI: 0.84 to 1.08, AUC = 0.52, Fig 2.5B) 
in the perinephric adipose tissue was found to have any tumour grading categorising potential. 
Similarly, neither staining intensity (aOR = 1.00, 95 % CI: 0.79 to 1.25, AUC = 0.63, Fig 2.5C) nor 
proportion of positive pixels (aOR = 0.95, 95 % CI: 0.84 to 1.07, AUC = 0.49, Fig 2.5D) was found 
to have any predictive potential for tumour size. Regarding the metastatic discrimination potential, 
for one unit increase in average grey value of GRP78 staining intensity in perinephric adipose tissue, 
the odds of ccRCC being diagnosed with metastasis increased by 17 % (95 % CI: 0.99 to 1.38, 
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AUC=0.73, Fig 2.5E). However, no metastatic discrimination potential was found for proportion of 
positive pixels (OR = 1.06, 95 % CI: 0.91 to 1.23, AUC = 0.55, Fig 2.5F).  
Table 2.4 Distribution of GRP78 expression in paranephric adipose tissue (N=60) among 





95 % CI Proportion of 
positive pixels 
95 % CI 
Tumour grade      
Grade 1 1 190.7 - 0.07 - 
Grade 2 25 185.2 [183.4, 187.0] 0.13 [0.10, 0.15] 
Grade 3 21 183.8 [180.1, 187.5] 0.13 [0.11, 0.15] 
Grade 4 13 189.3 [187.5, 191.1] 0.12 [0.09, 0.14] 
Tumour stage      
Stage 1 28 184.2 [181.9, 186.6] 0.13 [0.11, 0.15] 
Stage 2 3 187.2 [173.7, 200.7] 0.16 [0.05, 0.27] 
Stage 3 27 187.1 [184.6, 189.6] 0.11 [0.10, 0.13] 
Stage 4 2 185.1 [164.3, 205.8] 0.14 [-0.09, 0.37] 
Tumour size       
≤70 mm 38 184.8 [182.9, 186.7] 0.13 [0.11, 0.14] 
>70 mm 22 187.3 [184.4, 190.1] 0.12 [0.11, 0.14] 
Metastasis      
No metastasis 52 185.1 [183.4, 186.8] 0.12 [0.11, 0.14] 





Fig 2.5 ROC curve when GRP78 expression in perinephric adipose tissue was applied to 
predict the presence of metastasis 
GRP78 expression in ccRCC perinephric adipose tissue was applied to predict ccRCC aggressiveness, using 
ROC curves (A) ROC curve when staining intensity in adipose tissue was applied to predict tumour grade (OR 
= 1.01, AUC = 0.57); (B) ROC curve when proportion of positive GRP78 staining in adipose tissue was applied 
to predict tumour grade (OR = 1.00, AUC = 0.52); (C) ROC curve when staining intensity in adipose tissue 
was applied to predict tumour size (OR = 1.08, AUC = 0.63); (D) ROC curve when proportion of positive 
GRP78 staining in adipose tissue was applied to predict tumour size (OR = 0.99, AUC = 0.49); (E) ROC curve 
when staining intensity in adipose tissue was applied to predict whether there is a presence of metastasis (OR 
= 1.17, AUC = 0.73); (F) ROC curve when proportion of positive GRP78 staining in adipose tissue was applied 
to predict whether there is a presence of metastasis (OR = 1.06, AUC = 0.55). Abbreviations: AUC, area under 
the curve; ccRCC, clear cell renal cell carcinoma; OR, odds ratio; ROC, receiver operating characteristics. 
2.5.6 Difference of GRP78 staining intensity in ccRCC associated adipose tissues and benign 
tumour associated adipose tissues  
The GRP78 staining intensity between ccRCC and benign tumour associated adipose tissues were 
compared to examine the risk stratifying potential of GRP78 expression in fat tissue (Fig 2.6). There 
was no statistically significant difference in expression of GRP78 between ccRCC-associated (N=60) 
and benign tumour-associated adipose tissue (N = 7) (mean difference of average grey value = -3.26, 
p = 0.17). The distribution of GRP78 staining intensities in tumour-associated adipose tissues among 
benign tumours and different grades of ccRCC were further explored (Table 2.5). The box plot (Fig 
2.7) demonstrated that, compared with grade 2 and grade 3 ccRCC, grade4 ccRCC and benign 
tumours exhibited a lower expression of GRP78 with higher every grey values. 
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Fig 2.6 Difference of GRP78 staining intensity between benign tumour associated adipose 
tissue and ccRCC associated adipose tissue 
There was a higher expression of GRP78 in ccRCC-associated adipose tissue (N = 60) compared with that in 
benign tumour-associated adipose tissue (N = 7), as indicated by a lower average grey value in ccRCC tumour 
associated adipose tissue than benign tumour-associated adipose tissue (mean difference of average grey value 
= -3.26, P = 0.17). Abbreviation: ccRCC, clear cell renal cell carcinoma 
 
Table 2.5 Distribution of GRP78 staining intensity in benign tumour-associated adipose tissue 
and ccRCC associated paranephric adipose tissue 
 N Staining intensity 95 % CI 
ccRCC tumour grade    
Grade 1 1 190.7  - 
Grade 2 25 185.2 [183.4, 187.0] 
Grade 3 21 183.8 [180.1, 187.5] 
Grade 4 13 189.3 [187.5, 191.1] 
Benign tumoura 7 188.9 [185.8, 192.0] 
a Five oncocytoma and two non-neoplastic cystic benign tumours were combined into “benign tumour”. 




Fig 2.7 Distribution of GRP78 staining intensity in tumour associated adipose tissue among 
benign tumour and different ccRCC grades 
Compared with grade 2 (N = 25) and grade 3 (N = 21) ccRCC, grade 4 ccRCC (N = 13) and benign tumour 
(N = 7) exhibited a lower expression of GRP78, as indicated by greater average grey values. Abbreviation: 




In this study, the GRP78 expression was not upregulated in ccRCC tumour tissue compared with 
paired non-neoplastic renal tissue. Moreover, GRP78 expression levels in both renal tumour tissue 
and tumour-associated perinephric adipose tissue were not associated with grade or size of ccRCC 
tumours, except for a weak metastatic predictive potential that was found for GRP78 staining intensity 
in ccRCC tumour-associated perinephric adipose tissue. However, due to the number (N = 8) in the 
least frequent outcome variable (presence with metastasis) being less than 10, no covariate was 
introduced in the model to adjust bias. Moreover, this finding was not supported when proportion of 
positive pixels was applied to measure GRP78 expression. Although descriptive analysis found 
benign tumour-associated perinephric adipose tissue exhibited higher average grey value of  GRP78 
staining intensity than ccRCC-associated perinephric adipose tissue, it is not reasonable to deduce 
weak GRP78 staining intensity (as demonstrated by higher average grey value) is related to a better 
prognosis, due to an even weaker GRP78 staining intensity that was found in grade 4 ccRCC tumour-
associated perinephric adipose tissue. 
Contrary to the findings by Fu et al. [37], upregulation of GRP78 expression was not found in renal 
tumour tissue. This apparent disparity may be explained by methodologic differences in the approach 
to accounting for tissue heterogeneity. Compared with ccRCC tumour tissue, the normal nephron has 
much greater tissue heterogeneity, being composed of glomeruli and tubules with lumens of various 
size [243]. Obviously, the tubular lumen will remain unstained in IHC. Theoretically, glomeruli, the 
major components of which are capillary bundles, will be more weakly stained by GRP78 than the 
rest of the nephron structure, because the ER does not exist in erythrocytes [244]. Hence, failure to 
appropriately account for tissue heterogeneity may introduce bias when comparing the proportion of 
positively stained areas between renal tumour tissue and paired normal renal tissue. However, the 
previous publication did not use a method that mitigated the risk of the bias of tissue heterogeneity. 
On the other hand, in the present study, tubular lumens and glomeruli were manually eliminated prior 
to comparing the proportions of GRP78 positively stained areas between tumour and adjacent non-
neoplastic renal tissue. Similarly, the conflicting results between staining intensity and proportion of 
positive pixels may be partially explained by adipose tissue heterogeneity as a result of variation in 
size of adipocytes. For example, larger adipocytes for participants with higher BMI may leave the 
cellular stainable area smaller (lipid being washed from cells during processing) (Figs 2.8A and 2.8B), 
which was consistent with the statistically significant inverse association observed between BMI and 
proportion of positive pixels (correlation coefficient = - 0.20, p = 0.02) (Fig 2.8C). However, we did 
not find any significant association between BMI and staining intensity (correlation coefficient = - 
0.16, p = 0.15) (Fig 2.8D). 
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Fig 2.8 The impact of adipose tissue heterogeneity on proportion of positive pixels 
 (A) Images were captured at ×10 under 50 % view. Scale bar = 100 µm. BMI = 18.55; Average grey value = 
191.74; Proportion of positive pixels = 0.19; (B) Images were captured at ×10 under 50 % view. Scale bar = 
100 µm. BMI = 43.18; Average grey value = 178.42; Proportion of positive pixels = 0.13; (C) Scatter plot of 
BMI versus proportion of positive GRP78 stained pixels in adipose tissue. Coefficient = - 0.20, p = 0.02; (D) 
Scatter plot of BMI versus average grey value of GRP78 staining in adipose tissue. Coefficient = - 0.16, p = 
0.15.  
Abbreviation: BMI, body mass index; F_avegrey, average grey value of GRP78 staining in adipose tissue; 
F_proportion, proportion of positive GRP78 stained pixels in adipose tissue. 
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The hypoxic cancer microenvironment suppresses the differentiation of tumour cells. Likewise, 
undifferentiated tumour cells tend to grow faster, exacerbating hypoxia within the cancer 
microenvironent [245]. The activation of ER stress is an adaptive behavior in response to such a 
suboptimal microenvironment [246]. The observed adipose tissue GRP78 staining intensity generally 
met with this supposition, showing a gradually increasing staining intensity from grade 0 to grade 3. 
Opposite to an expected over expression of GRP78, the GRP78 staining intensity was the lowest in 
grade 4 ccRCC. It is difficult to interpret the result further, due to small sample size and the lack of 
examination of the whole ER stress signaling network. 
This study has the largest sample size to date and was based on the investigation of a different race 
population compared with the previously published study by Fu et al.. Other strengths of this study 
include use of appropriate statistical tests and software-assisted DAB chromogen quantification of 
both proportion of positive pixels and average grey value of GRP78 staining intensity. On the other 
hand, the findings in this study are subjected to two major limitations. Firstly, this study only 
examined the expression of one ER stress marker, GRP78. Although the activation of GRP78 is 
considered as an initial sign of ER stress, the one time-point assessment of GRP78 expression cannot 
reflect the full-course status of ER stress [247], because ER stress involves mutiple downstream 
signaling pathways that are mediated by different signaling proteins [248]. Secondly, quantifying 
DAB chromogen intensity in IHC has long been a controversial issue, because the brightness of a 
DAB-stained region is not directly proportional to the concentration of localized antigen [247]. 
However, this is an inherent limitation of the IHC stainining. In the process of image analysis, it was 
found that the result of average grey value fit with the intuitive impression of the staining intensity.  
Collectively, the findings failed to demonstrate any utility of GRP78 as a risk stratifying marker for 
ccRCC. This does not necessarily refute a role for activated ER stress as a potential therapeutic target 
for kidney cancer, because the peak expression of different ER stress markers may vary with different 
stages in cancer development [249]. Further studies in this area are warranted.  
 Conclusion 
GRP78 is not upregulated in renal tumour tissue compared with paired normal renal tissue. Thus, for 
the purpose of risk stratification of ccRCC, GRP78 would not appear to be a useful marker. Since the 
predictive value of GRP78 expression in adipose tissue is uncertain due to the presence of conflicting 
findings according to methodologic approach, it is important to eastablish an adipose tissue 
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Obesity is an established risk factor for developing RCC. However, recent findings suggest that obese 
patients with RCC may have better prognosis. This obesity paradox highlights the uncertain roles 
played by adipose tissue in RCC progression. Activation of ER stress has been observed in human 
disease associated with obesity and multiple animal models. Using IHC and a patient cohort, Chapter 
2 of this thesis describes how GRP78, an ER stress marker, was upregulated in the perinephric adipose 
tissue of RCC patients who had higher BMI (Spearman correlation coefficient= - 0.16, p = 0.15). The 
upregulation of GRP78 was related to a lower metastatic rate (95 % CI of OR: 0.72 to 1.01, p = 0.07), 
which is in agreement with obese RCC patients having better prognosis, within the obesity paradox. 
However, evidence from this one-point IHC study is insufficient to deduce that activated ER stress 
in the obese perinephric microenvironment modulates RCC progression. Hence, a cell culture-based 
study to mimic the ER stress-activated obese microenvironment of adipose tissue was initiated. The 
adipogenic differentiation of the primary stromal vascular fraction isolated from human perinephric 
adipose tissue was induced in a scaffold-free 3D culture environment simply by coating 96-well plates 
with 1 % agarose. As evidenced by accumulation of adiponectin in the culture medium and 
enhancement of Nile red fluorescence staining over the time of adipogenic differentiation, this 
method can be used to produce reproducible and functional adipocyte spheroids. A co-culture 
platform including the adipocyte spheroids will be applied to study the macrophage behaviour in the 




The increased economic burden from obesity-associated comorbidities, such as cancer, has boosted 
the research interest in the adipose tissue microenvironment [162]. Since adipose tissue is universally 
distributed across the human body, many solid tumours grow closely to the adipose tissue or directly 
in the adipose tissue stroma, such as breast cancer. The role of the interaction between adipose tissue 
and cancer cells in the tumour development is complicated. Adipose tissue is an active endocrine 
organ, secreting many adipokines and cytokines, such as leptin, adiponectin, monocyte 
chemoattractant protein-1 (MCP-1, also known as CCL2), IL-6, IL-8, IL-10 and TNF α, exerting 
either pro-tumourigenic or anti-tumourigenic functions [118]. Additionally, the lipid metabolism and 
morphology of adipose tissue are altered to adapt to the cancer development, promoting tumour 
growth and causing cachexia [250]. However, the prognostic role of obesity in predicting mortality 
of cancer remains uncertain. On one hand, increased BMI is a known risk factor for developing 
cancers. On the other hand, increased adiposity after cancer diagnosis is a favourable prognostic 
factor for many cancers, including RCC [251]. 
The structure and function of adipose tissue vary with distribution. More sensitive to insulin, 
subcutaneous adipose tissue with smaller adipocytes is better at buffering the lipid flux in circulation 
[252]. Rich in vasculature, immune cell infiltration and large adipocytes, visceral adipose tissue is 
more active in lipolysis but more susceptible to insulin resistance [251]. Additionally, the pattern of 
adipose tissue distribution in the human body carries prognostic information for cancers. For example, 
a high visceral fat index was reported to be associated with shorter OS for metastatic colorectal cancer 
after bevacizumab treatment [253]. However, subcutaneous adiposity was a favourable prognostic 
factor for OS in renal, pancreatic, oesophageal, stomach and respiratory cancers [135]. To determine 
whether, or not, adipocyte-cancer cell interactions mediate cancer progression, it is crucial to establish 
an in vitro model which reproduces the microenvironment and crosstalk between adipose tissue and 
cancer cells. 
Mainly obtained from the procedure of liposuction, subcutaneous adipose tissue has been widely used 
to isolate primary adipocytes in preclinical research [254] Since the role of the adipose tissue 
microenvironment in cancer development and progression has gained common recognition, 
adipocytes directly isolated from the tumour microenvironment are needed to investigate their 
interactions with cancer cells. For example, breast cancer-related research has extensively applied 
adipocytes isolated from the adipose stroma of breast cancer [135]. As a clinical waste of radical 
nephrectomy surgery, perinephric adipose tissue (adipose tissue between renal capsule and Gerota’s 
Fascia) is an easily obtained visceral adipose tissue, which exerts little ethical concern when applied 
in preclinical research [255]. Separated from the paranephric fat by the Gerota’s Fascia, perinephric 
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fat has direct anatomical interaction with the kidney. Sharing common lymphatic vessels with the 
kidney, the host or infiltrating cells or cytokines secreted in the perinephric adipose tissue may affect 
tumour metastasis [256, 257]. Hence, the value of adipocytes isolated from perinephric adipose tissue 
should be noted, though publications about relevant applications are limited in the field of the kidney 
cancer-associated microenvironment. 
Using 3D culture to reproduce the tumour microenvironment is a trend in cancer research. 3D culture 
of adipocytes has shown advantages over traditional two-dimensional cell culture in a recent 
publication [258]. First, adipocytes grown under a 3D culture environment develop large unilocular 
lipid droplets in the cytoplasm. The lipid droplets have a similar morphology to those found in mature 
adipocytes under physiological conditions. Second, adipocyte spheroids were more sensitive to the 
stimulation of uremic toxins, as evidenced by a significant downregulation of adiponectin and 
upregulation of IL-8 observed in adipocyte spheroids after exposure to indoxyl sulphate, than in 
general adipocytes. Third, the 3D cell aggregates are flexible to manipulate in constructing the co-
culture system by changing the density or location of the spheroids according to the requirement of 
experiments [258]. 
It has been reported that human ASC could form 3D cell aggregates using the hanging drop technique 
[259] or special culture dishes with an ultra-low attachment surface [260]. However, these methods 
depend on a difficult handing technique and/or expensive laboratory consumables. The liquid overlay 
technique, simply using a thin coating of agarose, has successfully generated more homogeneous and 
reproducible cancer cell aggregates compared with the hanging drop technique [261]. However, its 
application in generating human adipocyte spheroids has not been reported. The culture dish produced 
for adherent cell culture is normally gas-plasma treated, the surface of which is more hydrophilic and 
negatively charged than untreated polystyrene material [262]. Agarose is a neutrally charged 
hydrophilic material, which cannot bind to cell attachment proteins present in the culture medium. 
Lacking any embedded or bond fibrous proteins, such as collagen, the agarose coated surface cannot 
form cell-matrix junctions, forcing cells into a suspended status, enabling 3D spheroid formation 
through cell-cell interactions [263]. 
The core idea of the present chapter is to build a 3D culture platform using the liquid overlay 
technique to culture the adipocytes derived from human perinephric adipose tissue. The hypotheses 
include: 1) the technique can reproducibly produce functional adipocyte spheroids which are 
responsive to ER stress; 2) increasing seeding density of adipocyte spheroids can make a pro-
inflammatory adipose tissue microenvironment; and 3) increasing seeding density of adipocyte 
spheroids can mimic an ER stress-activated adipose tissue microenvironment in kidney cancer.   
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 Methods 
3.4.1 Isolation and culture of human perinephric stromal vascular fraction 
This study received ethics approval from the Metro South Human Research Ethics Committee 
(HREC/16/QPAH/353). Perinephric adipose tissue was obtained after radical nephrectomy surgery 
from consented participants diagnosed with renal tumours. Demographic and pathological 
characteristics of the study participants are described in Table 3.1. The excised perinephric adipose 
tissue was submerged in ice-cold Hank’s Balanced Salt Solution (HBBS) (ThermoFisher 14025076) 
containing 400 U/mL of penicillin and 400 µg/mL streptomycin (4 % P/S) (Gibco 15070063) 
immediately after nephrectomy. SVF was isolated according to the methods described by Naderi et 
al. [264] and Lee et al. [265]. 
Collagenase type I (Gibco 15070063) solution (2 mg/mL) was prepared by dissolving the collagenase 
in fetal bovine serum (FBS)-free HBBS and filtering the solution through a strainer (pore size 0.2 
µm). The adipose tissue was minced in a sterilised petri dish which was placed on ice and then was 
transferred to the collagenase type I solution at a ratio of 3 g of tissue per 10 mL of the solution. After 
gentle shaking (150 RPM) for 1.5 h at 37 ˚C, the “fat cake” in the top layer was removed and the 
aqueous phase was filtered through a cell strainer (pore size 100 µm) and centrifuged at 500 g for 5 
min. Erythrocytes were removed by adding a red blood cell (RBC) lysis buffer with gentle shaking 
for 10 min at room temperature (Roche 11814389001). Cell pellets were then suspended in MSC 
culture medium (ScienCell 7501) at a density of 4 × 104/mL and grown in 75 cm2 flasks which had 
been coated with 15 µg/mL of L-lysine (ScienCell 0403). When reaching 70-80 % confluence, cells 
were sub-cultured with a 1-4 split using accutase (Gibco A1110501) (Fig 3.1). Images showing the 
morphology of SVF prior to adipogenic differentiation are displayed in Fig 3.2. 
3.4.2 Culture of 3T3-L1 cell line 
The 3T3-L1 cell line was a kind gift from Dr Sumaira Hasnain (Mater Research Institute-The 
University of Queensland). Dulbecco's Modified Eagle Medium/Nutrient Mixture F -12 
(DMEM-F12) (Gibco 11320033) containing 10 % FBS and 1 % P/S (Gibco 15070063) was 
applied as the growth medium for the 3T3-L1 cells and the base medium for adipogenic 
differentiation medium. The adipogenic differentiation medium was prepared freshly 
and contained 0.5 mM of 3-isobutyl-1-methylxanthine (IBMX) (Sigma I5879), 1 µM of 
dexamethasone (Sigma D4902) and 10 µg/mL of human recombinant insulin (Sigma 91077c). The 
recipe was adapted from the article published by Lane et al. [266]. Images showing the morphology 
of 3T3-L1 cells prior to adipogenic differentiation are displayed in Fig 3.3. 
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Fig 3.1 Workflow of isolating SVF 
Preparation: 1) 10 mL of collagenase type I solution per 3 g of tissue was prepared by dissolving collagenase 
in HBBS (2 mg/mL) and filtering through a 0.2 µm strainer. 2) The adipose tissue was minced in a petri dish 
placed on ice. Digestion: 1) After several washes with HBBS, the adipose tissue was transferred into to the 
collagenase solution and incubated at 37 ˚C for 1.5 h with gentle shaking. 2) The aqueous phase was filtered 
through a 70 µm cell strainer then flow through was centrifuged at 500×G for 5min. Purification: 1) The RBC 
lysis buffer was warmed to room temperature, then the cell pellets were incubated for 10 min with 2 mL of the 
RBC lysis buffer with gentle shaking. 2) After centrifuging at 500×G for 5 min and removing the supernatant, 
the purified cell pellets were suspended in growth medium. 
Abbreviations: HBBS, Hank’s Balanced Salt Solution; RBC, red blood cell; SVF, stroma vascular fraction 
3.4.3 Flow cytometry analysis 
Flow cytometry analysis was performed to identify MSC. Cells were harvested with human Fc block 
solution (BD 564220) to block non-specific Fc receptor binding and were incubated with specific 
antibody for 30 min on ice. Live and dead cell discrimination was performed by adding DAPI before 
sample analysis. Details on antibodies and live/dead cell dye are summarised in Appendix 1. If not 
specified, 1 × 106 cells were suspended in 100 µL of the staining solution per sample. The samples 
were analysed using the instrument BD LSR Fortessa X-20. Non-stained cells were used to set the 
voltage of the instruments. If not specified, non-stained cells were used to gate the positive 
population. However, a fluorescence minus one (FMO) control was used to gate the positive 
population for the rare event. Flow cytometry data were analysed using the FlowJo Software.  
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3.4.4 Adipogenic differentiation of MSC and 3T3-L1 cells using a liquid overlay technique-
based 3D culture environment 
The inner 60 wells of a 96 well plate were coated with 70 µL of sterilised 1 % agarose and solidified 
at 37 ˚C for 2 h. Sterilised phosphate-buffered saline (PBS) solution containing 1 % P/S was filled 
into the outer 36 wells to avoid the edge effect. MSC and 3T3-L1 cells were seeded at a density of 
5,000 per well in 100 µL of MSC culture medium and DMEM/F12 growth medium, respectively. 24 
h later (day 0), the old medium was replaced with 150 µL of MSC adipogenic differentiation medium 
(ScienCell 7541) for MSC and the freshly made adipogenic differentiation medium for 3T3-L1 cells. 
For MSC, the medium was changed on day 6 and day 12. The supernatant was collected on day 0, 6, 
12 and 18 to measure the concentration of total adiponectin by enzyme-linked immune-sorbent assay 
(ELISA) (R&D DY1065). For 3T3-L1 cells, the medium was changed on day 7. The supernatant was 
collected on day 0, 7 and 14 to measure the concentration of total adiponectin by ELISA (R&D 
DY1119). 
3.4.5 Staining and imaging of adipocyte spheroids 
On day 0, 6, 12 and 18 (or on day 0, 7, 14 and 21 for 3T3-L1 cells), harvested spheroids were fixed 
with 4 % paraformaldehyde (Sigma F8775) for 15 min and were embedded in tissue freezing medium 
(GeneralData TFM-5). The solidified blocks were sectioned using a Leica CM 1950 cryostat at a 
thickness of 12 µm at -20˚C. After permeabilisation with 0.1 % Tween 20 for 5 min, the slides were 
incubated in a Nile red (Sigma 72458) and DAPI (Invitrogen D1306) dual staining solution (1 µg/mL 
in PBS) for 10 min. Images were photographed with a FV3000 confocal microscope at ×20 
magnification using the laser 561 and 405 under the same brightness and background settings. The 
protocol of oil red O staining was adapted from the method published by Lillie et al. [267]. In this 
method, the slides were rinsed in water and then in 60 % isopropyl alcohol (a few seconds for both 
washes) before being stained with oil red O solution. The oil red O staining solution was freshly made 
by diluting 6 mL of the saturated oil red O stock solution (0.5 % in isopropyl alcohol, Sigma O1391) 
with 4 mL of distilled water. After centrifuging, the clear supernatant was filtered directly onto the 
section. After differentiation with 60 % isopropyl alcohol (a few seconds) and haematoxylin counter 
staining, slides were mounted using Kaiser’s glycerine-jelly (recipe see Appendix 2). The agarose 
spheroid blocks were prepared for haematoxylin and eosin (H&E) staining using an internal protocol 
introduced by Dr Justin Large (Histology Core Facility, Translational Research Institute, Brisbane). 
Briefly, the paraformaldehyde-fixed spheroids were embedded in 2 % agarose at 37 ˚C in a pre-
warmed microcentrifuge tube. The solidified block was removed by carefully cutting off the bottom 
of the tube and then transferred in a cassette filled with foam pads prior to routine histological 
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processing. Slides with Oil red O and H&E staining were scanned with an Olympus slide scanner 
VS120 using the ×20 objective. 
3.4.6 Quantitative real-time polymerase chain reaction 
Three technique replicates were applied in quantitative reverse transcription polymerase chain 
reaction (q-rtPCR) to measure the mRNA expression. Spheroids were collected in RNAlater 
(ThermoFisher AM7020). Total RNA was extracted using a TRIzol reagent (Invitrogen 15596026). 
DNA was eliminated by a DNA removal kit with DNase 1 (Invitrogen AM1906). cDNA was 
generated using a cDNA reverse transcription kit (Applied Biosystems 4368813). q-rtPCR data were 
obtained using the instrument LightCycler480, Roche LifeScience with SensiFast SYBR low-Rox 
mix (Bioline BIO-94005) added to 1 µg of cDNA. Results were normalised to mean expression of 
the housekeeping gene (18S ribosomal RNA for human and β-actin for mouse) and expressed as a 
fold change compared to the control group. Initial real-time amplification was examined by 
electrophoresis to confirm the size of the products, by referring to the Ultra Low Range DNA Ladder 
(Invitrogen 10597012). SYBR Safe DNA gel stain (Invitrogen S33102) was used to stain the 4 % 
agarose Tris/Borate/Ethylenediaminetetraacetic acid (TBE) buffer. The voltage was set to be 10 V 
per cm and the running time was 1 h 15 min. After PCR amplification, a melting curve was generated 
to check the specificity of the product. Primer sequences are listed in Appendix 3. Images of 
electrophoretic gels demonstrating the specificity of the PCR products are displayed in Appendix 4. 
3.4.7 Statistical analysis 
Comparisons between groups were made using the analysis of variance (ANOVA), paired or unpaired 
t-test when appropriate. When there was a statistically significant difference in ordinary ANOVA, 
post hoc testings were performed to determine where the difference occurred between groups. When 
there was a statistically-significant difference in one-way repeated measures ANOVA, Tukey’s 
multiple comparisons were performed to determine the difference occurring between groups. p<0.05 
was considered statistically significant. Statistical analysis was performed using GraphPad Prism 7.0.   
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 Results 
3.5.1 Morphologic observation of human perinephric adipose tissue isolated SVF and 3T3-L1 
cells prior to adipogenic differentiation 
Undifferentiated SVF isolated from the adipose tissue started adhering at 20 h after seeding, 
exhibiting a polygonal morphology (10-25 µm) (Fig 3.2a). Cells elongated over the amplification 
period, exhibiting heterogeneous morphological patterns, such as spindle, polygon and “string of 
beads” (Figs 3.2b and 3.2c). It took approximately 6 days for cells to reach 70 % confluence and 
become homogeneous in shape (80-100 µm in diameter) (Fig 3.2d). The morphologic characteristics 
of 3T3-L1 cell line are displayed in Fig 3.3. 
 
Fig 3.2 Morphologic characteristics of stromal vascular fraction 
a Cell attachment started from 20 h after seeding (×40). b, c Heterogeneous morphological patterns were 
observed during the amplification period. b was photographed on the day 2 (×40). c was photographed on the 
day 5 (×40). d On day 6, cells reached approximately 70 % confluence and were homogeneous in shape (×40). 
Scale bars = 50 µm. 
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Fig 3.3 Morphologic characteristics of 3T3-L1 cells 
Cells were seeded at a density of 104/ml. Cells were growing in adherent and exhibited fibroblast-like 
morphology. It took 72 h for cells to reach approximately 70 % confluent. a 4 h, scale bar = 50 µm (×40); b 
26 h, scale bar = 100 µm (×10); c 48 h, scale bar = 100 µm (×10); d 72 h, scale bar = 100 µm (×10). 
3.5.2 SVF was double positive for CD105 and CD90 but were negative for CD14 
CD105 and CD90 are positive markers for mesodermal stem cells. They have been widely tested for 
MSC identification [268]. Flow cytometry results demonstrated that 93.2 % of SVF was double 
positive for CD105 and CD90 after the cells had been sub-cultured 3 times (Fig 3.4c). For assessing 
the purity of the stem cells, the cell surface expression of CD14 which is one of the key late 
differentiation markers of myeloid lineage cells was tested [269]. 
Flow cytometry results demonstrated that the stem cells were negative for CD14 (Fig 3.4h). It has 
also been reported that adipose tissue is a source of pluripotent stem cells [270]. Hence, the expression 
of the pluripotency marker, stage-specific embryonic antigen-3 (SSEA-3), was tested. Flow 
cytometry results demonstrated that 0.96 % of SVF was positive for SSEA-3 (Fig 3.4f). FMO control 
was used to gate the positive population for SSEA-3 (Fig 3.4e) and CD14 (Fig 3.4g). 
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Fig 3.4 SVF was double positive for CD105 and CD90 but were negative for CD14. 
a and d demonstrate the gating strategy to identify live cells. Demonstrated in b, the location of the positive 
population was gated using the unstained control. c demonstrates that 93.2 % of the stromal vascular fraction 
(SVF) was CD105+/CD90+. Demonstrated in e and g, the location of the positive population was gated using 
the fluorescence minus one (FMO) control. f demonstrates that 0.96 % of the SVF was positive for SSEA-3, 
and in h, the SVF was negative for CD14. 
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3.5.3 Homogeneous adipocyte spheroids were generated using the liquid overlay technique-
based 3D culture. 
H&E staining demonstrated that on day 18, large unilocular lipid droplets had formed in the 
cytoplasm (Fig 3.5). Spheroids increased in size with adipogenic differentiation of MSC (Fig 3.6a). 
On day 18, adipocyte spheroids were floating above the medium. Nile red and Oil red O staining 
revealed that the lipid gradually accumulated in the cytoplasm (Figs 3.6b and 3.6c). Consistently, 
ELISA results showed the concentration of the total adiponectin was gradually increased in the 
culture medium over adipogenic differentiation when spheroids were plated singly in 96 well plates 
(Fig 3.6d). Consistently, the lipid droplets gradually accumulated, and the total adiponectin was 
gradually increased with adipogenic differentiation of 3T3-L1 cells (Fig 3.7). Adipocyte spheroids 
were differentiated from MSC isolated from 3 donors (Table 3.1). 
 
Fig 3.5 H&E staining of MSC-derived adipocyte spheroids 
Images were scanned with Olympus slide scanner VS120 using the ×20 objective. Scale bars = 20 µm. a Day 
0; b Day 6; c Day 18; Arrows indicate unilocular lipid droplet formed in cytoplasm. 













Patient 1 29-Jan-1961 Female 30.5 Oncocytoma 80mm # # 
Patient 2 10-Aug-1967 Male 31.4 ccRCC 120mm 2 3 
Patient 3 1-Apr-1963 Female 35 ccRCC 65mm 3 3 
# Tumours were staged according to the 7th TNM Classification of malignant tumours and graded according 
to the International Society for Urological Pathology (ISUP) grading system for renal cell carcinoma, which 




Fig 3.6 Adipogenic differentiation of MSC 
a Increase in size of spheroids over 18 days of adipogenic differentiation is demonstrated in the bright field 
images. b Images of Nile red staining (scale bars = 50 µm) photographed with a FV3000 confocal microscope 
at ×20 magnification using the 561 and 405 nm lasers under the same brightness and background settings 
demonstrated that the lipid (red fluorescence) increasingly accumulated in the spheroids. c The result was 
confirmed by images of Oil red O staining (scale bars = 100 µm) which were scanned with Olympus slide 
scanner VS120 using the ×20 objective. d Results in ELISA demonstrated an increasing adiponectin 
concentration in the culture medium with differentiation. Of note, the concentration of adiponectin on day 0 
was below the lower limit of assay sensitivity. **p<0.01, ns, p>0.05, Tukey’s multiple comparisons after 
repeated measures one-way ANOVA, error bars represent estimated standard errors of the mean. Data were 
pooled from 3 independent experiments using MSC derived from 3 donors (see Table 3.1). Error bars in raw 
data indicate the standard deviation of the technique duplicates in ELISA.  
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Fig 3.7 Adipogenic differentiation of 3T3-L1 cells 
a. Images were photographed with a FV3000 confocal microscope at ×20 magnification using the lasers of 
561 and 405 nm under the same brightness and background settings. Scale bars = 50 µm. Nile red staining 
revealed that the lipid accumulated in the cytoplasm over time. b. ELISA results demonstrated the 
concentration of the total adiponectin was gradually increased in the culture medium with adipogenic 
differentiation when spheroids were plated singly in 96 well plates. Data were pooled from three independent 
experiments. ****p<0.0001, post hoc testing after one-way ANOVA, error bars indicate standard estimated 
errors of the mean. c. Scale bars = 100 µm. The Oil red O staining confirmed that the lipid gradually 
accumulated in the cytoplasm. d. Scale bars = 20 µm. Examples of H&E staining demonstrated that necrosis 
may be appeared in the core of the spheroid on Day 21. 
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3.5.4 ER stress affected adiponectin and MCP-1 secretion in adipocyte spheroids. 
Mature adipocyte spheroids were collected and placed in a 24-well plate at a density of 5 spheroids 
per well at the end of the adipogenic differentiation period (18 days). Spheroids were maintained in 
the FBS-free medium containing 5 µg/mL of tunicamycin for 24 h. Tunicamycin is a drug which 
inhibits N-linked glycosylation, thereby blocking protein folding and causing ER stress [271].q-
rtPCR results demonstrated that mRNA expression of GRP78 and spliced X-box binding protein 1 
(sXBP1, another ER stress protein) was upregulated. In contrast, with the increase in ER stress, the 
expression of abundant transcript 1 (APM-1) and MCP-1 was downregulated (Fig 3.8a). These results 
were confirmed by ELISA for adiponectin (Fig 3.8b) and MCP-1 (Fig 3.8c). However, the effect of 
tunicamycin on mRNA expression and cytokine secretion of IL-8 was uncertain, due to insignificant 
changes being observed after the treatment (Figs 3.8a and 3.8d). Consistently, 3T3-L1-derived 
adipocyte spheroids were responsive to ER stress as demonstrated by an upregulation of mRNA 
expression of GRP78 and sXBP1 after exposure to tunicamycin (Fig 3.9a). ER stress also affected 
adiponectin secretion by adipocyte spheroids derived from 3T3-L1 cells (Fig 3.9b).  
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Fig 3.8 ER stress affected mRNA expression and cytokine secretion of APM-1 and MCP-1. 
a demonstrates mRNA expression of GRP78, sXBP1, APM-1 MCP-1 and IL-8 in adipocyte spheroids cultured 
in the medium with or without tunicamycin (Tm) (5 µg/mL) for 24 h. The fold change represents the gene 
expression in experimental vs control conditions. *p<0.05, **p<0.01, ***p<0.001, ns, p>0.05, unpaired t-test. 
Error bars indicate estimated standard errors of the mean. b, c and d demonstrate adiponectin (b), MCP-1 (c) 
and IL-8 (d) concentration in the culture supernatant maintaining 5 adipocyte spheroids. Error bars indicate 
estimated standard errors of the mean. *p<0.05, **p<0.01, ns, p>0.05, paired ratio t test. Results were pooled 
from 3 independent experiments using mesenchymal stem cells derived from 3 donors (see Table 3.1). Error 
bars in raw data indicate the standard deviation of the technique duplicates in ELISA. 
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Fig 3.9 ER stress affected adiponectin secretion by 3T3-L1-derived adipocyte spheroids. 
Adipocyte spheroids were collected and placed in a 24-well plate at a density of 20 spheroids per well at the 
end of the adipogenic differentiation (14 days). Spheroids were maintained in the FBS-free medium containing 
5 µg/mL of tunicamycin (Tm) for 24 h. a demonstrates that mRNA expression of GRP78 and sXBP1 was 
upregulated in adipocyte spheroids after exposure to Tm. The fold change represents the gene expression in 
experimental vs control conditions. ***p<0.001, **** p<0.0001, unpaired t-test. Error bars represent estimated 
standard errors of the mean. b demonstrates that ER stress interferes the adiponectin secretion by adipocyte 
spheroids. Error bars indicate estimated standard errors of the mean. *p<0.05, paired ratio t test. Results were 
pooled from 3 independent experiments. 
3.5.5 Increasing density of adipocyte spheroids did not disrupt the secretion of adiponectin.  
As was reported by Klingelhutz et al. [258], increasing the number of adipocyte spheroids 
(differentiated for 10 days) maintained in a single well of 24-well plates skewed the adipocyte 
associated microenvironment to produce a pro-inflammatory phenotype. For example, the 
concentration of adiponectin in the culture medium decreased when increasing the number of 
spheroids from 5 to 20. However, the direction of change was opposite to that for IL-8, which was 
increasingly secreted with the increment of the seeding density. The reproducibility of this finding 
was tested in this project under the same conditions using the human ASC-derived adipocyte 
spheroids (differentiated for 18 days). Unexpectedly, the level of adiponectin increased with the 
seeding density from 5 to 20 rather than decreasing (Fig 3.10a1). In the normalised result showing 
adiponectin secretion per 5 spheroids, the adiponectin level did not differ among groups maintaining 
varying numbers of spheroids (Fig 3.10a2). This finding was confirmed in another experiment using 
the 3T3-L1-derived adipocyte spheroids (differentiated for 14 days) which were seeded at varying 
densities (Figs 3.10b1 and 3.10b2). Consistent with published results, the level of IL-8 was positively 
associated with the number of spheroids (Fig 3.10c1) [258]. However, the difference among groups 
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diminished in the normalised result demonstrating the IL-8 secretion by every 5 spheroids (Fig 
3.10c2). Collectively, the increment of cytokine levels with increasing numbers of spheroids was 
mainly due to an accumulating effect rather than a cellular response to the changes in the 
microenvironment. 
 
Fig 3.10 Total secretion of adiponectin and IL-8 upregulated with addition of spheroids 
Maintained in the FBS-free DMEM-F12 medium, adipocyte spheroids were seeded in a 24-well plate with 
varying numbers of spheroids (from 5 to 20) in each well. The concentration of adiponectin and IL-8 was 
measured in the conditioned medium after 24 . a1 and b1 demonstrate the level of adiponectin increased with 
the increment of numbers of adipocyte spheroids derived from human mesenchymal stem cells and 3T3-L1 
cells, respectively. c1 demonstrates IL-8 secretion increases with addition of spheroids. The normalised 
concentration of human adiponectin, mouse adiponectin and human IL-8 produced by every 5 spheroids is 
respectively displayed in a2, b2 and c2, demonstrating no significant difference among groups. *p<0.05; 
**p<0.01; ***p<0.001; ns, p>0.05, post-hoc test after ordinary one-way ANOVA, error bars indicate standard 
estimated errors of the mean. 
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3.5.6 Increasing density of spheroids might protect adipocytes against ER stress. 
It was hypothesised that increasing the number of adipocyte spheroids maintained in a single well 
could generate a stressed microenvironment due to a rapid consumption of nutrients [258]. Nutrient 
starvation renders cells vulnerable to ER stress [272]. Hence, the ER stress sensitivity of the adipocyte 
spheroids was measured in response to the change of spheroid seeding density. Contrary to this 
hypothesis, q-rtPCR results did not show significant differences of GRP78 (Fig 3.11a1) and sXBP1 
(Fig 3.11b1) mRNA expression in human ASC-derived adipocyte spheroids with change of number 
of spheroids. Surprisingly, in the normalised results showing the average mRNA expression by 5 
spheroids in various conditions there was a significantly lower mRNA expression of GRP78 (Fig 
3.11a2) and sXBP1 (Fig 3.11b2) when 20 spheroids were maintained than 5. There was a trend that 
GRP78 mRNA expression upregulated with the increment of 3T3-L1-derived spheroids seeding 
density. However, the difference between groups was not significant in both unnormalised (Fig 
3.11c1) and normalised (Fig 3.11c2) results. In contrast, in both unnormalised (Fig 3.11d1) and 
normalised (Fig 3.11d2) results, sXBP1 mRNA expression upregulated with increasing number of 




Fig 3.11 GRP78 and sXBP1 mRNA expression in response to change of spheroids number 
Human mesenchymal stem cells and mouse 3T3-L1-derived adipocyte spheroids were maintained at a density 
from 5 to 20 for 24 h. Human GRP78 (a1), human sXBP1 (b1), mouse GRP78 (c1) and mouse sXBP1 (d1) 
mRNA expression are displayed as a fold change compared to the control (5 spheroids maintained in a single 
well). Normalised results (a2, b2, c2 and d2) demonstrate the average mRNA expression by 5 spheroids in 
various conditions. *p<0.05, **p<0.01, ***p<0.001, ns, p>0.05, post-hoc test after one-way ANOVA. Positive 
control was 20 spheroids treated by tunicamycin (Tm). 20 vs 20+Tm, paired ratio t test. Error bars represent 
estimated standard errors of the mean. Data were pooled from 3 independent experiments.  
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 Discussion 
The results demonstrate that the liquid overlay technique can cost-effectively generate reproducible 
mature adipocyte spheroids, which can functionally produce adiponectin, MCP-1 and IL-8. Human 
ASC and 3T3-L1 cells grown in the 3D culture environment exhibited strong capacity for adipogenic 
differentiation, indicating the liquid overlay technique can be applied to generate a platform for in 
vitro studies requiring an adipose tissue microenvironment.  
To the best of my knowledge, the liquid overlay-based 3D culture has never been reported to generate 
human adipocyte spheroids. It has been published recently that this technique was able to successfully 
generate 3T3-L1-derived murine adipocyte spheroids in a spontaneous manner, indicating that 
applying this model has gained increasing value [273]. Applying a 3D co-culture technique is a 
mainstream in research associated with the tumour microenvironment, which can reflect cell-cell and 
cell-matrix interactions. The ECM based hydrogel is widely applied in building the scaffolds in 3D 
culture [274]. However, the challenge is to put cells in the same co-culture system, simultaneously, 
especially when including mature adipocytes that normally require longer induction time than other 
cell types (e.g. macrophages). In this study, spheroids were maintained in the agarose coated plate 
over a period long enough required for adipogenic differentiation, providing a platform to prepare 
mature adipocyte spheroids before incorporating them into a co-culture system to interact with other 
cells. The scaffold-free property of the adipocyte spheroids makes them easy to be transferred 
between culture dish and medium, meeting with the design of experiments as required. 
Adipocyte spheroids established in the study were able to produce adiponectin, MCP-1 and IL-8. As 
adipocyte secretions, these cytokines are key mediators in maintaining physiological homeostasis or 
contributing to adipose tissue dysfunction in diseases [275]. Adiponectin is exclusively secreted by 
adipose tissue, exerting protective anti-inflammatory, anti-atherosclerotic functions and increasing 
insulin sensitivity [120]. MCP-1 (also known as CCL2) exerts monocyte/macrophage recruiting 
functions by interacting with its receptor CCR2 [276]. The abundance of MCP-1 in adipose tissue 
and circulation is related to macrophage infiltration in the adipose tissue and development of 
metabolic disorders, such as insulin resistance and hepatic steatosis [277]. IL-8 (also known as 
chemokine C-X-C motif ligand 8, CXCL8) is a chemoattractant which recruits neutrophils and 
macrophages, contributing to self-defence or tissue damage in inflammation [278]. The mRNA 
expression of IL-8 in human adipocytes is upregulated upon exposure to proinflammatory cytokines 
(e.g. IL-1beta and TNF α) but downregulated by dexamethasone [279].  
q-rtPCR results showing treatment of tunicamycin decreased the expression of APM-1 (human gene 
encoding adiponectin) and MCP-1 were consistent with previous studies. In other research, treatment 
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of human adipocytes with tunicamycin impaired the multimerisation of adiponectin to form the most 
bioactive isoform which has high molecular weight (>300KD) [280]. Similarly, the mRNA 
expression of MCP-1 was reported to be downregulated after exposure to tunicamycin in adipocytes 
differentiated from 3T3-L1 cells [281]. Marjon et al. reported that IL-8 secretion was upregulated in 
exposure to tunicamycin at a concentration of 5 µg/ml for 24 h [282]. In the present study, there was 
a non-significant trend for tunicamycin to upregulate IL-8 secretion. The published data from others 
only reflected the average result from technique triplicates in a single experiment. It should be noted 
that great variance within groups present in primary cell culture may blunt the statistical power to 
detect variance between groups when the sample size is small, which was the situation in the present 
study when data pooled from three independent experiments using adipocytes from different donors 
being analysed [283]. Hence, even the statistical result did not show a significant upregulation of IL-
8 upon tunicamycin treatment, it is insufficient to conclude that tunicamycin has no effect on IL-8 
expression in reality. 
In a similar 3D culture platform established by hanging-drop technique, Klingelhutz et al. found that 
increasing the density of adipocyte spheroids could mimic a pro-inflammatory microenvironment as 
demonstrated by an upregulation of IL-8 with downregulation of adiponectin [258]. In the present 
study, the concentration of both IL-8 and adiponectin has always been increased with increment of 
spheroids numbers. However, it was unclear in the previous publication whether the total 
concentration of cytokines or the average concentration normalised by number of spheroids was 
measured. Hence, the production of IL-8 and adiponectin by 5 spheroids was further analysed when 
different numbers of spheroids were maintained in the same space. The normalised results did not 
show any significant difference among groups, indicating the increment of cytokine levels with 
increasing numbers of spheroids was mainly due to an accumulating effect rather than a cellular 
response to the changes in the microenvironment. 
Similarly, discrepancies existed between unnormalised and normalised results regarding the mRNA 
expression of ER stress-related genes in response to changes in spheroid density. For human ASC-
derived adipocyte spheroids, increasing spheroid density did not aggravate ER stress as predicted. In 
contrast, a significantly lower mRNA expression of both GRP78 and sXBP1 was observed when there 
were more spheroids maintained (20 vs 5) in the normalised results. However, the results were not 
consistent with the findings in 3T3-L1-derived adipocyte spheroids as demonstrated by a positive 
association between sXBP1 mRNA expression and number of spheroids in the normalised results. 
Considering the human ASC-derived adipocyte spheroids have stronger adiponectin secreting 
capacity than 3T3-L1-derived adipocyte spheroids, the inverse trend of change might be related to a 
protective role of adiponectin against ER stress [284, 285]. However, the mechanism is uncertain 
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without further investigating the change of signaling pathways that are possibly involved. Compared 
to a significant and consistent upregulation of sXBP1 and GRP78 mediated by tunicamycin, 
manipulating the density of adipocyte spheroids is not an ideal technique to create an ER stress-
activated microenvironment. 
 Conclusion 
Taken together, the liquid overlay technique cost-effectively generates reproducible mature and 
functional adipocyte spheroids that secrete adiponectin, MCP-1 and IL-8, and are responsive to the 
ER stress inducer, tunicamycin. This technique can be applied to establish a platform for studies 
requiring either a healthy or stressed adipose tissue microenvironment, though manipulating spheroid 
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Adipose tissue is associated with many chronic inflammatory diseases, including cancer. Within the 
SVF of adipose tissue, the recruitment of pro-inflammatory (M1) macrophages plays a negative role 
in maintaining adipose tissue homeostasis, therefore initiating tumourigenesis. However, TAM 
exhibit a tissue-remodelling phenotype (M2), therefore facilitating tumour metastasis. Investigating 
the macrophage behaviour in the adipose tissue microenvironment assists in understanding the fat-
cancer interplay from the view of immune modulation. Applying a novel 3D culture technique, we 
co-cultured adipocyte spheroids and macrophages to investigate the invasion capacity of 
macrophages towards adipocyte spheroids and the polarisation effect of the adipose tissue 
microenvironment on macrophage phenotype. Simultaneously, we applied the same co-culture 
system to study the invasion capacity of cancer cells towards adipocyte spheroids in the presence of 
different macrophages. We discovered that the mature adipocyte spheroids caused an MCP-1 
independent, but CCR2 dependent recruitment of Raw 264.7 cells. The migration was abolished by 
tunicamycin treatment, which is an inducer for ER stress. Unpolarised macrophages shifted into an 
M2 macrophage phenotype when co-cultured with adipocyte spheroids. M1 and M2 macrophages 
exhibited distinct invasion capacity through the Matrigel coated trans-well membrane. The presence 
of M1 macrophages inhibited the invasive capacity of Kirsten mouse sarcoma virus-transformed non-
producer human osteosarcoma (KHOS) and 786-0 kidney cancer cells. Reprogramming the 





Adipose tissue is found in proximity to the primary site of many cancers and could be the invasive 
site in early stages of cancer metastasis. The interactions of malignant cells with the normal cell types 
in the adipose tissue may have impact on cancer prognosis [286]. For example, the infiltration of 
macrophages (CD68+) in the adipose stroma of benign breast tumour is an independent risk factor of 
developing malignant breast cancer [212]. Investigating the dynamic interactions of macrophages 
with adipocytes is crucial for comprehensively understanding the role of adipose tissue 
microenvironment in cancer development. 
The macrophage is a cell type characterised by a high level of plasticity in terms of phenotype, 
function and motility [287]. Adipose tissue macrophages have been identified as the primary source 
of cytokines produced by adipose tissue [288]. The phenotype switching of macrophages is often 
observed in obesity-associated adipose tissue as demonstrated by M1 macrophage aggregation and 
increased secretion of pro-inflammatory cytokines, such as MCP-1 [277]. Adiponectin produced by 
adipose tissue is known to maintain the anti-inflammatory profile of macrophages [289]. However, it 
has been recently found that under obese conditions, overexpression of microRNA-34a in adipose 
tissue inhibited the M2 polarisation of macrophages [161]. The skew of M2 macrophages into M1 in 
obesity aggravates metabolic disorders and inflammation, and therefore could be a mechanism 
underlying the increased risk of tumourigenesis [290, 291]. However, in the breast cancer tumour-
associated adipose tissue sampled from patients who had a high metastatic rate and poor cancer 
survival, the predominant macrophages observed were M2 macrophages [210]. The negative impacts 
of M2 macrophages on cancer prognosis are associated with inhibited T cell anti-tumour immunity, 
enhanced extravasation of cancer cells and angiogenetic effects [292]. 
Chapter 2 introduced a finding through IHC that GRP78 (an ER stress marker) was upregulated in 
the perinephric adipose tissue of ccRCC from patients with high BMI. Regression analysis revealed 
that the upregulated GRP78 expression might be associated with decreased cancer metastasis [293]. 
It would be of interest to know the effects of activated ER stress in perinephric adipose tissue on 
macrophage migration and polarisation, considering the interplay between macrophages and cancer 
prognosis. 
In this chapter, a co-culture system including cancer cells, macrophages and adipocyte spheroids (the 
modelling technique introduced in Chapter 3) was applied to measure the polarisation, migration 
and invasion of murine and human macrophages in an ER stress-activated or a normal adipose tissue 
microenvironment. Moreover, the invasion capacity of cancer cells towards adipocyte spheroids in 
the presence of either M1 or M2 macrophages was compared.  
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 Methods 
4.4.1  Purifying monocytes from peripheral blood mononuclear cells 
This study received ethics approval from the Metro South Human Research Ethics Committee 
(HREC/16/QPAH/353). Whole peripheral blood was obtained prior to radical nephrectomy surgery 
from consented participants diagnosed with renal tumours. Peripheral blood mononuclear cells 
(PBMC) were isolated by density gradient centrifugation following the Histopaque manual (Sigma 
10771) [277]. The expression of CD16 in human blood monocytes is increased during the course of 
inflammation, as demonstrated using CSF-1 treatment [294]. To make sure all the monocytes used in 
the experiments were initially homogeneous, only the classic monocytes (CD14+/CD16-) were 
purified using fluorescence-activated cell sorting (FACS) with the Beckman Coulter MoFlo Astrios 
EQ sorter. Gating strategy to purify monocytes from PBMC is displayed in Fig 4.1.  
 
Fig 4.1 Gating strategy to purify monocytes from PBMC 
Classic monocytes (CD14+/CD16-) were purified using fluorescence-activated cell sorting. Live/dead aqua 
was used to discriminate live cells from dead cells. 
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4.4.2  Differentiation of M1/M2 macrophages from monocytes 
M1 and M2 macrophages were generated based on the method introduced by Tarique et al. with 
modification [295]. The ingredients supplemented in culture medium have been summarised in 
Appendix 5. Briefly, purified monocytes were seeded in 6 well culture plates at a density of 500,000 
per well and maintained in the macrophage differentiation medium for 6 days. Then, cells were 
maintained in the M1 or M2 induction medium, or still in the macrophage differentiation medium 
(M0) for 2 days (Fig 4.2). At the end of the induction, cells were collected to check the expression of 
macrophage phenotype markers (CD80, CD86, CD163, CD206, CD209 and CD200R) by flow 
cytometry analysis. 
 
Fig 4.2 Paradigm of differentiating M1 and M2 macrophages from PBMC 
CD14+/CD16- monocytes sorted from donors diagnosed with renal tumours were cultured with colony 
stimulating factor (CSF)-1 containing medium for 6 days. Then, M1 macrophages were generated by 
stimulating with lipopolysaccharide (LPS) and interferon (INF)-γ; M2 macrophages were generated by 
stimulating with interleukin (IL)-4 and IL-13. 
4.4.3  Flow cytometry analysis  
Flow cytometry analysis was performed to quantify the expression of different surface markers on 
classically and alternatively activated macrophages. Cells were harvested with human Fc block 
solution (BD 564220) to block non-specific Fc receptor binding and were incubated with specific 
antibody for 30 min on ice. Live and dead cell discrimination was performed by adding viability dye 
before sample analysis. Details on antibodies and live/dead cell dye are summarised in Appendix 1. 
If not specified, 1 × 106 cells were suspended in 100 µL of the staining solution per sample. The 
samples were analysed using the instrument BD LSR Fortessa X-20. Non-stained cells were used to 
set the voltage of the instruments. Flow cytometry data were analysed using the FlowJo Software.  
4.4.4  Culture of cell lines 
The human RCC cell line, 786-0 (ATCC CRL-1932TM), the human osteosarcoma cell line, KHOS 
(ATCC CRL-1544 TM), and the mouse macrophage, Raw 264.7 cell line (ATCC TIB-71 TM) were 
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cultured in DMEM-F12 medium supplemented with 10 % FBS, 1 % P/S, and maintained at 37 ˚C 
atmosphere containing 5 % CO2. The KHOS cells used in this experiment were green fluorescence 
protein (GFP)-transfected and were a kind gift from Dr Liliana Endo-Munoz (The University of 
Queensland Diamantina Institute, Brisbane, Australia).  
4.4.5  Trans-well invasion and migration assay 
A pre-set of five mature adipocyte spheroids (adipogenic differentiation for 18 days) were placed in 
each well of the 24-well plates in DMEM-F12 culture medium (FBS-free) for 24 h before placing in 
the trans-well inserts. DMEM-F12 culture medium (FBS and adipocyte spheroid free) was used as 
negative control. The 6.5 mm inserts with 5 µm pores and polycarbonate membrane (Corning 3421) 
were applied in the invasion assay in which the induced M1/M2 macrophages were placed at a density 
of 20,000 per 100 µL in the DMEM-F12 culture medium (FBS-free). The inserts were pre-coated 
with 100 µL of the Corning Matrigel Growth Factor Reduced (lactose dehydrogenase elevating 
virus/LDEV free) Basement Membrane MatMatrix (Corning BDAA354230) at a concentration of 
250 µg/mL for 1.5 h at 37 ˚C, after which the Matrigel was removed. Cells placed in the inserts were 
allowed 24 h for the invasion assay. The setting of the migration assay for Raw 264.7 macrophages 
was the same as the invasion assay except that the membrane was not coated with Matrigel. The 6.5 
mm FluoroBlock inserts with 8 µm pores and dyed polyethylene terephthalate membrane (Corning 
35112) were applied in the invasion assay in which cancer cells were co-cultured with either M1 or 
M2 macrophages in DMEM-F12 FBS-free medium. Cancer cells were seeded at a density of 20,000 
per 100 µL; macrophages were seeded at a density of 10,000 per 100 µL. All cells were starved for 8 
h by replacing the full culture medium (containing 10 % FBS) with FBS-free culture medium prior 
to seeding in the inserts, except for M1 and M2 macrophages, for the purpose of maintaining their 
polarisation.  
4.4.6  Processing, staining, imaging and quantification of migrated/invaded macrophages  
The non-migrating/invading cells from the upper surface of the membrane were removed by a cotton 
tipped swab after the migration/invasion assay. Then, the cells on the bottom surface were fixed in 
4 % paraformaldehyde for 15 min, stained with 1 % crystal violet (Sigma C6158) for 10 min, washed 
with water, and mounted on glass slides with the bottom side down. Images for quantification were 
photographed using the Nikon Brightfield Manual Microscope using a ×40 objective for the migration 
assay and a ×20 objective for the invasion assay. Five imaging points were chosen for each sample. 
The points were located at the centre of the membrane and four midpoints of the radii which split the 
membrane in four equal sectors. The mean number of cells counted manually in the five fields of 
view represented the migrated/invaded macrophages for each sample.  
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4.4.7  Live cell staining of macrophages and cancer cells 
M1/M2 macrophages were stained with the CellTracker Red CMTPX Dye (Invitrogen C34552) at a 
concentration of 7 µg/mL (diluted in FBS-free DMEM-F12 medium) for 30 min at 37 ˚C. After two 
washes with PBS, cells were rested in M1/M2 induction medium for 8 h prior to co-culture. 786-0 
cancer cells were stained with the CellTrace Violet dye (Invitrogen C34557) at a concentration of 
10 µg/mL (diluted in PBS) for 30 min at 37 ˚C. After two washes with the full culture medium, cells 
were starved in FBS-free culture medium for 8 h prior to co-culture. 
4.4.8  Imaging and quantification of invaded cancer cells in the presence of macrophages 
The membrane housing on the FluoroBlock inserts can block the fluorescently-labelled cells in the 
top chamber of the inserts, thereby eliminating the processing steps prior to imaging [296]. Images 
for quantification were photographed using a ×10 objective with the Olympus IX73 Inverted Manual 
Microscope. Images (16 bit) were acquired in greyscale output at a display resolution of 1376×1038 
using the cellSens Software. The gain and exposure were optimised in each independent experiment 
based on the signal intensity and were kept consistent when taking photos. The method of choosing 
the imaging fields of view was the same as imaging of the migrated/invaded macrophages. 
Macrophages, KHOS cells and 786-0 cells were imaged under the CY3, GFP and DAPI excitation 
filters, respectively. The area of the invaded cells was quantified using the software FIJI. Thresholds 
of images were adjusted manually with the setting above the background noise while leaving all the 
invaded cells visible. The mean area in the five fields of view represented the area of invaded cells 
for each of the sample. 
4.4.9  Statistical analysis 
Comparisons between groups were made using the ANOVA, paired or unpaired t-test when 
appropriate. When there was a statistically significant difference in ordinary ANOVA, post hoc 
testings were performed to determine where the difference occurred between groups. When there was 
a statistically significant difference in one-way repeated measures ANOVA, Tukey’s multiple 
comparisons were performed to determine the difference occurred between groups. P<0.05 was 
considered statistically significant. Statistical analysis was performed using GraphPad Prism 7.0.  
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 Results 
4.5.1  Morphologic observation of M0, M1 and M2 macrophages 
Over the 6 days of differentiation, purified monocytes elongated and became adherent. Mature 
macrophages (M0) are heterogeneous in size and shape. Some cells were rounded and flatted. Others 
had stretched pseudopodia (Fig 4.3a). After 2 days of polarisation, M1 macrophages became more 
rounded, and less tightly adherent to the well surface (Fig 4.3b). However, some M2 macrophages 
had more stretched pseudopodia and others further increased their size with more flatly outspread 
cytoplasm (Fig 4.3c). 
 
Fig 4.3 Morphologic characteristics of M0, M1 and M2 macrophages 
Images were photographed using the ×20 objective with the Olympus IX73 Inverted Manual microscope. Scale 
bars = 100 µm.  
a. M0 macrophages; b. M1 macrophages; c. M2 macrophages 
 
4.5.2  M1 and M2 macrophages exhibited distinct phenotypic characterisation. 
After 2 days of polarisation with M1 and M2 differentiation media (Fig 4.2), the expression of a panel 
of surface markers was investigated on M0, M1 and M2 macrophages. M2 macrophages exhibited 
significantly higher expression of CD200R and CD206 than M1 macrophages. Similarly, the 
expression of CD163 and CD209 was higher in M2 macrophages than M1 macrophages. However, 
the differences were not statistically significant. There was a trend that the expression of CD80 and 
CD86 was higher in M1 macrophages than M2 macrophages. However, the differences were not 
statistically significant. The raw data of the mean fluorescence intensity (MFI) of the 6 CD markers 




Fig 4.4 Phenotypic characteristics of the M1 and M2 macrophages 
M2 macrophages exhibited high expression of CD163, CD200R, CD206 and CD209; M1 macrophages 
exhibited high expression of CD80 and CD86 in flow cytometry analysis. Dot plots represent the mean 
fluorescence intensity (MFI) of a specific CD marker measured in one out of the five independent experiments 
using pooled peripheral blood mononuclear cells derived from at least 3 donors. *p<0.05, **p<0.01, ns, 
p>0.05, Tukey’s multiple comparison after repeated measures one-way ANOVA. Error bars represent 
estimated standard errors of the mean.  
4.5.3  The expression of CD163 and CD209 in M0 macrophages was upregulated when co-
cultured with adipocyte spheroids. 
Based on published data, co-culture of human PBMC with pre-adipocytes upregulated the expression 
of CD163. Moreover, the expression level was increased over the period of adipogenic differentiation 
[297]. However, it has not been confirmed in the 3D culture system that co-culture with mature 
adipocyte spheroids could induce the unpolarised macrophages to shift into M2 macrophages. Hence, 
the M0 macrophages (100,000 cells in 100 µL of the FBS-free control medium) were seeded in the 
trans-well inserts (pore size = 0.4 µm, Corning CLS3413), which were placed above the 10 adipocyte 
spheroids, and allowed to co-culture for 24 h. Results from the flow cytometry analysis demonstrated 
that the expression of CD163 and CD209 was significantly higher in M0 macrophages co-cultured 
with the adipocyte spheroids than in M0 macrophages grown on their own. No significant difference 
was observed for the expression of other macrophage phenotype markers, including CD200R, 
CD206, CD80 and CD86 (Fig 4.5).  
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Fig 4.5 CD163 and CD209 were upregulated when M0 macrophages were co-cultured with 
the mature adipocyte spheroids. 
Co-culture of M0 macrophages with ten adipocyte spheroids for 24 h significantly upregulated expression of 
CD163 and CD209 in macrophages. However, no significant change was observed for other macrophage 
phenotype markers. Data reflect 5 independent experiments and each experiment was using the pooled 
peripheral blood mononuclear cells isolated from at least 3 donors. *p<0.05, **p<0.01, ns, p>0.05, paired t-
test. Error bars represent estimated standard errors. Abbreviation: MFI, mean fluorescence intensity. 
 
4.5.4  Exposure to tunicamycin did not shift M2 macrophages into M1. 
Since a negative association between ER stress level and kidney cancer metastatic rate was found 
previously and M2 macrophages in the tumour microenvironment may facilitate metastasis [293, 
298], the effect of ER stress on the M1 phenotype skew to M2 macrophages was investigated. 
However, neither an upregulation of M1 markers nor a downregulation of M2 markers was observed 
in M2 macrophages upon tunicamycin treatment at the concentration of 2 to 4 µg/mL in the flow 
cytometry analysis, indicating ER stress and macrophage polarisation may not be directly linked in 
the setting of cancer metastasis (Fig 4.6). Tunicamycin is a drug which inhibits N-linked 





Fig 4.6 Treatment with tunicamycin did not cause an M1 phenotype switch to M2 macrophages. 
a. Macrophage phenotype markers were tested by flow cytometry analysis in M2 macrophages treated 
with or without tunicamycin (Tm) at a concentration of 2 µg/mL for 24 h. No MFI (mean fluorescence 
intensity) of the markers exhibited significant difference under the two conditions. Data were pooled 
from two independent experiments with technique duplicates. ns, p>0.05, paired ratio t test. b. To 
confirm that Tm has no direct effect on phenotypes of macrophages, the experiment was repeated by 
treating M2 macrophages with increasing concentrations of Tm from 2 to 4 µg/mL. For all the 
markers, the variance of MFI was very small in response to different concentrations of Tm. 
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4.5.5 Tunicamycin diminished the migration of Raw 264.7 cells towards adipocyte spheroids. 
Trans-well migration results demonstrated that, compared with the control medium, medium 
maintaining 5 adipocyte spheroids caused a significant migration of Raw 264.7 cells. The migration 
was diminished when spheroids were pre-treated with tunicamycin (5 µg/mL) for 24 h (Fig 4.7a). 
Graphs of the migrated cell number pooled from 3 independent experiments and raw data are 
displayed in Fig 4.7b. Demographic information of participants has been displayed in Table 3.1 
(Chapter 3). Trypan blue exclusion assay and MTT assay results demonstrated that tunicamycin at 
the concentration of 2 µg/mL had less impact on cell proliferation and viability (Table 4.1 and Fig 
4.8). To exclude that the diminished migration reflected inhibited cell viability caused by 
tunicamycin, the migration assay by treating adipocyte spheroids with tunicamycin at the 
concentration of 2 µg/mL was repeated. Consistently, the migration of macrophages was blocked, 
with the 95 % CI of the difference between group means of migrated cell number being -79.7 to 236.2 
(Fig 4.9, Groups 1-2). 
 
Fig 4.7 Tunicamycin blocked the migration of Raw 264.7 cells. 
a. Images were photographed using the ×10 objective and cell numbers were quantified under the ×40 
objective. Scale bar=100 µm. b. Compared with the control (ct) medium, a significant migration was caused 
in the presence of adipocyte spheroids [ct vs 5 spheroids (Tm-)], which was blocked when the spheroids were 
treated with tunicamycin (Tm) at a concentration of 5 µg/ml [5 spheroids (Tm-) vs 5 spheroids (Tm+)]. Data 
reflect 3 independent experiments including technique duplicates. **p<0.01, ns, p>0.05, Tukey’s multiple 
comparisons after one-way repeated measures ANOVA. Error bars indicate estimated standard errors of the 
mean in pooled data and standard deviation of the mean in raw data.  
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Table 4.1 Results of Trypan blue exclusion and MTT assays when Raw 264.7 cells were 
treated with tunicamycin at different concentrations 
Concentration of 
tunicamycin 
Live/Live+Dead ratio Cell count OD value/ OD value for control 
×100% 
5 µg/mL 88 % 1.35×105/mL 39.74 % 
2.5 µg/mL 88 % 2.23×105/mL 44.04 % 
1.25 µg/mL 79 % 2.64×105/mL 52.58 % 
0.625 µg/mL 72 % 2.82×105/mL 56.98 % 
0 µg/mL 85 % 3.22×105/mL 100 % 
Raw 264.7 cells were seeded at a density of 5,000 per well in a 96 well plate and treated with tunicamycin at 
serially diluted concentrations for 24 h. Cell count and MTT assay results demonstrated that the proliferation 
of macrophages was inhibited dramatically in response to tunicamycin at the concentration of 5 µg/mL. OD = 
optical density. 
 
Fig 4.8 Morphology of Raw 264.7 cells in exposure to Tunicamycin at various concentrations 
Live cell images demonstrated the cells became more rounded with less protuberance in response to 
tunicamycin (Tm) at the concentration of 5 µg/mL. Images were photographed using a ×10 objective with the 
Olympus IX73 Inverted Manual microscope. Scale bars = 100 µm. a. 5µg/mL; b. 2.5 µg/mL; c. control.  
4.5.6  The diminished migration effect was not mediated by low secretion of MCP-1. 
MCP-1 is a potent chemokine for recruiting macrophages [299]. ELISA and q-rtPCR results 
demonstrated that the MCP-1 secreted by adipocyte spheroids was decreased by the treatment of 
tunicamycin at the concentration of 5 µg/mL (Figs 3.8a and 3.8c, Chapter 3). The possible 
mechanism underlying the diminished migration caused by tunicamycin was then further 
investigated. 24 h prior to placing Raw 264.7 cells in the trans-well inserts above the 5 adipocyte 
spheroids, culture medium maintaining adipocyte spheroids was replaced with FBS-free medium 
containing 90 nM of the CCR2 antagonist, INCB3344 (MCE HY-50674), or 2 µg/mL of the MCP-1 
neutralising antibody (R&D MAB679), or both reagents. Then, Raw 264.7 cells were allowed to 
migrate in such medium or the control medium for another 24 h. No migration blocking effect was 
observed in the presence of MCP-1 neutralising antibody alone (Fig 4.9, Groups 1-3). A trend of 
blocking effect was shown in the presence of CCR2 antagonist (Fig 4.9, Groups 1-4), especially when 
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both the antagonist and the neutralising antibody were added (Fig 4.9, Groups 1-5), however the 
differences were insignificant.  
 
Fig 4.9 Low concentration of MCP-1 was not the major mechanism underlying the blocked 
migration effect mediated by tunicamycin. 
Migration of Raw 264.7 cells towards the adipocyte spheroids was measured in the following 
microenvironment: Group 1, no treatment; Group 2, supplemented with 2 µg/mL of the tunicamycin (Tm); 
Group 3, supplemented with 2 µg/mL of the MCP-1 neutralising antibody (neutra-ab); Group 4, supplemented 
with 90 nM of the CCR2 antagonist, INCB3344; Group 5, supplemented with both MCP-1 neutralising 
antibody and CCR2 antagonist. The migration of Raw 264.7 cells was decreased dramatically when adipocyte 
spheroids was pre-treated with 2 µg/mL of Tm (Groups 1-2). No migration blocking effect was observed in 
the presence of MCP-1 neutralising antibody alone (Groups 1-3). However, a trend of blocking was shown in 
the presence of CCR2 antagonist (Groups 1-4), especially when both the antagonist and the neutralising 
antibody were added, with 95 % confidence intervals of the difference between group means being -37.5 to 
122.5 (Groups 1-5). Data reflect 3 independent experiments including technique duplicates. ns, p>0.05, 
Tukey’s multiple comparisons after the one-way repeated measures ANOVA. Error bars indicate estimated 
standard errors of the mean. 
4.5.7  M1 and M2 macrophages exhibited distinct invasion capacity.  
Similar to the result of Raw 264.7 cell migration, medium maintaining 5 adipocyte spheroids 
demonstrated a significantly stronger recruiting capacity for primary M2 macrophages compared with 
the control medium in the invasion assay. M1 macrophages did not invade through the Matrigel 
coated (250 µg/mL) trans-well inserts (Figs 4.10a and 4.10b).  
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Fig 4.10 Distinct invasion capacity between M1 and M2 macrophages 
a. M1 and M2 macrophages were seeded in the trans-well inserts (coated with Matrigel at 250 µg/mL), which 
were placed above the 5 adipocyte spheroids or above the control (ct) medium. Images of crystal violet-stained 
macrophages were photographed using the ×10 objective and cell number was quantified under the ×20 
objective. Scale bars = 100 µm. b. Compared with the ct medium, a significant invasion for M2 macrophages 
was caused in the presence of adipocyte spheroids. However, M1 macrophages did not invade through the 
Matrigel coated trans-well inserts. Data were compiled from 2 independent experiments, with each experiment 
including 4 technique replicates. The square dots represent the number of invaded macrophages towards the 
medium maintaining 5 adipocyte spheroids; the circle dots represent the number of invaded macrophages 
towards the ct medium. ****<0.0001, unpaired t test. Error bars represent estimated standard deviation of the 
mean.  
4.5.8  M1 and M2 macrophages exhibited distinct expression levels of integrin αMβ2. 
Being one of the most important cell adhesive receptors, integrin αMβ2 (CD18/CD11b) is abundant 
on the macrophage surface, which shares many ligands with ECM [300]. To evaluate whether the 
distinct invasion capacity between M1 and M2 macrophages may be associated with the different 
expression level of integrin αMβ2, the expression of CD18 and CD11b was measured using flow 
cytometry analysis. M2 macrophages demonstrated higher expression levels of both CD18 and 
CD11b (Fig 4.11). Demographic information of patients has been summarised in Table 4.2. 
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Fig 4.11 Distinct integrin expression levels between M1 and M2 macrophages 
a. Results of mean fluorescence intensity (MFI) measured by flow cytometry analysis demonstrate that the 
expression of both CD18 and CD11b was significantly higher in M2 macrophages compared with M1 
macrophages. *p<0.05, **p<0.01, ratio paired t test. Error bars represent estimated standard deviation of the 
mean. Data were pooled from 3 independent experiments, each of which was using peripheral blood 
mononuclear cells from a single participant. b. Compared with M1 macrophages, MFI of M2 macrophages 
demonstrates a positive shift along the CD18-axis and CD11b-axis for all samples in raw data.  













Patient 4 16-Sep-1955 Male 27 ccRCC 38mm 2 3 
Patient 5 15-June-1960 Male 42 ccRCC 90 mm 3 3 
Patient 6 21-May-1963 Male 38 ccRCC 45mm 2 3 
Tumours were staged according to the 7th TNM Classification of malignant tumours and graded according to 
the International Society for Urological Pathology (ISUP) grading system for renal cell carcinoma. 
Abbreviation: BMI, body mass index; ccRCC, clear cell renal cell carcinoma. 
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4.5.9  The presence of M1 macrophages inhibited the invasion capacity of cancer cells. 
To evaluate whether the presence of different macrophages would influence the invasion capacity of 
cancer cells, the invasion was measured of KHOS osteosarcoma cancer cells (Fig 4.12) and 786-0 
kidney cancer cells (Fig 4.13) towards the adipocyte spheroids or control medium when the cancer 
cells were co-cultured with different macrophage phenotypes. Adipocytes are important components 
in the bone marrow microenvironment [301]. The crosstalk between adipocytes and tumour cells may 
influence the bone metastasis of osteosarcoma [302]. Likewise, the spread of tumour cells into the 
perinephric adipose tissue is a marker of early metastasis for kidney cancer [303]. First, our data 
confirmed the results that M2 macrophages exhibited a significantly more active motility capacity 
through the Matrigel coated trans-well membrane when co-cultured with both KHOS (Fig 4.12b) and 
786-0 cancer cells (Fig 4.13b). Excitingly, KHOS cancer cells exhibited significantly weaker 
invasion capacity in the presence of M1 macrophages. However, the presence of M2 macrophages 
did not significantly enhance or weaken the invasion capacity of cancer cells (Figs 4.12a and 4.12c). 
Unexpectedly, the invasion capacity of 786-0 cancer cells did not show significant difference in the 
co-culture system in the presence of either M1 or M2 macrophages. However, 786-0 cancer cells 
exhibited significantly stronger invasion capacity when only cancer cells were placed above the 




Fig 4.12 Invasion assay of KHOS cells in the co-culture system with or without macrophages 
a. Images were acquired using the ×4 objective, by combining the GFP (green) and CY3 (red) channels. KHOS 
cells are green in colour. Macrophages (both M1 and M2) are red in colour. Scale bars = 400 µm. b. M1 
macrophages exhibited a significantly weaker invasion capacity than M2 macrophages when co-cultured with 
KHOS cancer cells. ***p<0.001, unpaired t-test. c. In the presence of M1 macrophages, the area of the invaded 
KHOS cancer cells was significantly less than the invasion area when KHOS cancer cells were placed alone 
in the trans-well inserts. There were significantly more invading KHOS cancer cells when co-cultured with 
M2 macrophages than with M1 macrophages. **p<0.01, ***p<0.001, ns, p>0.05, post hoc testing after 
ordinary one-way ANOVA. Results were derived from a pilot experiment followed by two repeats (repeat 1 
and 2). Each dot represents data from a single replicate. Error bars represent standard deviation. Abbreviation: 
ct, FBS-free DMEM-F12 control medium. 
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Fig 4.13 Invasion assay of 786-0 cells in the co-culture system with or without macrophages 
a. Images were acquired using the ×4 objective, by combining the DAPI (blue) and CY3 (red) channels. 786-
0 cells are blue in colour. Macrophages (both M1 and M2) are red in colour. Scale bars = 400 µm. b. M1 
macrophages exhibited a significantly weaker invasion capacity than M2 macrophages when co-cultured with 
786-0 cancer cells. ***p<0.001, unpaired t-test. c. 786-0 cancer cells exhibited significantly stronger invasion 
capacity when placed alone. No significant difference of invasive capacity was observed between 786-0 cancer 
cells co-cultured with M1 macrophages and 786-0 cancer cells co-cultured with M2 macrophages. ***p<0.001, 
****p<0.0001, ns, p>0.05, post hoc testing after ordinary one-way ANOVA. Results were derived from a pilot 
experiment followed by two repeats (repeat 1 and 2). Each dot represents data from a single replicate. Error 
bars represent standard deviation. Abbreviation: ct, FBS-free DMEM-F12 control medium. 
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 Discussion 
To the best of our knowledge, this is the first study using the liquid overlay-based 3D culture 
technique to establish a co-culture system to study the macrophage behaviour in the human adipose 
tissue microenvironment. It was found that the adipocyte spheroids caused an MCP-1 independent, 
but CCR2 dependent migration of Raw 264.7 cells, which could be blocked by the ER stress inducer, 
tunicamycin. Co-culture with the adipocyte spheroids shifted the unpolarised M0 macrophages into 
an M2 phenotype, as demonstrated by an upregulation of CD163 and CD209. Of note, M1 and M2 
macrophages demonstrated distinct invasion capacity with only M2 macrophages invading through 
the Matrigel-coated trans-well membrane towards the adipocyte spheroids. In addition, M2 
macrophages expressed a higher level of integrin αMβ2 (CD11b/CD18) than M1 macrophages, 
indicating the different expression level of integrin αMβ2 may be associated with the distinct invasion 
capacity between M1 and M2 macrophages. Both M1 and M2 macrophages suppressed the invasion 
of kidney cancer 786-0 cells in the trans-well assay. However, only the presence of M1 macrophages 
suppressed the invasion of osteosarcoma KHOS cells. The variation suggests the effects of TAM on 
metastases may be dependent on certain tumour microenvironment.  
Widely applied as a monocyte/macrophage migration inducer in experiments, MCP-1 (also known as 
CCL2) is a well-known chemoattractant for monocytes and macrophages. Administration of NOX-
E36 (an MCP-1 neutralising reagent) alleviated proteinuria and restored glomerular endothelial 
integrity in a diabetic nephropathy mouse model, however did not interfere with the absolute 
macrophage number in the nephron [304]. Coincidently, supplementation with MCP-1 neutralising 
antibody at the concentration of 2 µg/mL did not ablate or attenuate the migration of Raw 264.7 cells 
in this present study. It was recommended by the manufacturer that 0.5-2 µg/mL of the neutralising 
antibody can block 75 ng/mL of MCP-1 which was far beyond the concentration (approximately 2 
ng/mL) measured in the supernatant maintaining 5 adipocyte spheroids for 24 h. The blocked 
macrophage migratory effect potentially caused by totally or partially neutralising MCP-1 may be 
compensated by other chemokines secreted by the mature adipocyte spheroids, such as IL-8, CCL7, 
CCL8, CCL10, CCL13, CCL19, CCL21 [305]. Hence, the interfered MCP-1 secretion induced by 
tunicamycin must not be the major mechanism underlying the blocked macrophage migration effect 
observed in the study. Except for being the MCP-1 receptor, CCR2 can also bind to CCL7 and CCL12 
in mice [306]. This may be an explanation for the nearly significant migration-suppressing effect for 
Raw 264.7 cells mediated by the CCR2 antagonist. The N-glycosylation of CCR2 is functionally 
important for ligand binding and chemotaxis, indicating the diminished migration effect might be 
linked with an impaired post-translational modification of CCR2 mediated by tunicamycin [307].  
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Blocking MCP-1 in the culture medium did not interfere with the recruitment of Raw264.7 cells. 
Conversely, the migration of this immortalised macrophage cell line was diminished in the presence 
of the ER stress inducer, tunicamycin. The cell count assay (Table 4.1 and Fig 4.8) demonstrated that 
the cell number of Raw264.7 cells treated by 5 µg/mL tunicamycin was lower than Raw264.7 cells 
treated with tunicamycin at a concentration of 2 µg/mL (1.35×105/mL vs 2.23×105/mL). Even though 
showing such a different impact on cell proliferation, the migration blocking effect induced by 
tunicamycin at these two concentrations was very similar (Fig 4.9). Hence, the result was interpreted 
as a blocking effect that might be ER stress relevant. It would be very interesting to compare the 
result using PBMC derived macrophages and this could be a future direction of the study. 
This study reconfirmed the finding that the normal adipose tissue microenvironment favours the M2 
phenotype shift of macrophages, using both macrophages and adipocytes isolated from human 
samples. The mechanism is related to the activation of the full length adiponectin-IL-4-signal 
transducer and activator of transcription 6 (STAT 6) signaling pathway, which supports the high 
demand of glucose oxidation for M2 macrophages [308, 309]. Since a negative association between 
ER stress level and kidney cancer metastatic rate was found previously and M2 macrophages in the 
tumour microenvironment may facilitate metastasis [293, 298], we hypothesised that tunicamycin 
could induce the M1 phenotype skew for M2 macrophages. However, neither an upregulation of M1 
markers nor a downregulation of M2 markers was observed in M2 macrophages upon tunicamycin 
treatment, indicating ER stress and macrophage polarisation may not be directly linked in the setting 
of cancer metastasis. 
The distinct invasion capacity between M1 and M2 human macrophages that we observed resembles 
that reported by Cui et al. where the distinct invasion capacity between M1 and M2 mouse 
macrophages and relevant mechanisms were systematically investigated both in vitro and in vivo 
[310]. Unlike an upregulated protein level of integrin αMβ2 being observed in M2 human macrophages 
in our study, the integrin αMβ2 gene expression was reported to be lower in M2 than M1 mouse 
macrophages. However, the M2 macrophage motility promoting role of integrin αMβ2 demonstrated 
in their publication was consistent with our finding because the knock-down of integrin αMβ2 inhibited 
the migration of M2 macrophages. Of note, Cui et al. discovered that the integrin αD deficiency 
decreased the recruitment of M1 macrophages in inflamed mouse adipose tissue and improved insulin 
sensitivity and glucose tolerance. It will be important in future studies to evaluate the expression and 
function of integrin αD in human macrophages, which may provide a novel treatment for diabetes. 
The pro-metastatic role of M2 macrophages is partially ascribed to pro-angiogenic signaling 
pathways activated under a tumour-associated hypoxic microenvironment, which has been 
extensively reviewed [311]. Live imaging of tumour cell intravasation using animal models has also 
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confirmed that the motility of tumour cells occurred in close proximity to perivascular macrophages 
in the tumours [312]. Hence, we hypothesised that more cancer cells could invade through the 
Matrigel-coated trans-well membrane accompanied by M2 macrophages, considering the distinct 
invasion capacity between M1 and M2 macrophages observed in our study. Surprisingly, increased 
invasion of KHOS osteosarcoma cancer cells was observed in the presence of M2 macrophages 
compared with M1 macrophages. It would be questionable to conclude here that M2 macrophages 
facilitate the invasion of KHOS cells without comparing the invasion of KHOS cells in the absence 
of M2 macrophages. However, no significant difference was shown in this comparison. 
Unexpectedly, the greatest invasive capacity for kidney cancer 786-0 cells was shown when the 
cancer cell itself was placed in the top of the trans-well membrane, with no significant difference of 
invaded cancer cell number observed between the presence of M1 and M2 macrophages. The only 
common finding from these results is that M1 macrophages inhibit the invasion of cancer cells, 
however it is uncertain whether the mechanism is related to direct interaction or paracrine effects. 
Monitoring the metastasis-preventing effect by reprogramming tumour resident macrophage 
phenotypes using in vivo models is a future endeavour. 
 Conclusion 
Overall, these findings expand our understanding about how the adipose tissue microenvironment 
(healthy or stressed) may influence macrophage polarisation and migration/invasion in vitro. An 
understanding of how ER stress interferes with macrophage filtration and how the interaction of M1 
macrophages with cancer cells affects tumour invasion will be essential for targeting macrophages in 
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Quantitative image analysis using multiplex IHC is an important tool to identify the association 
between tissue-specific immune profiles and cancer aggressiveness. It was previously reported that 
the M2 phenotype skew for macrophages in breast cancer-associated adipose tissue predicted poor 
cancer prognosis. However, macrophage phenotypes and relevant prognostic value in human 
perinephric adipose tissue have never been reported in the setting of kidney cancer. Chapter 5 aimed 
to characterise the macrophage-associated immune profiles in perinephric adipose tissue and to 
explore the potential prognostic value of macrophage phenotypes in predicting distant metastases in 
ccRCC. A multiplex immunofluorescence panel was established to label the expression of 
macrophage phenotype markers, including CD163, CD206 and CD68, in archived FFPE human 
perinephric adipose tissue. Simultaneous detection of the three CD markers in the same tissue sample 
was processed using Vectra III multispectral microscopy and Inform 2.2.1 image analysis software. 
Compared to the perinephric adipose tissue derived from participants diagnosed with non-metastatic 
ccRCC and oncocytoma, the perinephric adipose tissue samples from metastatic ccRCC, considered 
the most aggressive of these groups, exhibited the highest expression of CD163 and CD206, which 




Orchestrated within the tumour microenvironment, TAM exert protumoural functions through 
inhibiting anti-tumour immunity, assisting angiogenesis and promoting metastasis (Fig 1.5, Chapter 
1). The protumoural functions of TAM have been demonstrated in an increasing number of clinical 
trials that found a positive correlation between high expression of M2 macrophages in tumour tissue 
and poor cancer prognosis (Table 1.2, Chapter 1). Adipose tissue is also an important depository of 
macrophages, with the proportion of macrophages increasing when obesity exists [313]. Obesity-
associated macrophage infiltration in adipose tissue is believed to contribute to increased risk of 
tumourigenesis through activating proinflammatory signaling pathways [1], although in the case of 
kidney cancer, this association has not been proven. There is some evidence that obesity-associated 
adipose tissue macrophages contribute to the stem-like properties of cancer cells, and thereby have a 
protumoural role [229]. The macrophage-associated immune phenotypes in adipose tissue may also 
be linked with cancer prognosis. For example, an M2 phenotype skew for macrophages was observed 
in mice within the tumour-associated adipose tissue experiencing changes of lipid metabolism, which 
were favourable for cancer cell development [150]. Relevant research in humans is limited to the field 
of breast cancer with findings supporting that high M2 macrophage expression in adipose stroma of 
breast tumours predicted poor cancer prognosis [210, 211]. As discussed previously, perinephric 
adipose tissue which is easily obtained after radical nephrectomy is an important but often ignored 
tumour-associated adipose tissue for kidney cancer [257]. Investigating the macrophage phenotypes 
in perinephric adipose tissue may help better understand roles of the heterogeneous adipose tissue in 
kidney cancer progression. The macrophage phenotypes may be identified using several CD 
antibodies, described in the following paragraphs. 
CD68 antibody has been widely used for identifying macrophages in the field of tumour 
microenvironment (Table 1.2, Chapter 1). CD68 is mainly expressed on the lysosomal membrane, 
with a small proportion of CD68 present on the cell membrane [314]. However, the belief that CD68 
positivity is indicative of phagocytosis rather than a specific marker for macrophages suggests that 
the current use of CD68 to identify circulating and tissue macrophages may be incorrect [315]. The 
new paradigm for use of CD68 to identify cellular function, rather than simply macrophage presence, 
is based on observations that CD68 antibodies have cross-reactions with fibroblasts and endothelial 
cells [316], and muscle cells phagocytosing lipids were CD68 positive [317].  
CD163 is predominately used as an M2 macrophage marker whose upregulation is associated with 
an unfavourable cancer prognosis (Table 1.2, Chapter 1). The transmembrane CD163 protein is a 
transmembrane scavenger receptor for haptoglobin-haemoglobin complexes. These complexes are 
mainly expressed on, but not limited to, monocytes and macrophages [318]. For example, a 
107 
significant portion of malignant bladder cancer cells is known to express CD163 [319]. CD163 
expressed on tissue-resident macrophages can recognise bacteria, therefore maintaining tissue 
homeostasis by innate immunity [320]. CD163 expression was also found to be upregulated upon 
stimulation of IL-4 and IL-13 in in vitro studies mimicking the M2-polarisation of macrophages (Fig 
4.4, Chapter 4). CD163-heme oxygenase-1 (HO-1) signaling is crucial for protecting against 
inflammatory injury by upregulating the anti-inflammatory cytokine IL-10 upon LPS stimulus [321].  
Consistent with CD163, expression of CD206 was upregulated in monocyte-derived macrophages 
after exposure to IL-4 and IL-13 (Fig 4.4, Chapter 4). The transmembrane pattern recognition protein 
CD206, also known as mannose receptor, is primarily expressed on macrophages and immature 
dendritic cells [322, 323]. As an M2 macrophage marker, the poor prognostic value of CD206 was 
reported in ccRCC tumour tissue [217]. It was also reported that CD206-positive macrophages may 
be located tightly bound to the endothelial cells of capillaries, providing VEGF to endothelial cells 
and therefore promoting tumour growth [324]. 
Simultaneous detection of multiple epitopes in the same tissue section, known as multiplex IHC, has 
become a powerful tool in exploring the complex tumour microenvironment [325]. The technique 
enables detection of multiple markers using fewer samples without disrupting the tissue integrity. 
Compared to an image labelled with only one epitope, multiplexed images contain more useful 
information, such as colocalisation of markers, and distribution of markers relative to one another. 
When imaging multiplex immunofluorescent staining, each fluorophore-labelled target of interest is 
excited by one pre-setting wavelength. The emitted fluorescence only goes through one filter in the 
imaging collecting instrument [326]. The spectral unmixing for multiplex immunofluorescence is 
therefore more accurate than the colour deconvolution tool which is applied in analysing brightfield 
chromogen IHC. Development of the tyramide signal amplification (TSA) technique promotes the 
widespread application of multiplex immunofluorescent detection. TSA is an enzyme-mediated 
detection method that utilises the catalytic activity of horseradish peroxidase (HRP) which is 
conjugated to the secondary antibody [327]. Briefly, the fluorophore-labelled tyramide derivatives 
are converted to an active form that covalently binds to protein residues when H2O2 is catalysed by 
HRP. The tyramine-fluorophore is therefore deposited in proximity to the sites of epitope-antibody 
interactions. However, the primary and secondary antibodies are washed away prior to the next round 
of staining. Hence, use of TSA technique overcomes the limitation of choosing secondary antibodies 
from distinct animal species, which also must be linked with different signal reporters.  
In this chapter, a multiplex immunofluorescence panel was optimised to detect simultaneously the 
expression of CD68, CD163 and CD206 in the archived FFPE human perinephric adipose tissue from 
ccRCC patients. Three pixel-based algorithms, based on either individually optimised thresholding 
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or consistent maximal and minimal thresholding, were applied to quantify the expression of the CD 
markers across the whole image and in the segmented cytoplasm compartment. The possible 
association of macrophage phenotypes and kidney cancer aggressiveness, in particular with regard to 
distant metastasis of ccRCC, was explored.   
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 Methods 
5.4.1 Study participants 
This study received ethics approval from the Metro South Human Research Ethics Committee 
(HREC/05/QPAH/95; HREC/16/QPAH/353) and utilised archived FFPE perinephric adipose tissue 
from consenting patients who underwent nephrectomy for renal tumours at the Princess Alexandra 
Hospital, Brisbane, Australia between June 2013 and September 2017 [236]. Inclusion criteria for the 
cohort of metastasis are, 1) diagnosis of ccRCC; 2) availability of perinephric adipose tissue with 
quality suitable for immunofluorescent staining; 3) presence of distant metastasis. The cohort of non-
metastasis was established by matching the cohort of metastasis for BMI in the range of 25 to 30 
kg/m2. Moreover, the cohorts of metastasis and non-metastasis were matched as much as possible for 
gender, age, tumour stage and tumour grade. It was unaccepted in the matching procedure if any 
participant in the cohort of metastasis was older or diagnosed with more aggressive ccRCC compared 
to the matched counterpart when the perfect matching was impossible. Participants diagnosed with 
oncocytoma having available fat tissue constituted the third cohort. A flow chart of participation is 
displayed in Fig 5.1.  
 
Fig 5.1 Flow chart of participation in the study 
Five participants constituted the cohort of metastasis. Another 5 participants who matched for BMI, and 
matched as much as possible for age, gender, tumour stage and tumour grade, constituted the cohort of non-
metastasis. The two cohorts were included in the paired-t test or repeated measures two-way ANOVA; The 
ccRCC cohorts of metastasis and non-metastasis, and another oncocytoma cohort were included in the ordinary 
or two-way ANOVA. Abbreviation: ANOVA, analysis of variance; BMI, body mass index; ccRCC, clear cell 
renal cell carcinoma.  
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5.4.2 Antibody optimisation 
All staining work in this chapter was processed by the core Histology facility at the Translational 
Research Institute. The perinephric adipose tissue was sequentially stained with 3 primary antibodies. 
The antibodies were CD163 (clone EDHu-1 mouse monoclonal antibody/mAb, BIO-RAD 
MCA1853T), CD206 (rabbit polyclonal antibody/pAb, Abcam Ab64693) and CD68 antibody (clone 
KP1 mouse mAb, Abcam ab955). Antibody-fluorophore pairs were determined based on staining 
intensities of fluorophores and expression levels of respective antigens. The pairs were: CD163-
Rhodamine 6G, CD206-Alexa Fluor 610 and CD68-CY5. The appropriate sequence of applying the 
primary antibodies in multiplex staining was determined through optimisation trials to make sure the 
antibody applied earlier was easier to be fully removed than that applied later. Titration of the primary 
antibody, the incubation time of the secondary antibody and TSA reagent were determined in uniplex 
DAB IHC (Fig 5.2) followed by uniplex immunofluorescent staining to achieve a balance between 
specific staining patterns and minimised bleed-through. The staining pattern in uniplex 
immunofluorescent staining is displayed in Figs 5.3, 5.4 and 5.5. 
 
Fig 5.2 DAB staining pattern of the antigens in perinephric adipose tissue 
Images were captured at x40 using the Nikon Brightfield microscope. Scale bars = 50 µm. Sub-serial sections 
from the same block were stained with the CD163 antibody at the dilution ratio of 1:500 (a) or stained with 
the CD206 antibody (1:3000) (b) or stained with the CD68 antibody (1:100) (c) using Ventana autostainer 
with Biocare Medical MACH1 Universal Polymer Detection reagents. The expression of CD163 was the most 




Fig 5.3 Unmixed spectral images of the perinephric adipose tissue stained with CD163 antibody 
The slide was incubated with the CD163 antibody (1:500) and scanned with Vectra III multispectral 
microscopy at ×20 objective (exposure time: 100 ms). Spectra were unmixed using the InForm 2.21 software. 
Specific staining patterns (bright staining in cell membrane and cytoplasm) of CD163, shown in the channel 
of cyanine (CY) 3, are labelled with white arrows (upper left). The two arrows are placed in the same location 
in the Texas Red-spectral unmixed image (upper right), CY5-spectral unmixed image (bottom left) and FITC-
spectral unmixed image (bottom right). The distinct fluorescent pattern between the CY3-spectral unmixed 
image and FITC-spectral unmixed image demonstrated that the fluorescence appearing in the CY3 channel 
was real staining for CD163 rather than autofluorescence. The disappearance of the CD163-specific staining 
pattern in Texas Red and CY5-spectral unmixed images demonstrated the CD163 fluorescence labelling did 
not appear in neighbouring channels.  
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Fig 5.4 Unmixed spectral images of the perinephric adipose tissue stained with CD206 antibody 
The slide was incubated with the CD206 antibody (1:3000) and scanned with Vectra III multispectral 
microscopy at ×20 objective (exposure time: 150 ms). Spectra were unmixed using the InForm 2.21 software. 
Specific staining patterns (bright tiny dots along the adipocyte cell boarders or filled in the space between 
adipocytes) of CD206, shown in the channel of Texas Red, are labelled with white circles (upper left). The 
two circles are placed in the same location in cyanine (CY) 3-spectral unmixed image (upper right), CY5-
spectral unmixed image (bottom left) and FITC-spectral unmixed image (bottom right). The distinct 
fluorescent pattern between the Texas Red-spectral unmixed image and FITC-spectral unmixed image 
demonstrated the fluorescence appeared in the Texas Red channel was real staining for CD206 rather than 
autofluorescence. The disappearance of the CD206-specific staining pattern in CY3 and CY5-spectral unmixed 
images demonstrated the CD206 fluorescence labelling did not appear in neighbouring channels.  
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Fig 5.5 Unmixed spectral images of the perinephric adipose tissue stained with CD68 antibody 
The slide was incubated with the CD68 antibody (1:100) and scanned with Vectra III multispectral microscopy 
at ×20 objective (exposure time: 250 ms). Spectra were unmixed using the InForm 2.21 software. Specific 
staining patterns (sporadic bright dots) of CD68, shown in the channel of cyanine (CY) 5, are labelled with a 
white arrow heads (upper left). The arrow heads are placed in the same location in CY3-spectral unmixed 
image (upper right), Texas Red-spectral unmixed image (bottom left) and FITC-spectral unmixed image 
(bottom right). The distinct fluorescence pattern between the CY5-spectral unmixed image and FITC-spectral 
unmixed image demonstrated that the fluorescence appearing in the CY5 channel was real staining for CD68 
rather than autofluorescence. The disappearance of the CD68-specific staining pattern in CY3 and Texas Red-
spectral unmixed images demonstrated that the fluorescence labelling CD68 did not appear in neighbouring 
channels.  
5.4.3 Multiplex immunofluorescent staining 
Sections of 4 μm thickness were cut onto Superfrost Plus slides. The multiplex immunofluorescent 
staining on fresh sections was completed with the Ventana Discovery Ultra autostainer (Leica 
Instruments, Arizona, USA). To minimise the variability of antibody titres, all slides were processed 
at the same time. Antigen retrieval was performed on the deparaffinised slides with Cell Conditioning 
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1 solution (Ventana Medical system 950-124) for 64 min at 95 °C. All slides were first blocked with 
Discovery Inhibitor (Roche 760-4840) for 8 min. The CD163 primary antibody was applied first at a 
1:500 dilution, incubated at 36 °C for 40 min, and visualised with the Discovery Rhodamine 6G kit 
(Roche 760-244). The secondary antibody (Discovery OmniMap anti-mouse HRP, Ventana Medical 
systems 760-4310) incubation time was 4 min; TSA reagent incubation time was 8 min. Antibody 
denaturation was performed with Cell Conditioning 2 solution (Ventana Medical Systems 950-123) 
for 24 min at 100 °C. Next, the CD206 antibody was applied at a 1:3000 dilution, incubated at 36 °C 
for 32 min, and visualised with the Discovery Red 610 Kit (Roche 760-245). The secondary antibody 
(Discovery OmniMap anti-rabbit HRP, Ventana Medical Systems 760-4311) had an incubation time 
of 4 min; the TSA reagent incubation time was 8 min. Antibody denaturation was again performed 
with the Cell Conditioning 2 solution for 24 min at 100 °C. Lastly, the CD68 antibody was applied 
at a 1:100 dilution, incubated at 36 °C for 40 min, and visualised with the Discovery CY5 kit (Roche 
760-238). The incubation time for the secondary antibody (Ventana Medical Systems 760-4310) was 
16 min; the TSA reagent incubation time was 8 min. The slides were then counterstained with 
Discovery DAPI (Roche 760-4196), and cover-slipped with Prolong Gold anti-fade reagent 
(Invitrogen P36930). The invasive edge of human ccRCC FFPE tumour tissue was used as positive 
control (Fig 5.6a) [217, 328]. An example of the perinephric adipose tissue stained with the three 
primary antibodies is displayed in Fig 5.6b. Perinephric adipose tissue without primary antibody, 
secondary antibody, detection reagents and DAPI, but treated identically to the multiplex staining in 
terms of steps of antigen retrieval and heat stripping was used as a negative control (Fig 5.6c). 
Perinephric adipose tissue without primary antibody but treated identically to the multiplex staining 
was used as another negative control (Fig 5.6d).  
5.4.4 Imaging of fluorescent slides 
Upon completion of the multiplex immunofluorescent staining, stained slides were all scanned in one 
batch using the Vectra III multispectral microscope (PerkinElmer) according to the instructions 
provided by the manufacturer [329]. The bands of cyanine (CY) 3, CY5, Texas Red and DAPI (used 
for auto-focusing setting) were chosen to create the protocol of imaging the multispectral fluorescent 
images. CY3 is closely neighbouring to Rhodamine 6G (the fluorophore used to visualise CD163); 
Texas Red is closely neighbouring to Alexa Fluo 610 (the fluorophore used to visualise CD206). 
Hence, the two filters of CY3 and Texas Red were chosen to filter the fluorescent signals of CD163 
and CD206, respectively. The exposure time was also optimised and kept consistent over imaging. 
Images of analysis were sampled from five individual fields randomly chosen on the slide at the ×20 
objective. The spectral unmixing of the obtained images (IM3 files) was then processed in the InForm 
2.2.1 software. The fluorescence data in each channel were extracted by loading the spectral library 
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“CY3, CY5, Texas red, DAPI and autofluoresence” (Fig 5.7). The autofluorescence spectrum was 
extracted from a representative unstained sample. After assigning each fluorophore with a specific 
colour, the multiplexed image was created by combining the individual unmixed images. The 
fluorescence spectral view of the fluorophores (mentioned above) is displayed in Appendix 6. 
 
Fig 5.6 Examples of positive control, experimental sample and negative controls 
Images were scanned with Vectra III multispectral microscopy at ×20 objective. CD163 positive pixels are 
yellow (exposure time: 100 ms); CD68 positive pixels are green (exposure time: 250 ms); CD206 positive 
pixels are red (exposure time 150 ms). DAPI-stained nuclei are blue (exposure time: 100 ms). a The invasive 
edge of ccRCC tumour tissue known to express CD163, CD206 and CD68 is positive for all three markers, 
indicating the staining procedure was working. b A representative multiplexed image of the perinephric 
adipose tissue (experimental sample) which was co-stained with CD163, CD206, CD68 and nuclei is 
displayed. c The non-stained negative control demonstrated there was no CD marker-specific staining caused 
by the adipose tissue-specific autofluorescence. d The negative control without primary antibody demonstrated 
there was no CD marker-specific staining caused by the secondary antibodies or the detection system. 
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Fig 5.7 Spectral library loaded for spectral unmixing 
The spectral segments DAPI, CY3, CY5, Texas Red and autofluorescence had good separation within each of 
the imaging bands. The Y axis was scaled to the same value, which was the maximal signal value in all of the 
bands. Abbreviation: CY, cyanine 
5.4.5 Image analysis 
The expression of each individual CD marker was quantified using the colocalisation and 
segmentation tool inbuilt in the InForm 2.2.1 image analysis software. The data collecting process 
was undertaken in a blinded manner by asking a colleague to finish patient de-identification by 
recoding the images.  
5.4.5.1 Colocalisation analysis 
Colocalisation is a pixel-based analysis for quantifying percentage of the overlapping components 
across an image based on the threshold setting for each component [330]. The spectra were chosen 
based on the colocalisation of interest. The unmixed component in an image was visually thresholded 
in a greyscale view to generate a binary mask to resemble the specific staining pattern. The masked 
area showing the pattern of autofluorescence was selected as a region of disinterest and excluded 
from the analysis (Fig 5.8). Except for percentage of colocalised pixels, mean intensity of a 
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component across the whole image and total intensity of a component in the segmented area were 
also exported. Upon data collection based on an individual threshold setting, homogeneous maximal 
and minimal threshold settings were applied to all images again to collect data of the variables 
mentioned previously. The lower limits of the minimal and maximal thresholds were summarised 
from the individually-optimised thresholds of all samples (Table 5.1). The upper limit was set to be 
“10” which was beyond the intensity of the brightest pixel that appeared. 
 
Fig 5.8 Example of generating a mask to segment CD206-positive pixels beyond a threshold 
a demonstrates the unmixed staining in Texas Red channel. The white colour represents CD206-positive 
pixels. The red pixels in b were a mask generated by applying a threshold (0.2-10) to resemble the staining 
pattern in a. The white circle demonstrates an excluded autofluorescence-like staining pattern in image 
analysis. 
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Table 5.1 Maximal and minimal threshold setting 
Minimal thresholding 
CD163-CY3 CD206-Texas Red CD68-CY5 
0.2-10 0.2-10 0.15-10 
Maximal thresholding 
CD163-CY3 CD206-Texas Red CD68-CY5 
0.06-10 0.08-10 0.05-10 
After applying an individually optimised threshold, the maximal and minimal threshold settings were applied 
sequentially to all images again to obtain data of interest. Abbreviation: CY, cyanine 
5.4.5.2 Cytoplasm segmentation 
A nuclear segmentation algorithm and a cytoplasm algorithm were applied to output a cytoplasm 
mask according to a published protocol with modifications [331]. The positivity of each unmixed 
component was quantified within the cytoplasm compartment. The process was repeated for all 
images. The minimal size and typical size of nuclei have been set, respectively, to be 30 pixels and 
320 pixels after multiple trials, to make sure DAPI-counterstained nuclei could be recognised as much 
as possible. The “Split More/Split Less” slider was adjusted to be 3.0 for the purpose of segmenting 
the nuclei as accurately as possible. The stained cells have heterogeneous staining patterns, with only 
a portion of the cells demonstrating a typical membrane-like staining pattern (Fig 5.9a). To include 
the positive pixels located in the cellular processes that reach long distances from the nuclei, the outer 
distance of cytoplasm to nucleus was set to be a fixed 10 pixels (Fig 5.9b). To include the positive 
pixels that may overlap with the nuclear DAPI stain (Fig 5.9c), the size of the nuclei was shrunk by 
40 %. An example of cytoplasm segmentation followed by nuclear segmentation is displayed in Fig 
5.10. After segmenting cytoplasm, the positivity of each unmixed component was quantified within 
the cytoplasm compartment by applying the three threshold settings (individually optimised, 
maximum and minimum) introduced previously. Simultaneously, the cell counting was exported 
automatically. 
 
Fig 5.9 Heterogeneous staining patterns of CD markers in cellular compartments 
The composite image displays various staining patterns of the CD markers in cellular compartments. a 
demonstrates the stained pixels are found closely around the nucleus. b demonstrates the stained cellular 




Fig 5.10 Examples of nuclear and cytoplasmic segmentation 
a demonstrates the composite multiplexed images of a sample co-stained with the antibodies for CD163, 
CD206, CD68 and counterstained with DAPI. The green masks in b demonstrate the segmented nuclei. The 
colourful masks in shapes of “doughnuts” around the green nuclear masks demonstrate the segmented 
cytoplasm in c. The positivity of each unmixed component was quantified within the cytoplasmic compartment 
using three pixel-based algorithms. 
5.4.6 Adipocyte size analysis 
The volume of adipocytes has close correlation with adipocyte morphology, with small adipocyte 
volume indicating hyperplastic morphology whereas large adipocyte volume indicating hypertrophic 
morphology [332]. The size of adipocytes was measured in the same images used for macrophage 
quantification by excluding adipocytes touching the edge. The quantification was assisted by using 
the “Adiposoft” tool in the software of Image J, which has been validated in a previous publication 
[333]. First, an automatic algorithm was applied to extract adipocytes with the minimal and maximal 
diameter settings being 30 and 300, respectively. Then, the image was further processed in manual 
edition by deleting adipocytes with inaccurate outlines and adding unrecognised adipocytes. Finally, 
the area of each adipocyte (output units: pixels) was exported. An example of an image processed by 
“Adiposoft” is displayed in Fig 5.11. 
5.4.7 Statistical analysis 
Comparisons between groups were made using the paired t-test, one-way ANOVA or two-way 
ANOVA when appropriate. Two-way ANOVA was conducted to analyse the effect of tumour 
subtype (three levels: metastatic ccRCC, non-metastatic ccRCC and oncocytoma) and thresholding 
(three levels: individual, minimal and maximal thresholds) on dependent variables of interest. 
Repeated measures two-way ANOVA was conducted to analyse the effect of tumour subtype (two 
levels: metastatic and non-metastatic ccRCC) and thresholding (three levels: individual, minimal and 
maximal thresholds) on dependent variables of interest. Tukey’s or Sidak multiple comparisons were 
performed after ANOVA if tumour subtype accounted for more than 10 % of total variation of the 
variables of interest. Cohen’s d was calculated to measure the effect size to quantify the difference 
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between the cohort of metastatic ccRCC and the cohort of non-metastatic ccRCC. p<0.05 was 
considered statistically significant. Statistical analysis was performed using the software GraphPad 
Prism 7.0. 
 
Fig 5.11 Output of an image processed by “Adiposoft” 
The outline of adipocytes is highlighted in yellow. Cells that touch the edge of the section were not counted. 
Area of individual adipocytes was exported automatically. 
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 Results  
5.5.1 Patient characteristics 
Two hundred and sixty seven participants recorded in the database were assessed for eligibility. After 
excluding 90 participants who did not meet the inclusion criteria (missing data about kidney cancer 
diagnosis n=5, diagnosis other than ccRCC n=85), 177 participants were assessed for tissue 
availability. 59 participants with perinephric adipose tissue available for IHC were further assessed 
for the presence of distant metastasis. Five participants with distant metastasis and another 5 
participants without distant metastasis who were matched for BMI, and matched as much as possible 
for gender, age, tumour stage and grade constituted two sets of matched data. A third cohort was 
made up of 5 participants diagnosed with oncocytoma who had qualified adipose tissue available (Fig 
5.1). Demographic and pathological diagnostic characteristics of participants in the three cohorts are 
summarised in Table 5.2. Summary of staining results and median size of adipocytes are displayed 
in Table 5.3.  
Table 5.2 Characteristics of the study population 
ccRCC with distant metastasis Matched ccRCC without distant metastasis 
ID Sex Age BMI (kg/m2) Stage Grade ID Sex Age BMI (kg/m2) Stage Grade 
125 F 55 25.5 1 2 248 F 54 27.3 *3 2 
208 F 69 28.2 3 3 257 *M 62 29.2 3 3 
131 M 54 27.4 3 3 206 M 61 26.8 3 3 
179 M 39 27.5 3 4 89 M 46 27.5 3 4 
186 M 44 28.8 3 2 226 M *73 28.9 3 2 
Oncocytoma  
ID Sex Age BMI (kg/m2) Stage# Grade# 
150 M 76 38.4   
215 M 74 29.4   
219 M 75 25.8   
229 M 75 28.4   
261 F 67 23.6   
# Tumours were staged according to the 7th TNM Classification of malignant tumours and graded according 
to the International Society for Urological Pathology (ISUP) grading system, which were not applicable for 
oncocytoma. * There was not a perfectly matched participant to join the cohort. Abbreviation: BMI, body mass 
index; ccRCC, clear cell renal cell carcinoma 
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0.110 % (0.091) 0.828 % (0.857) 0.202 % (0.181) 1.178 
Maximal 
thresholding 
0.088 % (0.089) 0.514 % (0.714) 0.122 % (0.166) 0.837 
Minimal 
thresholding 








































0.342 % (0.288) 0.700 % (0.505) 0.380 % (0.473) 0.871 
Maximal 
thresholding 
0.264 % (0.224) 0.610 % (0.571) 0.214 % (0.196) 0.798 
Minimal 
thresholding 








































0.048 % (0.069) 0.672 % (1.015) 0.001 % (0.001) 1.755 
Maximal 
thresholding 
0.018% (0.029) 0.498 % (1.080) 0.072 % (0.129) 0.628 
Minimal 
thresholding 
































0.066 % (0.075) 0.274 % (0.300) 0.064 % (0.095) 0.951 
Maximal 
thresholding 
0.050 % (0.063) 0.202 % (0.246) 0.038 % (0.064) 0.847 
Minimal 
thresholding 




1.507 (1.465) 13.111 (17.452) 0.988 (1.112) 0.937 
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0.858 (1.196) 6.256 (9.247) 0.468 (0.735) 0.819 
Minimal 
thresholding 
3.224 (3.471) 16.382 (22.928) 4.029 (5.119) 0.802 





6.783 (7.122) 10.115 (9.205) 3.285 (4.272) 0.405 
Maximal 
thresholding 
3.454 (4.872) 9.282 (9.818) 0.936 (1.004) 0.752 
Minimal 
thresholding 
6.983 (7.079) 14.111 (11.932) 6.242 (3.854) 0.727 





0.365 (0.676) 6.262 (12.860) 0.431 (0.963) 0.648 
Maximal 
thresholding 
0.054 (0.121) 5.980 (13.010) 0.430 (0.962) 0.644 
Minimal 
thresholding 
0.679 (1.375) 12.691 (27.230) 4.103 (5.625) 0.623 
CD206/CD163 





1.507 (1.465) 13.111 (17.452) 0.988 (1.112) 0.937 
Maximal 
thresholding 
0.858 (1.196) 6.256 (9.247) 0.468 (0.735) 0.819 
Minimal 
thresholding 
3.224 (3.471) 16.382 (22.928) 4.029 (5.119) 0.802 
Median size of adipocytes (sd)*  13434 (2255) 9518 (3153) 13412 (2046) 1.430 
All variables regarding expression intensity are displayed in the units of fluorescence counts which had been 
normalised for exposure and weighted using the method of total weighting. 
# The effect size was calculated using the online effect size calculator. 
http://www.polyu.edu.hk/mm/effectsizefaqs/calculator/calculator.html 
* The unit for size of adipocytes was pixel. There were 969, 1108 and 975 adipocytes counted in the cohorts 
of non-metastatic ccRCC, metastatic ccRCC and oncocytoma, respectively.  
Abbreviation: ccRCC, clear cell renal cell carcinoma; sd, standard deviation  
5.5.2 Difference of mean intensity of individual CD marker across the whole image between 
different subytpes of renal tumours 
The mean value of CD206 mean intensity across the whole image was higher in metastatic ccRCC 
perinephric adipose tissue (0.012) compared to non-metastatic ccRCC perinephric adipose tissue 
(0.003) and oncocytoma perinephric adipose tissue (0.003). However, the differences were not 
statistically significant (Figs 5.12 a1-3). The mean value of CD163 mean intensity across the whole 
image was higher in metastatic ccRCC perinephric adipose tissue (0.014) compared to non-metastatic 
ccRCC perinephric adipose tissue (0.004) and oncocytoma perinephric adipose tissue (0.003). 
However, the differences were not statistically significant (Figs 5.12 b1-3). The mean value of CD68 
mean intensity across the whole image was lower in metastatic ccRCC perinephric adipose tissue 
(0.005) compared to non-metastatic ccRCC perinephric adipose tissue (0.028) and oncocytoma 
perinephric adipose tissue (0.045). However, the differences were not statistically significant (Figs 
5.12 c1-3).   
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Fig 5.12 Mean intensity of individual CD markers across the whole image 
(a1) Scatter plots of the raw data of mean intensity of CD206 across the whole image in ccRCC and 
oncocytoma; (a2) Scatter plots of the mean value of the mean intensity of CD206 across the whole image in 
ccRCC (non-met ccRCC vs met ccRCC); (a3) Bar graphs of the mean value of mean intensity of CD206 across 
the whole image in ccRCC and oncocytoma; (b1) Scatter plots of the raw data of mean intensity of CD163 
across the whole image in ccRCC and oncocytoma; (b2) Scatter plots of the mean value of the mean intensity 
of CD163 across the whole image in ccRCC (non-met ccRCC vs met ccRCC); (b3) Bar graphs of the mean 
value of mean intensity of CD163 across the whole image in ccRCC and oncocytoma; (c1) Scatter plots of the 
raw data of mean intensity of CD68 across the whole image in ccRCC and oncocytoma; (c2) Scatter plots of 
the mean value of the mean intensity of CD68 across the whole image in ccRCC (non-met ccRCC vs met 
ccRCC); (c3) Bar graphs of the mean value of mean intensity of CD68 across the whole image in ccRCC and 
oncocytoma; Lines across the raw data indicate mean value. ns, p>0.05, paired t-test or Tukey’s multiple 
comparisons after one-way ANOVA. Error bars represent estimated standard errors of the mean. Abbreviation: 
met, metastatic; ccRCC, clear cell renal cell carcinoma. 
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5.5.3 Metastatic ccRCC perinephric adipose tissue exhibited higher expression of CD206. 
Repeated measures two-way ANOVA was conducted to analyse the association of tumour subtype 
(two levels: metastatic and non-metastatic ccRCC) and thresholding (three levels: individual, 
maximal and minimal) with positivity of CD206 across the whole image, total intensity of CD206 in 
the segmented area and CD206 positive cell number in the cytoplasm. For CD206 positivity (Fig 5.13 
a2), the interaction effect of the two factors was non-significant, F (2, 8) = 0.85, p = 0.46, but the 
effect of thresholding which accounted for 6.08 % of total variation was significant, F (2, 8) = 5.68, 
p=0.03. Tumour subtype accounted for 14.29 % of total variation, however the effect was non-
significant, F (1, 4) = 1.55, p = 0.28. Sidak test showed that the positivity of CD206 was higher in 
metastatic ccRCC compared to non-metastatic ccRCC using individual thresholding (p = 0.02), but 
there were no differences between tumour subtypes when the maximal (p = 0.20) or minimal (p = 
0.32) thresholding were applied. For CD206 total intensity (Fig 5.13 b2), the interaction effect was 
non-significant, F (2, 8) = 1.05, p = 0.39, but the effect of thresholding was significant, even only 
accounting for 0.18 % of the total variance, F (2, 8) = 7.84, p = 0.01. Tumour subtype accounted for 
14.97 % of total variation, however the effect was non-significant, F (1, 4) = 1.60, p = 0.28. Sidak 
test showed that the total intensity of CD206 was higher in metastatic ccRCC compared to non-
metastatic ccRCC using all thresholding (p < 0.0001). For CD206 positive cell number (Fig 5.13 c2), 
the interaction effect was non-significant, F (2, 8) = 1.88, p = 0.21, and the effect of thresholding 
which accounted for 4.15 % of total variation was non-significant, F (2, 8) = 3.4, p = 0.08. Tumour 
subtype accounted for 15.91 % of total variation, however the effect was non-significant, F (1, 4) = 
2.23, p=0.21. Sidak test showed that the positive CD206 cell number in cytoplasm was higher in 
metastatic ccRCC compared to non-metastatic ccRCC using the individual (p = 0.01) and the minimal 
(p = 0.007) thresholding, but there were no differences between tumour subtypes when the maximal 
(p = 0.29) thresholding was applied. 
An ordinary two-way ANOVA was conducted to analyse the association of tumour subtype (three 
levels: metastatic ccRCC, non-metastatic ccRCC and oncocytoma) and thresholding (three levels: 
individual, maximal and minimal) with positivity of CD206 across the whole image, total intensity 
of CD206 in the segmented area and CD206 positive cell number in the cytoplasm. For CD206 
positivity (Fig 5.13 a3), there was not a significant interaction between the two factors, F (4, 36) = 
0.60, p = 0.67, but there was a significant main effect (accounting for 14.45 % of total variation) 
caused by thresholding, F (2, 36) = 3.70, p = 0.03. The factor, tumour subtype, accounted for 10.62 % 
of total variance and yielded an F ratio of F (2, 36) = 2.72, p = 0.08, indicating a non-significant 
difference of CD206 positivity between tumour subtypes. Tukey’s multiple comparison did not find 
any significant difference in post hoc testing. For CD206 total intensity (Fig 5.13 b3), there was not 
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a significant interaction between the two factors, F (4, 36) = 0.02, p = 0.99, and the effect caused by 
thresholding (only accounting for 0.47 % of total variation) was not significant, F (2, 36) = 0.10, p = 
0.90. The main factor, tumour subtype (accounting for 19.08 % of total variation), yielded an F ratio 
of F (2, 36) = 4.28, p = 0.02, indicating a significant difference of CD206 total intensity in segmented 
area between tumour subtypes. However, Tukey’s multiple comparison did not find any significant 
difference in post hoc testing. For CD206 positive cell number (Fig 5.13 c3), there was not a 
significant interaction between the two factors, F (4, 36) = 0.24, p = 0.91, and the effect caused by 
thresholding (accounting for 4.15 % of total variation) was not significant, F (2, 36) = 1.00, p = 0.38. 
The main factor, tumour subtype (accounting for 19.61 % of total variation), yielded an F ratio of F 
(2, 36) = 4.76, p = 0.01, indicating a significant difference of CD206 positive cell number in 
cytoplasm between tumour subtypes. However, Tukey’s multiple comparison did not find any 




Fig 5.13 CD206 expression 
(a1) Scatter plots of the raw data of CD206 positivity in ccRCC and oncocytoma; (a2) Scatter plots of mean 
value of CD206 positivity in ccRCC (non-met ccRCC vs met ccRCC); (a3) Bar graphs of mean value of CD206 
positivity in ccRCC and oncocytoma; (b1) Scatter plots of total intensity of CD206 in segmented area in ccRCC 
and oncocytoma; (b2) Scatter plots of mean value of total intensity of CD206 in segmented area in ccRCC 
(non-met ccRCC vs met ccRCC); (b3) Bar graphs of mean value of total intensity of CD206 in segmented area 
in ccRCC and oncocytoma; (c1) Scatter plots of the raw data of CD206 positive cell number in cytoplasm in 
ccRCC and oncocytoma; (c2) Scatter plots of the mean value of CD206 positive cell number in cytoplasm in 
ccRCC (non-met ccRCC vs met ccRCC); (c3) Bar graphs of the mean value of CD206 positive cell number in 
cytoplasm in ccRCC and oncocytoma; Lines across the raw data indicate mean value. ns, p>0.05, *, p < 0.05, 
**, p < 0.01, ****, p < 0.0001, Sidak test after repeated measures two-way ANOVA or Tukey’s multiple 
comparisons after two-way ANOVA. Error bars represent estimated standard errors of the mean. Abbreviation: 
met, metastatic; ccRCC, clear cell renal cell carcinoma; onco, oncocytoma. 
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5.5.4 Metastatic ccRCC perinephric adipose tissue exhibited higher expression of CD163. 
Repeated measures two-way ANOVA was conducted to analyse the association of tumour subtype 
(two levels: metastatic and non-metastatic ccRCC) and thresholding (three levels: individual, 
maximal and minimal) with positivity of CD163 across the whole image, total intensity of CD163 in 
the segmented area and CD163 positive cell number in the cytoplasm. For CD163 positivity (Fig 5.14 
a2), the interaction effect was non-significant, F (2, 8) = 0.53, p = 0.61, but the effect of thresholding 
which accounted for 3.22 % of total variation was significant, F (2, 8) = 7.95, p = 0.01. Tumour 
subtype accounted for 17.10 % of total variation, however the effect was non-significant, F (1, 4) = 
1.67, p = 0.27. Sidak test showed that the positivity of CD163 was higher in metastatic ccRCC 
compared to non-metastatic ccRCC using all thresholding (p < 0.001). For CD163 total intensity (Fig 
5.14 b2), the interaction effect was non-significant, F (2, 8) = 1.22, p = 0.35, and the effect of 
thresholding which only accounted for 0.03 % of total variation was non-significant, F (2, 8) = 2.25, 
p=0.17. Tumour subtype accounted for 20.32 % of total variation, however the effect was non-
significant, F (1, 4) = 1.75, p = 0.26. Sidak test showed that the total intensity of CD163 was higher 
in metastatic ccRCC compared to non-metastatic ccRCC using all thresholding (p < 0.0001). For 
CD163 positive cell number (Fig 5.14 c2), the interaction effect was non-significant, F (2, 8) = 1.88, 
p = 0.21, and the effect of thresholding which accounted for 4.15 % of total variation was non-
significant, F (2, 8) = 3.1, p=0.10. Tumour subtype accounted for 10.43 % of total variation, however 
the effect was non-significant, F (1, 4) = 0.80, p = 0.42. Sidak test showed that the positive CD163 
cell number in cytoplasm was higher in metastatic ccRCC compared to non-metastatic ccRCC using 
the individual (p < 0.05), the maximal (p < 0.01), and the minimal (p < 0.001) thresholding. 
An ordinary two-way ANOVA was conducted to analyse the association of tumour subtype (three 
levels: metastatic ccRCC, non-metastatic ccRCC and oncocytoma) and thresholding (three levels: 
individual, maximal and minimal) with positivity of CD163 across the whole image, total intensity 
of CD163 in the segmented area and CD163 positive cell number in the cytoplasm. For CD163 
positivity (Fig 5.14 a3), there was not a significant interaction between the two factors, F (4, 36) = 
0.08, p = 0.99, and the effect (accounting for 5.74 % of total variation) caused by thresholding was 
not significant, F (2, 36) = 1.31, p = 0.28. The main factor, tumour subtype, accounted for 14.65 % 
of total variance and yielded an F ratio of F (2, 36) = 3.34, p = 0.05, indicating a significant difference 
of CD163 positivity between tumour subtypes. However, Tukey’s multiple comparison did not find 
any significant difference in post hoc testing. For CD163 total intensity (Fig 5.14 b3), there was not 
a significant interaction between the two factors, F (4, 36) = 0.003, p > 0.99, and effect caused by 
thresholding (only accounting for 0.04 % of total variation) was not significant, F (2, 36) = 0.01, p = 
0.99. The main factor, tumour subtype (accounting for 29.31 % of total variation), yielded an F ratio 
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of F (2, 36) = 7.47, p = 0.002, indicating a significant difference of CD163 total intensity in segmented 
area between tumour subtypes. However, Tukey’s multiple comparison did not find any significant 
difference in post hoc testing. For CD163 positive cell number (Fig 5.14 c3), there was not a 
significant interaction between the two factors, F (4, 36) = 0.10, p = 0.98, and the effect caused by 
thresholding (accounting for 6.05 % of total variation) was not significant, F (2, 36) = 1.45, p = 0.25. 
The main factor, tumour subtype (accounting for 18.18 % of total variation), yielded an F ratio of F 
(2, 36) = 4.37, p = 0.02, indicating a significant difference of CD163 positive cell number in 
cytoplasm between tumour subtypes. However, Tukey’s multiple comparison did not find any 




Fig 5.14 CD163 expression 
(a1) Scatter plots of the raw data of CD163 positivity in ccRCC and oncocytoma; (a2) Scatter plots of mean 
value of CD163 positivity in ccRCC (non-met ccRCC vs met ccRCC); (a3) Bar graphs of mean value of CD163 
positivity in ccRCC and oncocytoma; (b1) Scatter plots of total intensity of CD163 in segmented area in ccRCC 
and oncocytoma; (b2) Scatter plots of mean value of total intensity of CD163 in segmented area in ccRCC 
(non-met ccRCC vs met ccRCC); (b3) Bar graphs of mean value of total intensity of CD163 in segmented area 
in ccRCC and oncocytoma; (c1) Scatter plots of the raw data of CD163 positive cell number in cytoplasm in 
ccRCC and oncocytoma; (c2) Scatter plots of the mean value of CD163 positive cell number in cytoplasm in 
ccRCC (non-met ccRCC vs met ccRCC); (c3) Bar graphs of the mean value of CD163 positive cell number in 
cytoplasm in ccRCC and oncocytoma; Lines across the raw data indicate mean value. ns, p>0.05, *, p < 0.05, 
**, p < 0.01, ***, p < 0.001, ****, p < 0.0001, Sidak test after repeated measures two-way ANOVA or Tukey’s 
multiple comparisons after two-way ANOVA. Error bars represent estimated standard errors of the mean. 




5.5.5 No difference of CD68 expression in ccRCC perinephric adipose tissue (non-metastatic 
vs metastatic ccRCC) and oncocytoma perinephric adipose tissue 
Repeated measures two-way ANOVA was conducted to analyse the association of tumour subtype 
(two levels: metastatic and non-metastatic ccRCC) and thresholding (three levels: individual, 
maximal and minimal) with positivity of CD68 across the whole image, total intensity of CD68 in 
the segmented area and CD68 positive cell number in the cytoplasm. For CD68 positivity (Fig 5.15 
a2), the interaction effect was non-significant, F (2, 8) = 0.80, p = 0.48, but the effect of thresholding 
which accounted for 11.27 % of total variation was significant, F (2, 8) = 5.30, p = 0.03. Tumour 
subtype only accounted for 1.94 % of total variation, and the effect was non-significant, F (1, 4) = 
0.19, p = 0.69. For CD68 total intensity (Fig 5.15 b2), the interaction effect was non-significant, F 
(2, 8) = 0.68, p = 0.53, but the effect of thresholding was significant, even only accounting for 0.47 % 
of total variation, F (2, 8) = 5.08, p = 0.04. Tumour subtype accounted for 9.42 % of total variation, 
however the effect was non-significant, F (1, 4) = 0.80, p = 0.42. For CD68 positive cell number (Fig 
5.15 c2), the interaction effect was non-significant, F (2, 8) = 0.88, p = 0.45, and the effect of 
thresholding which accounted for 1.68 % of total variation was non-significant, F (2, 8) = 1.24, p = 
0.34. Tumour subtype accounted for 9.60 % of total variation, and the effect was non-significant, F 
(1, 4) = 0.99, p = 0.38. 
An ordinary two-way ANOVA was conducted to analyse the association of tumour subtype (three 
levels: metastatic ccRCC, non-metastatic ccRCC and oncocytoma) and thresholding (three levels: 
individual, maximal and minimal) with positivity of CD68 across the whole image, total intensity of 
CD68 in the segmented area and CD68 positive cell number in the cytoplasm. For CD68 positivity 
(Fig 5.15 a3), there was not a significant interaction between the two factors, F (4, 36) = 1.73, p = 
0.17, but the effect of thresholding which accounted for 22.71 % of total variation was significant, F 
(2, 36) = 6.54, p < 0.01. Tumour subtype, only accounted for 2.82 % of total variance and yielded an 
F ratio of F (2, 36) = 0.81, p = 0.45, indicating there was not a significant difference of CD68 positivity 
between tumour subtypes. For CD68 total intensity (Fig 5.15 b3), there was not a significant 
interaction between the two factors, F (4, 36) = 0.08, p = 0.99, and the effect caused by thresholding 
(accounting for 1.88 % of total variation) was not significant, F (2, 36) = 0.39, p = 0.68. The factor, 
tumour subtype (accounting for 9.81 % of total variation), yielded an F ratio of F (2, 36) = 2.02, p = 
0.15, indicating there was not a significant difference of CD68 positive cell number in cytoplasm 
between tumour subtypes. For CD68 positive cell number (Fig 5.15 c3), there was not a significant 
interaction between the two factors, F (4, 36) = 0.13, p = 0.97, and effect caused by thresholding 
(accounting for 2.47 % of total variation) was not significant, F (2, 36) = 0.52, p = 0.60. The factor, 
tumour subtype (accounting for 10.52 % of total variation), yielded an F ratio of F (2, 36) = 2.21, p = 
132 
0.12, indicating there was not a significant difference of CD68 positive cell number in cytoplasm 
between tumour subtypes. Moreover, Tukey’s multiple comparison did not find any significant 
difference in post hoc testing. 
 
Fig 5.15 CD68 expression 
(a1) Scatter plots of the raw data of CD68 positivity in ccRCC and oncocytoma; (a2) Scatter plots of mean 
value of CD68 positivity in ccRCC (non-met ccRCC vs met ccRCC); (a3) Bar graphs of mean value of CD68 
positivity in ccRCC and oncocytoma; (b1) Scatter plots of total intensity of CD68 in the segmented area in 
ccRCC and oncocytoma; (b2) Scatter plots of mean value of total intensity of CD68 in the segmented area in 
ccRCC (non-met ccRCC vs met ccRCC); (b3) Bar graphs of mean value of total intensity of CD68 in the 
segmented area in ccRCC and oncocytoma; (c1) Scatter plots of the raw data of CD68 positive cell number in 
the cytoplasm in ccRCC and oncocytoma; (c2) Scatter plots of the mean value of CD68 positive cell number 
in the cytoplasm in ccRCC (non-met ccRCC vs met ccRCC); (c3) Bar graphs of the mean value of CD68 
positive cell number in the cytoplasm in ccRCC and oncocytoma; Lines across the raw data indicate mean 
value. ns, p>0.05, Repeated measures two-way ANOVA or Tukey’s multiple comparisons after two-way 
ANOVA. Error bars represent estimated standard errors of the mean. Abbreviation: met, metastatic; ccRCC, 
clear cell renal cell carcinoma; onco, oncocytoma. 
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5.5.6 Metastatic ccRCC perinephric adipose tissue exhibited higher expression of 
CD163/CD206 double positive cells. 
Given that metastatic ccRCC exhibited higher expression of CD206 and CD163 when analysing their 
expression, individually. Repeated measures two-way ANOVA was conducted to analyse the 
association of tumour subtype (two levels: metastatic and non-metastatic ccRCC) and thresholding 
with double positivity of CD206/CD163 across the whole image and CD206/CD163 double positive 
cell number in the cytoplasm. For CD206/CD163 double positivity (Fig 5.16 a2), the interaction 
effect was non-significant, F (2, 8) = 1.11, p = 0.38, but the effect of thresholding which accounted 
for 3.17 % of total variation was significant, F (2, 8) = 4.62, p = 0.05. Tumour subtype accounted for 
17.23 % of total variation, however the effect was non-significant, F (1, 4) = 3.25, p = 0.15. Sidak 
test showed that the double positivity of CD206/CD163 was higher in metastatic ccRCC compared 
to non-metastatic ccRCC using all thresholding (p < 0.01). For CD206/CD163 double positive cell 
number (Fig 5.16 b2), the interaction effect was non-significant, F (2, 8) = 1.88, p = 0.21, and the 
effect of thresholding which accounted for 4.15 % of total variation was non-significant, F (2, 8) = 
3.41, p = 0.08. Tumour subtype accounted for 15.91 % of total variation, however the effect was non-
significant, F (1, 4) = 2.23, p = 0.21. Sidak test showed that the CD206/CD163 double positive cell 
number in cytoplasm was higher in metastatic ccRCC compared to non-metastatic ccRCC using the 
individual (p < 0.05) and the minimal (p < 0.01) thresholding, but there were no differences between 
tumour subtypes when the maximal thresholding (p = 0.29) was applied. 
An ordinary two-way ANOVA was conducted to analyse the association of tumour subtype (three 
levels: metastatic ccRCC, non-metastatic ccRCC and oncocytoma) and thresholding with double 
positivity of CD206/CD163 across the whole image and CD206/CD163 double positive cell number 
in the cytoplasm. For CD206/CD163 double positivity (Fig 5.16 a3), there was not a significant 
interaction between the two factors, F (4, 36) = 0.17, p = 0.95, and the effect caused by thresholding 
(accounting for 6.81 % of total variation) was not significant, F (2, 36) = 1.61, p = 0.21. The main 
factor, tumour subtype, accounted for 15.51 % of total variance and yielded an F ratio of F (2, 36) = 
3.66, p = 0.04, indicating a significant difference of CD206/CD163 double positivity between tumour 
subtypes. However, Tukey’s multiple comparison did not find any significant difference in post hoc 
testing. For CD206/CD163 double positive cell number (Fig 5.16 b3), there was not a significant 
interaction between the two factors, F (4, 36) = 0.24, p = 0.91, and the effect caused by thresholding 
(accounting for 4.15 % of total variation) was not significant, F (2, 36) = 1.01, p = 0.38. The main 
factor, tumour subtype (accounting for 19.61 % of total variation), yielded an F ratio of F (2, 36) = 
4.76, p = 0.01, indicating a significant difference of CD206/CD163 double positive cell number in 
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cytoplasm between tumour subtypes. However, Tukey’s multiple comparison did not find any 
significant difference in post hoc testing. 
 
Fig 5.16 Colocalising expression of CD206/CD163 
(a1) Scatter plots of the raw data of CD206/CD163 double positivity in ccRCC and oncocytoma; (a2) Scatter 
plots of mean value of CD206/CD163 double positivity in ccRCC (non-met ccRCC vs met ccRCC); (a3) Bar 
graphs of mean value of CD206/CD163 double positivity in ccRCC and oncocytoma; (b1) Scatter plots of the 
raw data of CD206/CD163 double positive cell number in the cytoplasm in ccRCC and oncocytoma; (b2) 
Scatter plots of the mean value of CD206/CD163 double positive cell number in the cytoplasm in ccRCC (non-
met ccRCC vs met ccRCC); (c3) Bar graphs of the mean value of CD206/CD163 double positive cell number 
in the cytoplasm in ccRCC and oncocytoma; Lines across the raw data indicate mean value. ns, p>0.05, *, p < 
0.05, **, p < 0.01, ***, p < 0.001, Sidak test after repeated measures two-way ANOVA or Tukey’s multiple 
comparisons after two-way ANOVA. Error bars represent estimated standard errors of the mean. Abbreviation: 
met, metastatic; ccRCC, clear cell renal cell carcinoma; onco, oncocytoma. 
5.5.7 Metastatic ccRCC exhibited smaller size of adipocytes. 
Four out of the five participants in the cohort of metastatic ccRCC exhibited smaller median size of adipocytes 
compared to their counterparts in the cohort of non-metastatic ccRCC, even the difference from the paired-t 
test was not significant (Fig 5.17 b). The mean value of the median size of adipocytes was smaller in 
metastatic ccRCC perinephric adipose tissue (9518 pixels) compared to non-metastatic ccRCC 
perinephric adipose tissue (13434 pixels) and oncocytoma perinephric adipose tissue (13412 pixels), 
and the differences between groups were statistically significant. However, Tukey’s multiple 
comparison did not find any significant difference in post hoc testing (Fig 5.17 c).  
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Fig 5.17 Median size of adipocytes 
(a) Scatter plots of raw data of median size of adipocytes in ccRCC and oncocytoma; (b) Scatter plots of mean 
value of median size of adipocytes in ccRCC (non-met ccRCC vs met ccRCC); (c) Bar graphs of mean value 
of median size of adipocytes in ccRCC and oncocytoma; ns, p>0.05, * p<0.05, paired t-test or Tukey’s multiple 




This is the first study using the multiplex immunofluorescence and digital analysis approaches to 
profile the immune phenotypes of macrophages in human perinephric adipose tissue. Based on the 
analysis of all the outcome variables that related to the expressive levels of the CD markers, it was 
found that almost all of the ccRCC samples with distant metastases expressed higher levels of CD206 
and CD163, compared to the matched ccRCC samples without distant metastases, using all three 
thresholding. Similarly, compared to the cohort of oncocytoma which is a benign subtype of renal 
tumour, the cohort of ccRCC with distant metastasis exhibited higher mean expressive levels of 
CD206 and CD163. However, compared to the relatively small difference caused by the factor of 
tumour subtypes, which in most cases accounted for less than 10 % of the total variation of the CD68 
expression, the effects caused by the factor of thresholding cannot be ignored. Hence, there is not 
enough evidence to deduce that the expression of CD68 varies between different subtypes of renal 
tumours with distinct aggressiveness. Moreover, it was found that there would possibly be a negative 
association between median sizes of adipocytes in the perinephric adipose tissue with the 
aggressiveness of renal tumours, as evidenced by smaller sizes measured in ccRCC samples with 
distant metastasis compared to the ccRCC cohort without distant metastasis and the oncocytoma 
cohort.  
A team from Fudan University in Shanghai had investigated the prognostic value of macrophage 
phenotypes in ccRCC tumour tissue [217]. They discovered that an M2 phenotype in tumour tissue 
characterised by high CD206 and low CD11c expression was an independent prognostic factor for 
shorter ccRCC-specific survival. However, they did not find any prognostic potential for CD68. 
Consistent with their findings, CD68 expression in perinephric adipose tissue in the present study did 
not show a stable trend of variation between different subtypes of renal tumours, however CD206 
expressive levels varied between different subtypes of renal tumours, with the most aggressive 
subtype, metastatic ccRCC, demonstrating the highest expression. The kidney cancer-specific 
prognostic value of macrophage immune profiles had never been investigated in kidney cancer-
associated adipose tissue. However, relevant research questions had been addressed in breast cancer. 
For example, similar to the finding in this study that metastatic ccRCC exhibited higher expression 
of CD163, it was reported that high CD163 expression in the adipose stroma of breast cancer 
independently predicted shorter cancer-specific survival [210]. However, unlike the result in another 
study based in the US, which found a prognostic potential for CD68 in discriminating invasive (high 
expression) and benign (low expression) breast tumours [213], CD68 expression levels in the 
perinephric adipose tissue in this present study did not show any discriminative potential for 
metastatic and non-metastatic ccRCC. The discrepancy may be due to different quantification 
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methods: subjective semi-quantitative evaluation was applied in the previous study, whereas 
objective digital quantification was applied in this present study based on three thresholding. 
As a pilot experiment, this study provided valuable information, such as effect size and standard 
deviation, which is an important reference to decide optimal sample size in future studies to obtain 
adequate statistical power [334]. Taking the CD206/CD163 double positivity measured under the 
individual thresholding as an example, at least 15 paired samples are required when choosing a type 
1 error (α) of 0.05 and a type 2 error (β) of 0.1 in the two-tailed paired-t test, using the following 
formula: “N = [(zα/2+zβ)σ/δ]2”, where the standard deviation of the paired difference (σ) = 0.3,  the 
mean difference (δ) = 0.208, zα/2 = 1.96, zβ = 1.282, N = paired sample number [335]. Given that only 
5 paired samples were included to compare the difference between non-metastatic and metastatic 
ccRCC, there is a possibility that the “large” effect size of most outcome variables related to the 
expression of CD206 and CD163 (according to the Cohen’s d value in Table 5.3) observed in this 
study might be caused by random variation [336]. However, the results reflected the expression of 
two different M2 markers and their colocalisation information. Additionally, the outcomes which 
were measured using various methods (i.e. mean intensity across the whole image, positivity across 
the whole image, total intensity in the segmented area and positive cell number in the cytoplasm) and 
under three thresholding were mostly consistent. Moreover, the trend that more aggressive ccRCC 
exhibited higher expression of M2 markers had been confirmed in previous relevant studies (Table 
1.2, Chapter 1). Hence, a statistically significant difference between groups is likely to be detected 
within a larger sample size. 
Another important finding in this study is that metastatic ccRCC adipose tissue exhibited smaller size 
of adipocytes compared to non-metastatic ccRCC and oncocytoma adipose tissue. Given that BMI, 
and age are important confounding factors when assessing the size of adipocytes, participants in the 
cohort of non-metastatic and metastatic ccRCC were matched for BMI and age initially [337]. Hence, 
the size differences in this case indicated that the metastatic ccRCC associated perinephric adipose 
tissue was undergoing more active cachexia related remodelling, such as fibrosis, adipocyte atrophy 
and browning [338]. It is unclear the association between this phenomenon and the other observation 
that increased infiltration of M2 macrophages in metastatic ccRCC adipose tissue. One possible 
mechanism is that M2 macrophages disrupted normal ECM structure in the cancer microenvironment 
through secreting MMP 9, which facilitated the invasion of renal tumours [339]. Monocyte-specific 
MMP-9 knock-out mice model could be established to assess the contribution of M2 macrophages in 
cancer metastasis. A recent study has revealed that recruited macrophages in the adipose tissue can 
functionally mediate lipid metabolism in obesity [222]. From the view of cancer metabolism, 
macrophages in the perinephric adipose tissue may be involved in the process of disrupting the 
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metabolic homeostasis in the adipose tissue therefore assisting the energy requirement of the 
neighboring cancer cells. Metabolomic profiling of macrophages in the tumour-associated adipose 
tissue could be a future direction to unveil the interaction of cancer metabolism and metastasis. 
 Conclusion 
For the first time, this study confirmed in the perinephric adipose tissue that high expression of M2 
macrophages may be associated with a high chance of metastasis, which is a prevalent paradigm. 
Metastasis-associated perinephric adipose tissue may undergo cachexia-related remodelling as 
indicated by the smaller size of adipocytes observed in metastasis-associated perinephric adipose 
tissue. How the crosstalk between macrophages and tumour-associated adipose tissue affects the 




Chapter 6  
Discussion and future directions 
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 Overview 
Accumulating evidence indicates there is a close interplay between adipose tissue biology and kidney 
cancer development. For example, obesity is an established risk factor for developing kidney cancer. 
Paradoxically, obese patients may have a better prognosis for kidney cancer. Of note, the most 
common subtype of kidney cancer, ccRCC, is characterised by lipid accumulation in cancer cells. 
However, roles of adipose tissue microenvironment remain elusive in kidney cancer.  
The thesis explored GRP78 expression and macrophage immune phenotypes in human perinephric 
adipose tissue in an attempt to define their potential prognostic values for ccRCC, particularly with 
regard to metastasis. Additionally, a novel and cost-effective liquid overlay-based technique was 
applied to establish a 3D model to mimic the ER stress-activated perinephric adipose tissue 
microenvironment. Thereafter, macrophage behaviour, including migration/invasion and polarisation, 
was investigated in a co-culture system which included adipocyte spheroids and cancer cells. 
 There were 7 major findings:  
1) GRP78 expression was not upregulated in ccRCC tissue compared to the adjacent normal kidney; 
2) High ER stress levels in perinephric adipose tissue might be associated with a lower chance of 
developing metastasis in ccRCC; 
3) The liquid overlay-based technique cost-effectively generated functional adipocyte spheroids that 
secreted adiponectin, MCP-1 and IL-8, and were responsive to the ER stress activator, tunicamycin; 
4) Tunicamycin blocked the migration of the murine macrophage cell line Raw 264.7 towards 
adipocyte spheroids in an MCP-1 independent manner; 
5) M1 macrophages differed from M2 macrophages in invasion capacity towards adipocyte spheroids, 
with invasive behaviour only observed for M2 macrophages; 
6) The presence of M1 macrophages inhibited the invasion of KHOS and 786-0 cancer cell lines; 
7) Metastatic ccRCC perinephric adipose tissue exhibited higher expression of CD206 and CD163 
compared to the matched non-metastatic ccRCC samples. 
The comprehensive discussions provided following the major findings in Chapters 2 to 5 will not be 
reiterated in this chapter. Instead, some considerations have emerged from the results and these may 
help better understand the topics or advance the approaches for future research. These topics will be 
discussed in greater depth in the present discussion and future directions Chapter. Future directions 
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will be raised by reflecting limitations of the studies that were included in the thesis or by referring 
to other methodologies that have recently been published and applied in relevant research.  
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 Discussion 
6.2.1 Tissue heterogeneity will affect image analysis. 
The findings in Chapter 2 demonstrated GRP78 expression in ccRCC tumour tissue was not a 
valuable risk stratification marker of ccRCC. Neither the staining intensity based quantification nor 
the proportion of positive pixel based quantification detected a significate upregulation of GRP78 
expression in ccRCC tumour tissue compared with the adjacent normal renal tissue, in contrast to 
what had been published previously [37]. To minimise the bias caused by heterogeneity between 
ccRCC tumour tissue and normal renal tissue, tissue compartments that may demonstrate a weak 
staining pattern of GRP78 or are impossible to stain, such as glomeruli, fibrosis and tubular lumen 
space, were manually eliminated from image analysis. Hence, the results faithfully reflected the very 
small difference in GRP78 expression between ccRCC tumour tissue and normal renal tissue, with 
little impact of tissue heterogeneity (Table 2.2, Chapter 2). Failure to account for tissue 
heterogeneity may, therefore, introduce bias when comparing the proportion of positively stained 
areas in different tissue types. However, the physiological or pathological conditions may also 
introduce bias relating to tissue heterogeneity even if there is only one type of tissue involved in 
analysis. For example, the statistically significant inverse association observed between BMI and 
proportion of positive pixels (correlation coefficient= - 0.20, p = 0.02) was contrary to the notion that 
ER stress can be caused by obesity (Fig 2.8C, Chapter 2) [340]. However, such a trend was observed 
when staining intensity was used to quantify the expression of GRP78, though the coefficient was 
small and insignificant (Fig 2.8D, Chapter 2). Further comparison between the staining patterns in 
tissues originated from two representative participants suggested that larger adipocytes for 
participants with higher BMI may leave the cellular stainable area smaller, because lipid was washed 
away during staining processing (Figs 2.8A and 2.8B, Chapter 2). Hence, the change in adipose 
tissue morphology under obese conditions needs to be considered when performing image analysis. 
6.2.2 Why did the topic progress from ER stress to macrophage behaviour? 
A metastatic discrimination potential was found for GRP78 expression in perinephric adipose tissue, 
with one unit increase in average grey value of GRP78 staining (negatively associated with staining 
intensity) poorly (p = 0.07) correlating with a 17 % increased probability of ccRCC being diagnosed 
with metastasis (Fig 2.5E, Chapter 2). The result indicated that high ER stress levels in perinephric 
adipose tissue may exert protective functions by preventing metastasis in ccRCC. However, due to 
the small number of participants diagnosed with metastasis by pathologists according to the TNM 
staging system (n=9), no covariate was introduced in the logistic regression model to adjust potential 
bias. Hence, the role as a ccRCC metastatic indicator for ER stress level in perinephric adipose tissue 
is uncertain. A 3D culture model was therefore established to study the role of the ER stress-activated 
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adipose tissue microenvironment in kidney cancer metastasis (Chapter 3). Considering recent studies 
have demonstrated the contributions of TAM on metastasis and relevant mechanisms had never been 
addressed from the view of ER stress, the thesis then focused on the effects of an ER stress activated 
adipose tissue microenvironment on macrophage behaviour, especially for macrophage polarisation 
and migration (Chapter 4). 
6.2.3 Adiponectin might protect adipocytes against the ER stress. 
It was hypothesised in Chapter 3 that increasing numbers of adipocyte spheroids maintained in a 
single well would cause ER stress due to a rapid consumption of nutrients. However, compared with 
5 spheroid states, average mRNA expression of GRP78 (Fig 3.11a2) and sXBP1 (Fig 3.11b2) were 
lower in 20 spheroid states. The mechanism might be related to a protective role of adiponectin 
against ER stress. It had been reported that the lipolysis mediated by ER stress may help maintain the 
metabolism homeostasis in conditions of nutrient deprivation [341]. The saturated fatty acids released 
from adipocytes activated the pro-apoptotic ATF2-CHOP cascade of UPR and decreased synthesis 
of proteins [342, 343]. Deng et al. have found that adiponectin rescued the apoptosis in palmitate acid 
mediated ER stress through activating the PPARα-AMP activated protein kinase (AMPK)-protein 
kinase C (PKC) signaling pathway, which suppressed the activation of ATF2 [285]. Given that the 
concentration of total adiponectin in the conditioned medium increased with increasing adipocyte 
spheroid numbers, the ER stress caused by nutrient deprivation might be compromised (Fig 3.10a1). 
Investigating the fatty acid profiles when the same numbers of spheroids (e.g. 20) are maintained in 
the starvation medium and in the adipocyte maintenance medium would help to understand whether 
nutrient deprivation would influence the lipolysis of adipocytes. A comparison of UPR components 
with or without addition of the adiponectin neutralising antibody would help to clarify whether 
adiponectin is responsible for the blunted response to ER stress. 
6.2.4 The mechanism underlying the unchanged M2 macrophage phenotype upon tunicamycin 
stimulation remains elusive. 
Given that ER stress levels in perinephric adipose tissue may be negatively associated with the 
likelihood of developing metastasis in ccRCC and that an M2-like macrophage phenotype may favour 
cancer metastasis, it was hypothesised that ER stress could induce the M1 phenotype skew for M2 
macrophages [293, 298]. However, results from flow cytometry analysis demonstrated that no dose 
response related upregulation of M1 markers or downregulation of M2 markers was observed in M2 
macrophages upon tunicamycin treatment at concentrations from 2 to 4 µg/mL (Fig 4.6, Chapter 4). 
Considering M2 macrophages may be vulnerable to high doses of tunicamycin, with 97.5 % cell death 
observed upon exposure to 5 µg/mL of tunicamycin in a pilot experiment, no further increases in the 
dose were used for the purpose of augmenting the level of ER stress. The short exposure time (24 h) 
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to tunicamycin might be a limitation to the conclusion drawn that tunicamycin was unlikely to trigger 
reprograming of M2 macrophages to the M1 phenotype. However, Tarique and his colleagues found 
that macrophage polarisation induced by cytokine stimuli was reversible, with the phenotype profiles 
dramatically changed over resting polarised macrophages in cytokine-free medium [295]. 
Considering that 24 h is normally enough for an effective stimulus [e.g. toll like receptor (TLR)-3] to 
induce an evident M1 skew for M2 macrophages, investigation of the polarising effect of prolonged 
exposure to low dose of tunicamycin was not undertaken, thereby avoiding the bias caused by a 
spontaneous reverse of macrophage phenotype [344]. It was recently published that another ER stress 
activator, palmitate acid, induced the M1 phenotype shift of M2 macrophages through activating the 
PERK- eIF2α signaling pathway, which is a shared downstream cascade of UPR that can be activated 
by tunicamycin [345]. It would be informative to screen the secretory profiles and expression of ER 
stress associated proteins in M2 macrophages upon tunicamycin stimulation, considering contrary 
regulatory roles for macrophage phenotypes were found between palmitate acid and tunicamycin. 
6.2.5 Limitations of the 3D models in the thesis 
The established 3D co-culture model introduced in Chapter 4 included cancer cell lines, M1 or M2 
macrophages, adipocyte spheroids and a polycarbonate membrane coated with growth factor reduced 
basement membrane matrix. Adipocyte spheroids were separated from other cells by the transwell 
inserts, allowing indirect interactions between components on either side of the filter. The model fits 
in the setting of most cases of kidney cancer, in which renal tumours are not grown directly in the 
adipose stroma, like breast cancer. However, the involvement of the exogenous ECM which was 
extracted from Engelbreth-Holm-Swarm mouse sarcoma did not resemble the heterogeneous 
microenvironment of ccRCC [346]. Supplementation of cytokines that have been known to induce 
macrophage phenotype modulations made the co-culture system more controllable. However, it did 
not allow the effects of the perinephric adipose tissue on the polarisation and filtration of PBMC 
derived monocytes to be monitored directly. Although it is known that the established adipocyte 
spheroids could secrete adipokines and are responsive to ER stress stimulus (Chapter 3), a 
continuous functional assessment was lacking in the co-culture system. Even though the macrophage 
immune phenotypes in perinephric adipose tissue have been profiled in Chapter 5, continuous 
monitoring has not been done to evaluate whether a model of TAM residing in adipocyte spheroids 
can be recreated by long-term co-culture. Even with the limitations in the existing models, they are 
compatible to different screening systems and can be easily adapted by incorporating different cell 
types. One of the relevant approaches will be introduced in the section of 6.3.3. 
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6.2.6 Limitations of the adipocyte spheroids differentiated in vitro  
Although intracellular unilocular lipid droplets (Fig 3.5c) and functional adiponectin secretion (Fig 
3.5d) were observed in the adipocyte spheroids differentiated using the liquid overlay-based 
technique, the adipocyte spheroids differentiated in vitro may present different characteristics 
compared to the mature adipocytes residing in the perinephric adipose tissue. Adipocyte 
differentiation is mediated by multiple factors [347, 348]. Hence, variabilities in cultural conditions 
can affect the phenotype of the induced adipocytes. For example, the physiological adipogenic 
differentiation happens under a specific oxygen tension (8-9 %) [349]. It was reported that the high 
oxygen level in the incubator (21 %) would inhibit the adipogenic differentiation of MSC and the 
mechanism was related to an activated gene expression of p53 [350]. Additionally, exposure of the 
high oxygen atmosphere induced a pro-inflammatory microenvironment, as evidenced by increased 
levels of reactive oxygen species and proinflammatory cytokines (e.g. IL-6 and IL-beta) being 
measured in the conditioned medium of ASC grown in vitro [349]. It has recently been noted that the 
growth hormone has antiadipogenic function via activating Wnt signaling [348, 351]. 
Supplementation with the growth hormone in the culture medium of MSC at a physiological 
concentration (5 ng/mL) could downregulate the expression of CCAAT/enhancer-binding protein 
alpha (C/EBPα, an adipogenic gene) while upregulating osteogenic genes, such as osterix and 
osteoprotegrin [352]. It should be noted that, in this thesis, 10 % FBS was supplemented in the 
adipogenic differentiation medium. FBS may contain some non-tested hormones that may affect the 
process of adipogenesis in an unknown manner [353, 354]. 
 Future directions 
6.3.1 Targeting cellular based ER stress profiles in perinephric adipose tissue 
The routine IHC analysis across the whole image may be affected by tissue heterogeneity when 
comparing the expression of biomarkers in different tissue types. It is cumbersome to tailor the image 
for the purpose of eliminating compartments that may bias the results. Segmentation of cellular 
compartment-based single-cell analysis in FFPE tissue has provided a solution, in which individual 
cells are segmented to obtain cellular or subcellular quantification of biomarkers of interest [355]. 
However, DAPI counterstain based nuclear segmentation has limitations when applied to detect ER 
stress markers in live cell imaging, since the dye affects UPR signaling [356]. Considering that the 
extent of literature reporting relevant applications in human FFPE tissue is limited, it would be worth 
investigating the cellular based ER stress profiles in perinephric adipose tissue using either uniplex 
or multiplex IHC. Similar research questions, such as the association between ER stress levels and 
cancer aggressiveness, could be addressed by profiling the expression of other ER stress markers of 
interest, such as CHOP and eIF2α, in individual cells. 
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6.3.2 Targeting lipid metabolism in ccRCC diagnosis and treatment 
Thanks to the increasing awareness of cancer screening, many cases of small renal masses (less than 
4 cm in diameter) are diagnosed incidentally [357]. Developing non-invasive diagnostic techniques 
to detect reliable prognostic markers for small renal masses is important, since these would help 
discriminate malignancies that have a high chance of metastasis. Simultaneously, the new diagnostic 
techniques would minimise overtreatment of patients who would have a better prognosis without 
ablation surgery [358]. Except for a macroscopic cellular accumulation of lipids, altered lipid 
metabolism exists in ccRCC [359]. Lipidomic signatures may provide useful information for ccRCC 
diagnosis. For example, compared to the normal renal tissue, ccRCC tumour tissue is characterised 
by increased levels of cholesterol esters, ether-type phospholipids and triacylglycerols, and decreased 
levels of polyunsaturated fatty acids and most phospholipids [360]. Given that the secretory profile 
of adipocytes co-cultured with cancer cells was not screened in this present project, future research 
is encouraged to map the lipid metabolism in the ccRCC tumour tissue as well as in perinephric 
adipose tissue using the novel imaging modalities, such as nuclear magnetic resonance spectroscopy, 
which can provide non-invasive tools to visualise alterations in lipid metabolism in vivo [361]. 
Relevant data can help us better understand the fat-tumour interplay from the view of lipid 
metabolism. It was reported that upregulation of fatty acid synthase (FAS) in ccRCC tissue was 
associated positively with ccRCC aggressiveness [362]. Treatment with the FAS inhibitor. C75, 
impaired the cell viability and invasiveness of ccRCC cell lines [363]. Hence, targeting lipid 
metabolism is a promising strategy for finding novel synergistic treatments for metastatic ccRCC. 
6.3.3 Adapting the 3D culture model by incorporating cancer-associated fibroblasts 
ccRCC is a highly vascularised solid tumour characterised by various degrees of intratumoural 
fibrosis, with potential impacts on cancer aggressiveness [364]. Cancer-associated fibroblasts (CAF) 
may have a protumoural role by supporting tumourigenesis, angiogenesis, EMT and metastasis [365]. 
Compared to normal fibroblasts, CAF secrete more components of ECM, such as collagens and MMP 
[366, 367]. Given that CAF is an important tumour stromal component, replacing the commercial 
Matrigel in the co-culture system with CAF may facilitate study of the effects of the ccRCC tumour 
microenvironment on macrophage polarisation and invasion. Sofia and colleagues designed a 3D 
model with direct interactions of CAF, primary monocytes and lung cancer cell lines, which were 
encapsulated in alginate and maintained for 3 weeks in suspension cell culture under continuous 
stirring [368]. They found that the model recreated the structure of tumour tissue with collagen fibres 
intercalating cancer cells. Moreover, without addition of exogenous cytokines, the secretory profiles 
of the co-culture system promoted an M2-like phenotype. In this co-culture system, CAF and 
monocytes were encapsulated with the tumour spheroids simultaneously. It would be of interest to 
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first build tumour spheroids with ECM accumulation, then monitor the invasion of monocytes into 
spheroids in real-time, and finally profile the macrophage immune phenotypes in spheroids. Given 
that the properties of CAF and their impacts on cancer development may vary between individuals, 
it would be valuable to record the volume of the spheroids over time and analyse the association of 
macrophage behaviour with the quantity of cytokines present in the conditioned medium, such as 
GM-CSF, CSF-1, IL-8, MCP-1, VEGF, TNF-α and MMP-9.  
6.3.4 Applying single-cell technologies to unravel intratumoural heterogeneity 
The tumour microenvironment is heterogeneous, with cell-cell interactions influencing the cancer 
progression. For example, it was reported in Chapter 4 that the presence of M1 macrophages 
inhibited the invasion of cancer cells, whereas the effects of M2 macrophages varied between KHOS 
(Fig 4.12c) and 786-0 (Fig 4.13c) cell lines. It is unclear whether the inhibited invasion in the presence 
of M1 macrophages was due to a phagocytic effect or the interactions of cancer cells and M2 
macrophages promoted the process of EMT in cancer cells. Applying single-cell RNA sequencing 
will enable detecting the holistic shift of the transcriptional features after modulating the cell 
composition in the co-culture system, therefore uncovering potential mechanisms underlying the 
distinct cellular behaviour [369]. By combining single-cell RNA sequencing with high-throughput 
digital imaging of RNA fluorescence in situ hybridization (FISH), the findings in in vitro models can 
be translated into patient samples, providing distributional information of those functional “units” 
across the tissue [370]. The spatial information can be further translated into risk predictive models 
for cancers. For example, combining single-cell RNA sequencing and FISH techniques, a group from 
Harvard has successfully used the spatial localisation of EMT and proliferative cell composition in 
primary and liver metastatic sites of pancreatic ductal adenocarcinoma to risk stratify patients [371]. 
6.3.5 Targeting adipose tissue to restore metabolic homeostasis in cachexia 
Associated with poor cancer survival, cachexia is characterised by ≥ 5 % weight loss and functional 
abnormalities including a hypermetabolic state, anaemia, tissue wasting and systemic inflammation 
[338]. Adipose tissue undergoes dramatic remodelling during cancer cachexia, including browning, 
adipocyte atrophy and increased fibrotic and inflammatory infiltration [372]. Adipose tissue has a 
great impact on the metabolism of cancer cells under cachexia. Huang et al. found that the process of 
adipogenesis in the adipose tissue was suppressed in an adipocyte-specific SQSTM1 ablated mouse 
model bearing prostate cancer, serving to save nutrition and energy to profit the demand of cancer 
progression. SQSTM1 is the gene encoding an autophagy-associated protein, P62. The mechanism 
was related to downregulated mTORC1 and PPAR α in adipocytes and an inverse upregulated profile 
in cancer cells [150]. It would be promising to modulate nutrient-utilising pathways in the adipose 
tissue to reverse the metabolic profiles that favour the growth of cancer cells. The importance of 
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adipose tissue-associated macrophages in maintaining the metabolic homeostasis in adipose tissue 
has been underestimated. Using single-cell based techniques, a functional subset of adipose tissue-
associated macrophages (CD9 and CD36 double positive) has been recently found. Recruited from 
circulating monocytes, the macrophages were also positive for triggering receptor expressed on 
myeloid cells 2 (Trem2) and conservatively expressed a genomic signature involved in lipid 
metabolism and endocytosis, including LIPA, CTSB, CTSL, FABP4, FABP5, LGAL3, CD9 and 
CD36. Functional analysis demonstrated that Trem2 expressing macrophages were key mediators in 
lipid metabolism upon loss of adipose tissue homeostasis in obesity [222]. Future research is 
warranted to profile the TREM2 signaling pathways in cachexia-associated adipose tissue to find 
potential drivers for the metabolic abnormalities in cachexia. The information yielded from these 
studies may facilitate novel drug design targeting cachexia. 
6.3.6 Exploring the mechanism underlying the “obesity paradox” in kidney cancer 
Fig 5.17 demonstrated that the perinephric adipose tissue sampled from metastatic ccRCC exhibited 
smaller adipocytes (measured by median size) than those from non-metastatic ccRCC and benign 
renal tumours. Given that the histological phenotype of the perinephric adipose tissue is characterised 
by multilocular brown adipocytes interspersing with unilocular white adipocytes, the result shown in 
Fig 5.17 could also be interpreted as the most aggressive ccRCC have fewer unilocular white 
adipocytes in the perinephric adipose tissue, which may be a sign of active fat browning [132]. If the 
perinephric adipose tissue of obese individuals is less “brownable” than its counterpart in lean 
individuals, the blunted tumour-associated adipose tissue remodelling, under obesity, could be a 
mechanism that explains the “obesity paradox” in kidney cancer. Further research is needed to 
elucidate the different content of brown adipocytes or brown fat precursor cells in perinephric adipose 
tissue of obese and lean individuals under a healthy status. Research mapping the whole-body BAT 
composition is available, however kidney tissue-specific data are missing [373]. Screening the 
process of BAT activation, vasculature remodelling and metabolic state within the perinephric 
adipose tissue in obese and lean subjects should provide their relevance in tumourigenesis. 
Furthermore, it would be necessary to elucidate whether the metabolic crosstalk between adipocytes 
and cancer cells exhibits a different profile when investigated in an obese or a lean microenvironment. 
If proved to be a cause of kidney cancer-associated cachexia or metastasis, targeting the browning of 




This thesis broadly explored the role of the adipose tissue microenvironment in kidney cancer, 
particularly focusing on using the perinephric adipose tissue. In addition to risk stratifying ccRCC 
patients using the IHC profiles of ER stress biomarkers and macrophage immunophenotypes, the 
thesis established a 3D co-culture model to investigate macrophage behaviour in the adipose tissue 
microenvironment. Many interesting findings have been discovered. Some are contrary to previous 
publications (e.g. no difference of GRP78 expression was observed between tumour tissue and normal 
renal tissue in ccRCC compared with Fu et al. who found increased GRP78 expression in tumour 
tissue [37]; ER stress did not upregulate with increasing numbers of adipocyte spheroids compared 
with Klingelhutz et al. who found the opposite [258]), and some have confirmed prevalent paradigms 
(e.g. ER stress upregulated with increasing BMI; co-culture of mature adipocytes promoted an M2 
phenotype skew in unpolarised macrophages; M2 macrophages exhibited stronger invasive capacity 
than M1 macrophages and the mechanism was related to distinct integrin expression levels between 
M1 and M2 macrophages). There are still some novel observations that cannot be fully and 
convincingly interpreted, based on the limited exploration of the mechanisms (e.g. Tunicamycin 
blocked the migration of Raw 267.4 cells; the presence of M1 macrophages inhibited the invasion of 
cancer cell lines, whereas the presence of M2 macrophages exerted contrary effects on the invasion 
of KHOS and 786-0 cancer cell lines). Thus, there is an urgent need to identify the regulatory 
mechanisms that drive those behaviours of adipose tissue-associated macrophages and to understand 
the fat-cancer interplay in determining the metastasis of ccRCC. Although lipid metabolism is beyond 
the scope of the thesis, it is associated with macrophage behaviour, adipose tissue homeostasis and 
cancer progression, and therefore can become the focus of future studies. Adipose tissue is a “treasure 
box”. Combining routine cell culture with advanced sequencing and imaging techniques would no 
doubt help better understand the molecular mechanisms underlying the association of adipose tissue 
with cancer progression. In line with the planned goals, the thesis has resulted in development of 
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Appendix 1. Summary of antibodies and live/dead cell dye for flow cytometry analysis 
Antibody Names of antibodies or dye Company (Cat. No.) Dilution  
APC Mouse Anti-Human CD105 BD (562408) 1:20 
PerCP-Cy5.5 Mouse Anti-Human CD90 BD (561557) 1:20 
PE Rat anti-SSEA-3 BD (5602337) 1:5 
PE Mouse Anti-Human CD16 BD (555407) 1:100 
APC Mouse Anti-Human CD14 BD (555399) 1:100 
PerCP Cy5.5 Mouse Anti-Human CD14 BD (550787) 1:50 
APC Mouse Anti-Human CD11b BioLegend (301309)  1:20 
PE Mouse Anti-Human CD18 BioLegend (374707) 1:20 
FITC Mouse Anti-Human CD209 BD (551264) 1: 20 
BV480 Mouse Anti-Human CD86 BD (566131) 1:50 
BV786 Mouse Anti-Human CD80 BD (564159) 1: 50 
PE Mouse Anti-Human CD163 BD (556018) 1: 20 
APC Mouse Anti-Human CD206 BD (550889) 1:20 
BV421 Mouse Anti-Human CD200 Receptor BD (566344) 1: 100 
Live/dead 
dye 
DAPI Invitrogen (D1306) 0.2 µg/mL 
FVS700 BD (564997) 1:3000 
Live/dead Aqua Invitrogen (L34957) 1:500 
 
Appendix 2. Recipe for making the Kaiser glycerine-jelly aqueous mounting medium 
Distilled water 80 mL 
Glycerine 20 mL 
Gelatine 3 g 
Chromic potassium sulphate 0.2 g 
Chromic potassium sulphate was dissolved in 30 mL of distilled water. Gelatine was dissolved in 50 mL of 
warm distilled water. Chromic potassium sulphate and gelatine solutions were mixed and glycerine was added. 
The pH was tested with an indicator and neutralised with sodium bicarbonate solution to pH 7.0. The recipe 




Appendix 3 List of gene-specific primers for q-rtPCR 
Target mRNA Sequence Size (bp) 
GRP78 
(human) 













F: GCAGAGATGGCACCCCTG 80 
R: GGTTTCACCGATGTCTCCCT  
MCP-1 
(human) 

















Appendix 4 Agarose gel electrophoresis of q-rtPCR products 
 
a and b demonstrate the electrophoretic gels of q-rtPCR products (names labelled in gels), which were 
photographed by BIO-RAD Gel Doc XR. 500 ng of the DNA ladders in the range of 10 bp to 300 bp were 
added. DNA was separated in 4 % agarose TBE buffer stained with SYBR safe. Bands did not appear in the 
NRT controls (lanes 3, 5, 7, 9 and 11 for a; lanes 1, 3 and 6 for b), indicating the DNA contamination presented 
in RNA preparation was negligible. The specificity of the PCR products for all primers was confirmed by the 
presence of predicted band sizes demonstrated in the gels (Appendix 3). 
Abbreviations: NRT, no reverse transcriptase control; q-rtPCR, quantitative real-time polymerase chain 
reaction; TBE, Tris/Borate/Ethylenediaminetetraacetic acid  
187 
Appendix 5 Summary of ingredients in the culture media used in generation of M1/M2 
macrophages 
Culture medium Ingredients  Catalogue number 
Macrophage differentiation medium CSF-1 (50 ng/mL) BioLegend 574802 
M1 induction medium 
LPS (20 ng/mL) Sigma L2654 
INF- γ (20 ng/mL) BioLegend 570202 
M2 induction medium 
IL-4 (20 ng/mL) BioLegend 574002 
IL-13 (20 ng/mL) BioLegend 571102 
RPMI-1640 was applied as the base medium. All culture media contained 10 % heat inactivated FBS and 1 % 
penicillin/streptomycin. Abbreviations: CSF, colony stimulating factor; IL, interleukin; INF, interferon; LPS, 
lipopolysaccharide. 
 
Appendix 6 Fluorescence spectral overview 
 
The filters cyanine 3 (Cy3) and Texas-Red were chosen to build the imaging protocol for the Vectra III 
multispectral slide scanner as alternatives for Rhodamine 6G (CD163-linked fluorophore) and Alexa Fluor 
610 (CD206-linked fluorophore), which were not built into the instrument. 
 
